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1. Introduction and objectives 
 
 
The nutritional needs and habits have been changed widely during the last decades 
especially the western diet. Food variety and availability make the individuals’ choices 
become  more   complicated.  This  would  reflect  the  gradient  in  nutritional  habits. 
Populations that have better  access to processed and market foods differ in their fat 
and fatty acids intakes from other populations that rely on their traditional food types. 
 
The eating patterns have been changed widely as a result of the increased in the living 
standards, industrialization, urbanization and the market globalization. However, those 
patterns have changed  to be unhealthier dietary habits combined  with less physical 
activities which make the energy balance goes to the overweight side (i.e. obesity) and 
nutrition related diseases (Ogura et al., 2010). 
 
That was first noticed in 1972 in Greenland Eskimos population when compared with 
Danish  population,  they  had  lower  levels  of  serum  cholesterol  (Chol),  low  density 
lipoprotein (LDL) and triglycerides (TG) with a low myocardial infarction rate (Amiano et 
al., 2001). Cree and Inuit nations  still eat large quantities of fish and marine products 
(i.e.  sea  food)  from  the  traditional  food   type   which  makes  their  n‐3  fatty  acids 
concentration  one  of  the  highest  grade  among  other  populations  (Dewaillya  et  al., 
2003). 
 
 
Establishing  the  nutritional  requirement  values  to  support  health  and  well‐being  of 
individuals  and  populations  have  and  still  are  topics  that  require  regular  scientific 
updates.  Constructing  taxonomies  and  scientific  categories  of  such  requirements  is 
considered to be very complex as they are adjusted with age and physiological status. In 
2008,  the  third  meeting  of  the  Food  and  Agriculture  Organization  /  World  Health 
 
Organization (FAO/WHO) experts was held on fat in human nutrition (Burlingame et al., 
 
2009). 
 
 
Recent publications have addressed the impact of fat and fatty acids on health, their 
role in the  body are somehow clear. Fat and fatty acids are now believed to have an 
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important role on the early life development, and later life nutrition related chronic 
disease. Fat  and fatty acids requirements through life stages have been studied. Fat 
contributes with increasing the food palatability and soft mixture, plus they have critical 
role in early growth development (embryonic progress to childhood). Certain fatty acids 
have specific roles in vivo. While long chain  n‐3 polyunsaturated fatty acids (LCPn‐3) 
enhance central nervous system (CNS) and brain  development,  saturated fatty acids 
(SFA)  and  trans‐fatty  acids  (TFA)  contribute  with  the  cardiovascular  disease  (CVD) 
(Burlingame et al., 2009). 
 
In  2004,  omega‐3  index  expression  had  been  defined  as  the  red  blood  cells  (RBC) 
percentage   of   Eicosapentaenoic  Acid  +  Docosahexanoic  Acid  (EPA  +DHA).  RBC  is 
preferable for assessing  omega‐3 with respect to the half‐life of RBC being 4‐6 times 
longer than plasma fractions (von  Schacky, 2010). Omega‐3 index is considered to be 
used as a risk biomarker for the coronary heart disease (CHD) especially sudden cardiac 
death (Harris, 2007a). 
 
Many studies have analzyed plasma phospholipids (PL) and cholesterol ester (CE) to 
estimate the fatty acids (FA) composition to estimate the short term of dietary fat intake 
(King et al., 2006; Tvrzicka et al., 2002). Fatty acid compositions of RBC reflect the longer 
dietary  intake  (Harris  and  Thomas,  2009).  However,  assessing  EFA  and  fatty  acids 
composition from whole blood is not widely practiced. Nevertheless, the ideal method 
to assess dietary fat intake still does not exist especially  for very long chain n‐3 fatty 
acids (Amiano et al., 2001). 
 
The objective  of  the  study  is  to  compare  the  fatty  acid  pattern  in  different  blood 
components to find the simplest and most appropriate method for the rapid validation 
of the essential fatty acids in humans. Comparing the different blood components can 
lead to a specifying the preferred component for easy and rapid analysis of fatty acids 
while giving valid information about the status of essential fatty acids. 
4 
 
 
 
 
2. Literature Review 
2.1. Fatty acid‐structure and nomenclature 
 
2.1.1. Structure 
 
 
Fatty acids exemplified by a repeating series of aliphatic tail of methylene group with 
hydrocarbon  (CH3) in one hand and the carboxyl group (‐COOH) on the other (Arab, 
2003). The length of carbon chain varies from 2 to 30 carbons or more. Fatty acids are 
 
considered as the major components of the dietary fats that derived from acylglycerols, 
free  fatty   acids,  phospholipids   and  sterol  esters.   Nevertheless,  Triglycerides  are 
considered the main source. 100g of TG yield approximately 95g fatty acids. However, 
fatty  acids  in  the  body  are  incorporated  with  blood  lipids,  in  fats  deposits  and  in 
structural lipids in biological membranes (Ratnayake and Galli, 2009). 
 
Regarding  the  bonds  between  carbon‐carbon  in  the  fatty  acids;  fatty  acids  can 
potentially be classified as saturated fatty acids if no double bonds occur, unsaturated 
fatty acids if they contain  1  or more double bonds in the chain. Fatty acid is called 
monounsaturated when it contains 1  double bond, and polyunsaturated (PUFA) when 
more  than  1  double  bonds  exist.  The  positions  of  these  double  bonds  within  the 
hydrocarbon chain have many possibilities which might formulate the fatty acid as cis or 
trans configured (Ratnayake and Galli, 2009). 
 
2.1.2. Nomenclature 
 
 
A chemical name should clearly describe the chemical structure. This has been a good 
practice for the fatty acids by using the systematic nomenclature which is recommended 
by the International  Union of Pure and Applied Chemistry [IUPAC‐IUB Commission on 
Biochemical  Nomenclature,  1978].  Fatty  acid  is  named  on  the  basis  of  the  carbon 
number, the number and the position of the  double bond is relative to the carboxyl 
group (Arab, 2003). The carboxyl carbon is regarded as  number 1 and the fatty acid 
chain’s carbons are numbered accordingly from the carboxylic carbon. While the IUPAC 
system is accurate but fatty acid names are too long thus biochemists and nutritionists 
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use  the  ‘n‐minus’  system  for  naturally  occurring  cis  unsaturated  fatty  acids  that 
categorize   the   fatty  acids  into  different  families  which  share  same  biosynthetic 
pathways. In regard to the bonds between carbon‐carbon in the fatty acids; fatty acids 
may classified as saturated fatty  acids if no double bonds occurred, unsaturated fatty 
acids if they contain one or more double bonds in the chain (Ratnayake and Galli 2009). 
 
Omega system is referred to the ‘n‐minus’ system. It was Holman RT who established 
the  numbering system for the unsaturation of fatty acids, the "omega nomenclature" 
(Holman 1964; Holman 1998). 
 
Delta (∆) system is another widely used system to identify fatty acids in which it is based 
on the  carbon atoms number between the carboxyl carbon and the nearest double 
bonds to the carboxylic group. In ∆ system; all double bonds position are specified and 
also their cis/trans configuration (Ratnayake and Galli 2009). 
 
2.2. Fatty Acid Classification 
 
 
Fatty acids can be classified according to (1) total number of C atoms (even and odd 
chains), or (2) to the length of hydrocarbon chain (short, medium and long chains), or (3) 
according to the nature of the hydrocarbon chain nature (saturated, unsaturated). 
 
2.2.1. According to the fatty acid synthesis 
 
2.2.1.1. Non‐essential fatty acids 
 
 
Saturated fatty  acids  and  monounsaturated  fatty  acids  are  non‐essential  fatty  acids 
because  humans  can derive  them  from Carbohydrate. SFA can be biosynthesized  in 
humans by the addition of 2‐carbon units to the acyl chain. MUFA are biosynthesized by 
the insertion of a cis double bond between C9 and C10 counting from the carboxyl end 
of the acyl chain. For example; oleic  acid  (18:1n‐9) can be derived from stearic acid 
(18:0) and palmitoleic acid (16:1n‐7) to palmitic acid (16:0) (Paganelli et al., 2001). 
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2.2.1.2. Essential fatty acids 
 
 
In 1929, Burr discovered the Long Chain Polyunsaturated Fatty Acid (LC PUFA) linoleic 
and linolenic  acids (Holman 1998; Burr GO et al., 1930). However, Burr and Burr are 
considered to be the first who invented the term essential fatty acid (EFA) in 1929 (Burr 
and  Holman  1988).  Arachidonic  Acid  (AA),  EPA,  and  DHA  might  be  considered  as 
conditionally essential as their production would be insufficient (Strijbosch et al., 2008). 
These publications have resulted towards identifying signs of fat  free diet seen in rat 
which both lionleic and linolenic acids implement that effect (Holman 1998), nowadays 
essential had a different definition in which they are the fatty acids that have to be 
obtained from the food (Crawford et al., 2009). 
 
Mammals lack the enzymes to introduce double bonds at carbon atoms beyond C9 thus 
all fatty acids containing a double bond at positions beyond C9 have to be supplied in 
the diet. The two lacking enzymes are named ∆12 and ∆15 desaturases. While in plant, 
Linoleic acid can be  desaturated  to α‐linolenic acid by the insertion of a double bond 
between carbon 3 and 4 (from the methyl carbon). In mammalian cells; three important 
families of fatty acids occurred: Omega‐3, Omega‐6, and Omega 9. The first two families 
are essential in mammals and must be supplemented from the diet. Consequently, cell 
membrane composition of the EFAs is determined by the dietary  intake (Strijbosch et 
al., 2008). 
 
The parental essential fatty acids are the two basic precursors of poly unsaturated fatty 
acids (PUFA) (lionleic acid 18:2n‐6) for the omega 6 family, and (α‐linolenic acid 18:3n3) 
for the omega‐3 family (Tvrzická et al., 2002). It should be clear that all EFA are PUFAs 
but not all PUFAs are EFA (Undurti 2008). 
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2.2.2. According to the fatty acid structure 
 
 
2.2.2.1.  Saturated fatty acids (SFA) 
 
 
Fatty  acid  contains  only  single  carbon  to  carbon  bonds,  in  nature  this  occurs  in 
unbranched structure with even carbon atoms. Chemical structure in general is R‐COOH 
wherein R group is straight hydrocarbon chain of the form CH3(CH2)X. According to the 
chain length; FAO/WHO Experts Consultation recommended the following subclasses: 
 
• Short chain fatty acids: between 3‐7 carbon atoms. 
 
• Medium chain fatty acids: between 8‐13 carbon atoms. 
 
• Long chain fatty acids: between 14 and 20 carbon atoms. 
 
• Very long chain fatty acids: within 21 or more carbon atoms. 
 
 
2.2.2.2.  Unsaturated fatty acids (USFA) 
 
 
Fatty acid contains double bonds and hence more chemically reactive than SFAs, the 
more double bonds the more reactivity found. According to the double bond number; 
Unsaturated Fatty Acids (USFA) are categorized into two subcategories: Monounsaturated 
Fatty Acids [MUFA], and Polyunsaturated Fatty Acids [PUFA]. However, according to the 
chain length; FAO/WHO Experts Consultation recommended the following subclasses: 
• Short chain unsaturated fatty acids: with 19 or fewer carbon atoms. 
 
• Long chain unsaturated fatty acids: with 20‐24 carbon atoms. 
 
• Very long unsaturated fatty acids: with 25 or more carbon atoms. (Ratnayake 
and Galli, 2009). 
 
2.2.2.3.  Cis‐Monounsaturated fatty acids (cis‐MUFA) 
 
 
Naturally the largest parts of the double bonds of the unsaturated fatty acids in food 
fats are found in the cis configuration (Ratnayake and Galli 2009). There is a suggestion 
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that MUFA reflect SFA dietary intake but doesn’t reflect MUFA intake which might be 
explained by MUFA being endogenously biosynthesized from PUFA (MA et al., 1995). 
 
2.2.2.4.  Trans‐fatty acids (TFA) 
 
 
USFA that contain at least one double bond in the trans configuration is called trans fat. 
The disadvantages of such recent FA are now known to lead to increase the risk of non 
communicable diseases such CHD and metabolic syndrome. Such FAs have affections on 
blood lipoproteins, while they increase Low Density Lipoprotein (LDL) (the same effect 
of SFA) and TG, they decrease HDL (Asgary et al., 2008). 
 
Small amount (2‐6%) of trans configuration of the USFA double bonds are presented in 
ruminant deposition and milk fats; although the most naturally USFAs double bonds of 
the food fats are found in cis configuration. It was in 1929 when trans isomers of fatty 
acids were demonstrated (Bertram  1928). The major intake of the trans fatty acids in 
human diets  arise  from food  technological  treatment  such  as  hydrogenation  of  oils 
(Ratnayake and Galli 2009). 
 
2.2.2.5.  Polyunsaturated fatty acids (PUFA) 
 
 
According to the double bonds location; natural PUFAs from the methyl terminus of the 
acyl chain with all cis configuration can be alienated into 12 different families from n‐1 
to n‐12. However,  regarding the presence and human health and nutrition, the most 
important two families are n‐3  and n‐6. Both are essential for humans because they 
cannot be synthesized from the organism,  and  have hence to be provided via dietary 
intake  (Ratnayake  and  Galli  2009).  High  long  chain   poly  unsaturated  fatty  acids 
(HLCPUFA) are found in retina membranes, brain synapses and sperm (Arab, 2003). 
 
2.2.2.5.1. n‐6 PUFA 
 
 
Linoleic  acid  structure  was  elucidated  by  (Erdmann  et  al.,  1909),  and  synthesis 
description  was, at a later time, presented by (Raphael et al., 1950). n‐6 PUFA is an 
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important family with respect to human health. It is considered essential. In nature, 
there are  many important n‐6 PUFAs such as lionleic acid (LA), γ linolenic acid (GLA), 
docosapentaenoic acid (DPA), aracidonic acid (AA), etc. Nevertheless, LA is the parent of 
this  family.  It  is  widely   distributed   in  almost  every  dietary  fat;  therefore  some 
population might over consume LA. In vivo, LA can produce AA and Dihomo‐ γ ‐Linolenic 
Acid (DGLA) and those are substrates for  eicosanoids. AA is mainly present in animal 
products especially free‐range animals and rarely in the plant kingdom (Ratnayake and 
Galli, 2009). 
 
2.2.2.5.2. n‐3 PUFA 
 
 
n‐3 PUFAs family is present in both the animal and plant kingdoms and it is considered 
very important with respect to human health and nutrition. There are many important 
n‐3  PUFAs  such   as  eicosapentaenoic  acid  EPA,  docosapentaenoic  acid  DPA,  and 
docosahexanoic acid DHA. Nevertheless, ALA α‐lionlenic acid is the parent of this family. 
However, each fatty acid has a main role in vivo. For example; EPA is a precursor for the 
n‐3  derived  prostaglandins  (PGs)  and  thromboxanes  (TXs),  DHA  is  the  precursor  of 
docosanoids and it is highly presented in some highly specialist  tissues like brain and 
retinal cells, sperm and cardiomyocytes (Ratnayake and Galli, 2009). 
 
Several studies have demonstrated that n‐3 FA lower levels of triacylglycerol and the 
increase level of HDL (Dewaillya et al., 2003), n‐3 FA can also decrease the atherogenic 
eicosanoids  production  and  modulate  plasma  lipids  (Sun  et  al.,  2008).  It  has  been 
suggested that plasma n‐3  PUFA (especially 22:6n3) form good biomarkers for dietary 
intake (MA et al., 1995). 
 
Fish is the richest source for major n‐3 PUFAs (EPA and DHA). However, there is a high 
correlation   between  serum  EPA  and  DHA  in  cholesteryl  ester  and  phospholipids 
fractions and fish intake which makes very long chain n‐3 PUFA considered as a valuable 
biomarker fish dietary intake (Amiano et al., 2001). 
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2.2.2.6.  Furan Fatty acids 
 
 
Spiteller has reviewed that there are a large group of unusual fatty acids distinguished 
by the furan  ring occurred in a low level in many natural products and also in human 
blood. Human beings obtain furan fatty acids from food (fish, soft corals, vegetable oils) 
and incorporate  them into PLs  and  CEs (Spiteller, 2005; Ratnayake and Galli, 2009). 
Furan fatty acids can be found in different amounts amongst all the blood samples, in 
serum they were found only in PL but not in CE or TG (Wahl et al., 1995). 
 
Furan FA (F‐acids) are identified by the fatty acids characterized by side chain of a propyl 
or pentyl in one of the alpha‐positions; and the other side chain with SFA with COOH 
end (Spiteller, 2005). Yet, some features of this family need to be clinically tested. For 
instance,  furan  fatty  acids  have  the  ability  to  be  radical  scavenging  which  might 
contribute to the cardioprotective functions of the fish and fish oil (Ratnayake and Galli, 
2009). 
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2.2.3. Membrane Lipids 
 
 
2.2.3.1.  Phospholipids 
 
 
Phospholipids are considered to be the main class of membrane lipids. They consist of 
four  substances: the platform where the fatty acids attached with, one or more fatty 
acids, phosphate  and an alcohol attached to the phosphate. They are also known as 
glycerophospholipids. As shown  in (Fig 2.2.3.1.) X group natures in the phospholipids 
produce  many  classes  such  as  phosphatidylcholine,  phosphatidylethanolamine,  and 
phosphatidylserine in biological membrane. However, R1 in the sn1 is usually esterified 
to SFA while R2 in the sn2 is esterified to PUFA while at sn3 the PL molecule is provided 
by a hydrophilic region (phosphorus with nitrogen base or sugar molecule). 
 
 
 
 
 
 
Fig 2.2.3.1. Chemical structure of phospholipids, P= phosphate, R1, R2= fatty acids, X= 
Choline, ethanolamine, serine, inositol or glycerol {Adapted from (Ratnayake and Galli 
2009)}. 
 
2.2.3.2.  Cholesterol 
 
 
Cholesterol is a member of the sterol lipids, although it is an important constituent of 
the membrane lipids. Sterol lipids consist of 3 main components: the steroid nucleus of 
the 4‐ring  structure, the hydrocarbon side chain and the alcohol group. Cholesterol is 
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regarded as the animal fat sterol as it rarely occurs in vegetable oils in trace amounts 
 
(Ratnayake and Galli 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  2.2.3.2.  Chemical  structure  of  a  cholesterol  {adapted  from  (Ratnayake  and  Galli 
2009)}. 
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2.3. Fat digestion, absorption and delivery to tissue 
 
 
Digestion   breaks   down   the large components    of   food   into   substances   the 
gastrointestinal tract lining can absorb. This process requires secretion of enzymes from 
different part of the Gastrointestinal (GI) tract. Triglycerides are the main component in 
the natural fat intake with  other few types of fatty acids such as SFA and USFA. The 
main site for fat digestion is the small intestine (Frances Sizer and Ellie Whitney, 2007). 
 
However, as dietary fat intake does not exist for pure fat and other components thus 
when fat enters the stomach it floats on the top of the fluid components in the stomach. 
Bile is the main factor  to emulsify fat in the small intestine while digestive enzymes 
complete  most  fat  digestion  in  the  small  intestine.  Those  digestive  enzymes  cleave 
triglycerides into free fatty acids, glycerol, and monoglycerides (Frances Sizer and Ellie 
Whitney, 2007) 
 
Free fatty acids are absorbed by the intestinal villi. The small volume of short chain fatty 
acids and glycerol allow them to be absorbed into the bloodstream immediately to be 
used by cells or stored in adipose tissue. However, short chain fatty acids is oxidized in 
the liver, while long chain fatty acids combines with protein (as they are not soluble in 
the  blood  aqueous  median)  to  form  chylomicrons  and pass  to  bloodstream  via the 
lymph vessels (Ratnayake and Galli 2009). 
 
Dietary fatty acids absorption would reach > 95%. On the other hand, absorption of 
dietary TG depends on the TGs physical natures that are found in the food (Ratnayake 
and Galli, 2009). To increase the absorption of the long chain PUFAs (especially DHA and 
EPA), Garaiova suggested to pre‐emulsification the oil mixture before eating while that 
had no effect on shorter chain SFAs absorption (Garaiova, 2007). 
 
TGs are mainly structured of fatty acids which are also found in PL and CE. Fatty acids in 
vivo are usually found combined and not as free fatty acids (Arab, 2003). 
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Similar amount of the n‐3 FAs intake either in form of capsules or salmon fish have 
different plasma EPA and DHA concentrations, from the later were significantly higher 
according to many studies (Ratnayake and Galli, 2009). 
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2.4. Fatty acids synthesis 
 
 
Many fatty acids can be synthesized, elongation and desaturated in vivo which affect 
the fatty acids measuring as indicator for the dietary intake (Arab, 2003). Nonessential 
fatty acids NEFA (SFA and MUFA) are totally identified to be supplied from dietary intake 
and also from in vivo biosynthesis from acetate precursors which might be PUFA or non‐ 
fatty  components  such  as  carbohydrates  and  glucogenic  amino  acids  (Brenna  and 
Lapillonne 2009). TFA, LA, ALA, Long Chain Saturated Fatty Acid LCSFA (22:0 and 24:0) 
are  obtained  from  dietary  intake,  while  16:0,  18:0,  16:1n7,   18:1n7  and  OA  are 
synthesized endogenously from carbohydrates (King et al., 2006). 
 
Synthesizing fatty acids in vivo swing between three processes; (1) synthesize SFA from 
acetyl Coenzyme A (CoA) units that derive from carbohydrate intake, (2) elongate the FA 
by entering 2 carbon atoms at once which create new fatty acid chain (usually occurs in 
endoplasmic reticulum),  and  (3)  desaturate  fatty  acid  by  entering  double  bond  and 
remove the hydrogen (converting the saturated bond to an unsaturated one). The last 
process requires desaturase enzymes, and mammalian are deficient in ∆12 that convert 
Oleic Acid (OA) to LA (n‐9 to n‐6), and ∆15 that convert LA to ALA (Arab 2003). 
 
LA  and  ALA  as  mentioned  before  are  considered  the  EFA  parent  in  which  their 
metabolized  produce  the main two families of PUFA. This metabolize  occurs by the 
same microsomal enzyme system (Ratnayake and Galli, 2009). In tissue structural lipids 
in both humans and animals the two  biochemistry (desaturation and elongation) are 
altering to produce up to 22 carbons fatty acid chain or long (Holman 1998). Human can 
enter double bonds at the ∆9 position but they cannot enter it  between ∆10 and the 
methyl terminal end. Those reactions use the same enzymes but they are independent 
and never cross their reactions series (Ratnayake and Galli, 2009). 
 
The pioneers  to describe  the in vivo conversion  of stearic  acid into oleic acid were 
(Schoenheimer  et  al.,  1936).  Synthesis  of  linoleic  acid  and  linolenic  acid  were  first 
described by (Raphael et al., 1950). Wider and Holman reported that LA is the precursor 
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of AA, while ALA is the precursor of the pentaene and hexaene acids. In rat fed fat free 
diet; oleic  acid was the precursor  of mead acid (which was known as trienoic acid) 
(Holman, 1998).  However, it is well known that LA and ALA are the precursors of the 
LCPn‐3 and LCPn‐6 (Sprecher  et  al., 1995). LA can be converted to LCPUFAn‐3 in vivo 
(Sun et al., 2008) 
 
Since 1963, there were many experimental studies investigating the effect of linoleate 
and  linolenate intake on the concentration of AA and ESA (eicostrienoic acid). It was 
shown that intake  of linolenate and linoleate reduce the ESA level in rat liver. When 
supplied the rat (through fat free diet course) with linolenate, a slight reduction on the 
AA and DPA levels appeared (Mohrhauer and Holman, 1963). 
 
Fatty acids’ intake has a noticeable effect on the de novo fatty acids biosynthesized. 
Both PUFA and SFA suppress FA synthesizing. High fat intake leads to a reduction in the 
de novo FA synthesis  (Arab 2003), while high carbohydrates intake elevates the liver 
conversion of carbohydrates to fatty  acids especially SFA (14:0 and 16:0), n‐7 and n‐9 
(King et al., 2006). However, habitual dietary intake, physical activity, genetic characters 
and  hormonal  status  have  also  an  influence  on  the  individuals’  fatty  acids  profile 
(Hodson et al., 2008; Ratnayake and Galli, 2009). 
 
Alcohol would be metabolized to SFA in vivo which increase  the SFA concentration. 
Alcohol also decreases the 18:2n6 in plasma PL and CE (MA et al., 1995), inhibit ∆6 and 
∆5 desaturases which decrease the conversion of LA to AA, ALA to EPA and DHA, and 
also decrease the LCPUFA concentration (Ratnayake and Galli 2009). However, alcohol 
drinkers showed to have higher 16:0 in RBC PL than non‐drinkers (Heude et al., 2002). 
 
Undurti in the Lipids in the Health and Diseases journal summarized the inhibitor and 
activator factors of ∆6 and ∆5 desaturases that interference the EFA metabolism. It was 
mentioned   that   SFA,   TFA,   cholesterol,   alcohol   intakes,   adrenaline   level,   insulin 
deficiency, diabetes, hypertension, oncogenic viruses (such hepatitis C), glucose rich diet 
and protein deficient inhibit ∆6 and ∆5 desaturases which reduce the formation of GLA, 
DGLA, AA, EPA, and DHA. Whilse fat free diet, caloric restriction, insulin and co‐factors 
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(e.g. zinc, magnesium, pyrixodine, and nicotinic acid) would enhance their regulation 
(Undurti,  2008); lipid lowering drugs have an effect on the LA conversion (Ratnayake 
and Galli, 2009) 
 
Smoking has an effect on the LA conversion, the serum LCPUFAs, and lower serum AA 
and  DHA.   Negative  smokers  might  face  changes  in  n‐3  biosynthetic  pathways  in 
epithelial cells; in  addition  women who smoke during their pregnancy would cause a 
reduction in their infants LCPUFA levels (Pawlosky, 2007; Ratnayake and Galli, 2009). 
 
Oral hormonal  replacement  therapy  in  postmenopausal  women  would  enhance  the 
elongation   and  the  desaturation  activity  that  transform  LA  to  AA  in  plasma  CE. 
Increasing AA level enhance the eicosanoids synthesizing which has an important role in 
CVD (Lewis‐Barned et al., 2000). 
 
LA metabolic cascade was described by (Marcel et al., 1968) as follows: 
18:2ω6 –› 18:3ω6 –› 20:3ω6 –› 20:4ω6 –› 22:4ω6 –› 22:5ω6 
 
 
ALA metabolic was described by (Klenk and Mohrhauer, 1960) as follows: 
18:3ω3 –› 18:4ω3 –› 20:4ω3 –› 20:5ω3 –› 22:5ω3 –› 22:6ω3 
 
 
AA and EPA biosynthesizing depends on the LA and ALA desaturation at the position 6. 
The  assumption  of  having  a  large  amount  of  DHA  and  low  levels  of  22:5n6  in  the 
membrane lipids would be justified by the faster conversion of EPA to 24:6n3 than AA to 
24:5n6 (Sprecher et al., 1995). The conversion of n‐6 PUFA is accelerated by the LA high 
 
intake and concentration with low ALA in lipids tissue (Ratnayake and Galli 2009). On 
the other  hand, the n‐3 and n‐6 reactions rates of desaturation and elongation were 
found to be similar (Sprecher et al., 1995). 
 
The conversion of ALA to n‐3 LCPUFA is not sufficiently provided and thus the adequate 
intake of EPA and DHA are recommended (Ratnayake and Galli, 2009). 
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Fig 2.4. Representation of the pathways of n–6 and n–3 fatty acid metabolism 
(Ratnayake and Galli, 2009) 
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2.5. Essential fatty acids in human health and disease prevention 
 
2.5.1. Heart diseases 
 
 
The attention paid for the blood lipid bprofile with respect to cardiovascular disease is 
ample.  Meta‐analyse‐studies  demonstrated  a  positive  correlation  between  total  fat 
intake and total  cholesterol, LDL and HDL cholesterol levels; however in other studies 
these results could not be confirmed. These conflicting results can be caused by the fact 
that the intake of fat vary widely in their fatty acids composition pattern. It is also well 
known  the  reduction  of  body  weight  through  changing  the  energy  balance  has  an 
impact on the blood lipid profile. For each 1 kg body weight loss, TGs were lessened by 
0.011 mmol/l, and HDL increased by 0.011 mmol/l (Elamdfa and Kornsteiner, 2009). 
 
 
High intake  of  SFA  and  cholesterol  along  with  low  intake  of  PUFA  stimulate  serum 
cholesterol level and CHD risk (Skeaff and Miller, 2009). Nevertheless, TFA consumption 
plays a role on the CHD as it affects the serum lipoproteins. TFA are considered as pro‐ 
inflammatory (Galli and Calder 2009). 
 
The role of EPA in preventing thrombosis and atherosclerosis was studied by (Dyerberg 
et al., 1978). In recent days, WHO is demonstrated with the protective effect of linolenic 
acid, EPA, and DHA and the inverse effect of the SFA myristic and palmitic with regards 
to the increasing the risk of cardiovascular disease and reducing the mortality (Anderson 
et al.,  2009).  Especially  n‐3  LCPUFA  (Skeaff  and  Miller,  2009)  from fish  and fish  oil 
supplements were found to be protective agents against cardiovascular diseases (Welch 
et al., 2006). The FAO/WHO was reported that replacing  SFAs  with PUFAs in dietary 
intake lower LDL‐cholesterol, total cholesterol/ HDL‐cholesterol ratio  and reduce the 
risk of CHD (Elmadfa and Kornsteiner, 2009). 
 
Harris has reported that the intake of n‐3 (EPA and DHA) fatty acids has a beneficial 
effect on the  heart disease. 850 mg/day would decrease 25% of death from CHD and 
45% of sudden cardiac death. In case of primary prevention two meals of fatty fish 
correspond   to   (500mg)   EPA+DHA  per  week   would   be  recommended,   while  for 
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secondary prevention 1 g EPA+DHA /day would decrease the risk of CHD death (Harris 
and  von   Schacky,  2004).  EPA  and  DHA  supplementation  reduce  the  CVD  risk  by 
stabilizing  the  arterial   plaque  which  is  considered  as  a  potential  mechanism  to 
secondary reduce inflammation (Harris, 2010a). 
 
In Japan, 7.8 out of 100.000 persons would suffer from sudden cardiac death (SCD) (von 
Schacky and Harris, 2007) with an omega‐3 index in RBC equal to 10%, while in Western 
countries the incidence is  much higher and amounts to 150 out of 100.000 with an 
omega‐3 index in RBC equal to 4.5%. In Seattle, a case‐control study showed that when 
omega‐3 index is 3.3% the sudden cardiac death was 1.0 while when the index increased 
to 6.5% the risk decreased to 0.1 person per 100,000 per year (von Schacky, 2009). 
 
2.5.2. Overweight and Obesity 
 
 
Recently, obesity is considered as an epidemic since the prevalence in most countries 
has increased significantly. FAO/WHO reported in 1994 that high fat intake increases the 
risk of obesity,  CHD and certain cancer types (Smit et al., 2009; Ogura et al., 2010; 
Kobayashi et al., 2001). 
 
While some prospective studies have demonstrated the hypothesis of food with high in 
fat and energy promote weight gain, other prospective studies debated this hypothesis 
and found some conflicting results. However, in short term intervention studies, it was 
clear that reducing body weight could be achieved by lowering the energy percentage 
from fat but not on an ad libitum basis (Elmadfa and Kornsteinerm, 2009). 
 
The  effect  of  diet  rich  in  medium‐chain  fatty  acids  on  controlling   weight   was 
demonstrated  by  (Kaunitz  et  al.,  1958).  n‐3  PUFA  might  positively  contribute  in 
controlling  some  metabolic  mechanism  of  obesity  (Nobili  et  al.,  2011).  In  rat‐based 
studies fish oil supplements were proven to decrease obesity but not in human. There is 
a positive relation between  EPA and body mass index (BMI) in human (Ogura et al., 
2010).  Adiposity  and  weight  increase  are  enhanced  with  diet  poor  in  PUFA  (Lweis‐ 
 
Barned et al., 2000). 
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2.5.3. Type 2 Diabetes Mellitus 
 
 
EFAs/PUFAs ratio has an important role in diabetes mellitus (Undurti 2008). According 
to the  strong association between type 2 diabetes and overweight and obesity, many 
studies were designed to establish the relation between type 2 diabetes and fat intake 
(Melanson et al., 2009,  Elmadfa and Kornsteiner,  2009). Cohort studies found some 
conflicting results. Reduction in body  weight and Insulin sensitivity was shown to be 
improved by regular physical activity (Elmadfa and Kornsteiner, 2009). 
 
Insulin  activates  ∆6  desaturase  while  diet  rich  in  glucose  suppress  ∆6  and  ∆5 
desaturases  (Undurti,  2008).  However,  there  are  evidences  that  insulin  resistance 
increases when diet is rich in SFA and poor in PUFA (Lweis‐Barned et al., 2000). In animal 
studies,  SFA  rich  food  reduces  insulin  sensitivity  as  opposed  to  n‐3  LCPUFA  which 
increase it. Although there has been no guarantee  evidence that replacing fat type or 
change in fat amount  have a constant  effect  on insulin  sensitivity,  limited evidence 
showed an improvement in insulin sensitivity and glycaemic index in  type 2 diabetes 
when swapping the SFA (animal source) with MUFA (vegetable source) (Sanders, 2009). 
 
2.5.4. Essential fatty acids and depression 
 
 
Abnormalities in fatty acids patterns were noticed in patients with psychiatric disorders 
such as high EPA/DHA ratio and low level of EPA and n‐3 PUFA in CE and PL. Second to 
adipose tissue, cells of central nervous system are richest in fat (Bourre 2004) especially 
PUFAs (Heude  et al., 2003). Thus,  any abnormalities  in amount  and  composition of 
ingested  PUFA’s  will  change  the  regulation  of  those  cells.  In  bipolar  patients,  RBC 
concentrations  of  AA  and  DHA  are  significantly  depleted  as  compared  to  healthy 
individuals affecting mood stabilizers. However, among schizophrenia patients, EPA was 
noticed to improve the disease symptoms (Chiu et al., 2003). 
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2.5.5. Cognitive function 
 
 
AA and DHA are well established to be major structural components of the brain. A trail 
investigation showed that when school aged children were supplemented with LCPUFA 
(DHA and EPA) their  learning and memory abilities were improved. Children with low 
level  of  n‐3  LCPUFA  appear  to  have  learning  problems.  However,  DHA  long  term 
supplementation  has  a  positive   effect   on   the  children   health   and   their   school 
performance (Dalton et al., 2009). 
 
2.5.6. Eicosanoid precursors and inflammation 
 
 
As  PUFA  are  responsible  for  the  production  of  eicosanoids  in  vivo,  Eicosanoids  are 
derived by the oxidation of n‐3 and n‐6 essential fatty acids mainly from AA (Arab, 2003) 
which is the  predominant PUFA in the body tissue is the product of desaturation and 
elongation of LA in the liver (Ratnayake and Galli, 2009). Eicosanoids are high potency 
hormones  (Arab,  2003)  and  they   are  the  connection  between  inflammation  and 
immunity from one side and the PUFA from the other (Simopoulos, 2002). Eicosanoids 
and  docosanoids  have  diverse  physiological  functions  in   blood  pressure,  platelet 
clotting, blood lipid profiles, the immune response and the inflammation  response to 
injury infection (Ratnayake and Galli, 2009). Both n‐3 and n‐6 have anti‐inflammatory 
properties as they produce different eicosanoids. Although the eicosanoids from n‐3 
and n‐6 have  reversed properties, EPA has higher affinity to cyclooxygenases and 5‐ 
lipoxygenase than AA (Simopoulos 2002). ALA, EPA and DHA play an important role in 
the immune function. While high intake of ALA (15g/d) suppress the IL‐1 and TNF (tumor 
necrosis factor), high intake of n‐6 (imbalance  of n6:n3 PUFAs) will over produce the 
pro‐inflammatory  prostaglandins  of  the  n‐6  series  and   cytokines.  Thus  it  can  be 
concluded that LA increases while n‐3 reduces the pro‐inflammatory cytokine secretion 
(Simopoulos,  2002).  Prostaglandin  E2  (PGE2) has  pro‐inflammatory  effect  which  can 
cause pain, fever and edema. When supplemented with 2g EPA and DHA, those n‐3 will 
work as anti‐inflammatory and decrease the bacterial infection (Arab, 2003). 
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The pivotal of n‐6 PUFA AA is a precursor of several lipid mediators that have biological 
actions (LTs,  PGs, TX and HETEs) (Gomolka et al., 2011). The metabolism of the AA 
cascade through the cyclooxygenase enzymes (which has two isoforms Cyclooxygenases 
1 (COX‐1)  and  Cyclooxygenases  2  (COX‐2))  increase  the  PG  and  Thromboxanes  (TX) 
series. COX‐1 and ‐2 are found in many normal human body’s tissues. While COX‐1 plays 
role in basal  production  of  eicosanoids, COX‐2  is enhanced  by certain inflammation 
factors and also plays a role in the PG production (Ratnayake and Galli, 2009) 
 
EFAs play a special role in regulating the prostaglandins (PGs) and the leukotrienes (LTs) 
which are released by almost all the body tissues. PGs and LTs play an important role in 
the inflammatory and immune system. DGLA, AA and EPA are the precursors of the 1‐, 
2‐ and, 3‐ LTs series, respectively (Belch and Hill, 2000). In addition, TFAs work as pro‐ 
 
inflammatory  and  trans  LA  and  trans  OA  are  stronger  than  trans  16:0  in  pro‐ 
 
inflammatory effect (Galli and Calder, 2009). 
 
 
Furthermore, EPA and DHA compete with AA on the production of PGs, TXs, LTs and 5‐ 
HETE  in  inflammatory  cells.  While  AA  produces  them,  EPA  and  DHA  suppress  their 
production (Ratnayake and Galli, 2009). 
 
2.5.7. Inflammatory bowel disease IBD 
 
 
The  IBD  diseases,  Crohn’s  disease  or  ulcerative  colitis  are  related  to  immunologic, 
environmental and genetic components. AA metabolites, prostaglandins, leukotrienes 
and cytokines are the most studied mediators. LTB4  which is the end product of AA is 
shown to be high in  ulcerative colitis patients. However, supplementation of Crohn’s 
disease patients with 2.7g of n‐3 decreased the relapse rate, which in the company of 
other studies concluded that n‐3 showed significant improvement for the IBD patients 
(Simopoulos, 2002). 
 
A cross sectional study done in Berlin, Vienna, and Bari to compare FAs profile between 
 
IBD patients and healthy individuals showed that SFA, MUFA were abnormal. Plasma 
 
15:0 and 24:0 decreased while  16:0 and 18:0 series  increased. PUFAs profiles  were 
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similar between the 2 groups – except for 22:4n‐6 which was higher in IBD patients‐ 
 
although most studies showed different levels in IBD patients (Hengstermanna et al., 
 
2008). 
 
 
2.5.8. Bacterial, viral, fungal and parasitic diseases 
 
 
PUFA is suggested to inactivate HIV virus. It was found that plasma PL in AIDS patients is 
low in DGLA, AA, and DHA levels icnreasing the onset and the development of AIDS. LA, 
ALA, and AA can  inactivate  both gram‐positive and gram‐negative bacteria. There is a 
hypothesis that EFA/PUFA  ratio  has similar aspirin‐like action and that subjects with 
lower  PUFA  levels  are  more  able  to  develop  HCV  (hepatitis  C  virus),  HIV  (human 
immunodeficiency virus), malaria and bacterial  infections. Throughout many studies it 
was established that PUFAs have anti‐bacterial, anti‐viral, anti‐fungal and anti‐parasitic 
actions (Undurti, 2008). 
 
2.6. Essential fatty acids deficiency (EFAD) 
 
 
LA and ALA are the essential fatty acids because they must be obtained from diet as the 
body does not have the ability to synthesize them in vivo. LA and ALA constitute the cell 
membranes and  accordingly EFA deficiency might alter the membrane structure and 
fluidity,  also  can  ffect  the  membrane‐bound  enzymes  and  receptors  performances 
(Undurti, 2008; Bourre, 2004). 
 
EFAD  is  the  combination  of  the  low  intake  with  increased  demand  of  physical 
requirements  and  sever  malabsorption  (Holman,  1998).  Chronic  malnutrition  which 
includes low intake of EFA and protein (which is important for enzyme and lipoproteins 
synthesizing) causes low  LA and  its products (Johnson et al.,  1985). Clinically,  EFAD 
would  be  distinguished  by  many  symptoms  such  as  growth  retard,  renal  toxicity, 
pulmonary abnormalities, and increased metabolic rate. However on the other hand in 
laboratarial experimentations, EFDA is distinguished by low level of omega‐3, omega‐6, 
AA, and high level of Mead Acid (Holman, 1998). 
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20:3n9 (mead acid) level in general is low in the plasma and tissue, while in the case of 
fatty acids  deficiency the conversion  of  OA to 20:3n9 is increased  according to the 
reduction  in  AA  level.  The  ratio  of  20:3n9/  20:4n6  is  therefore  increased  which  is 
considered as an EFAD biomarker (Ratnayake and Galli, 2009). The high level of Mead 
acid is a result of the conversion of the metabolic pathway. Usually, LA is converted to 
AA, while the deficiency and low intake of LA lead to a low level of AA which enhances 
Oleic acid to be converted to Mead Acid (20:3n9) (Ratnayake and Galli 2009; Mohrhauer 
and Holman, 1963). Increased level of all n‐7 fatty acids, and n‐9 (especially  OA) with 
low level of LA (and most n‐6 FA) would be signs of EFAD (Jeppesen et al., 1998). It was 
shown  in  a  study  feeding  rat  fat  free  diet  has  increased  dietary  linoleate  intake 
suppressed 20:3n9 level in liver and heart lipids (Mohrhauer and Holman, 1963). 
 
The index of triene/tetraene to indicate the EFAD status was established by Holman in 
 
1960, and this index is now known by Holman index. However, triene/tetraene ratio is 
being  used  to  indicate  the  EFAD  but  not  omega‐3  status  (Strijbosch  et  al.,  2008; 
Mohrhauer and Holman  1963). Holman has stated triene/tetraene ratio > 0.2 to be 
abnormal and EFAD ratio is > 0.4 in PL fraction (Holman 1960; Holman et al., 1979). 
 
Previously, EFAD was noticed clinically from the eczema symptoms in an infant who was 
on skimmed  milk and sucrose diet instead of mother’s milk, and the dermatitis that 
noticed in a man who also was on low fat diet for 6 months. EFAD occurs rapidly and 
severely in both young and adult subjects (Holman, 1998). 
 
However, EFAD affect all body tissues (RBC, heart tissue, liver, kidney, muscle, skin and 
depot fat of  rats (Holman, 1998). Since 1960s the correlation between CAD and EFAD 
were established by (Paganelli et al., 2001). It was found that the onset of certain types 
of   diseases   such   as   collagen   vascular   diseases,   hypertension,   diabetes   mellitus, 
metabolic  syndrome  X,  Alzheimer’s  disease,   CHD,  atherosclerosis  and  cancer  are 
significantly triggered by the severly low plasma and tissue levels of GLA, DGLA, AA, EPA 
and DHA (EFA/PUFA deficient) (Undurti, 2008). ALA deficiency affects the performance 
of the certain cerebral structure and altering sensor organs receptors which  decrease 
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the taste sensitivity. Subjects with ALA deficiency will need large amount of sugar to 
actually taste sweetness (Bourre, 2004). 
 
For n‐3 deficiency but not for DHA, 22:5n6/ 22:6n3 ratio is established in animal studies 
because 22:5n6 concentration increased in case of n‐3 deficiency (Ratnayake and Galli, 
2009). However, Holman was the first to report n‐3 deficiency in 1982 (Holman, 1998). 
Excessive  SFA  leads  to  n‐3  deficiency  due  to  their  effect  on  transport  mechanism 
(Paganelli et al., 2001). 
 
Increased intake of LA with low ALA intake decreases the EPA and DHA synthesis. In 
addition,  western  diet  is  extremely  high  in  LA  (10  folds  higher  than  ALA  intake) 
especially  with   people   who  do  not  consume  LCPUFAn‐3  (EPA/DHA).  Thus,  it  is 
recommended  to  increase  the  intake  of  ALA  (whether  from  plant  or  fatty  fish)  to 
prevent  the  EFAD  and  to  ensure  an  adequate  conversion  of  ALA  to  EPA  and  DHA 
(Ratnayake and Galli, 2009). 
 
2.7. An essential fatty acid index necessity 
 
 
In 2004, the definition of omega‐3 index was established in RBC to be the sum of EPA 
and DHA. Using RBC rather than serum to assess the EPA+DHA decreases the biological 
variability as RBC half‐life is 4‐6 times longer and less influenced by day‐to‐day dietary 
intake. Thus, RBC omega‐3 index is not influenced by fasting or feeding state. In case of 
short term dietary intake scenario, plasma fatty acid would be considered. Many factors 
affect omega‐3 index values such as age, gender, BMI, alcohol drinking, physical activity 
and diabetes (von Schacky, 2010). Omega‐3 index doesn’t only differ according to those 
factors but also it varies within (2.6% to 14.9%) and between populations (3.4% to 9.5%) 
as well. However, the upper limit of the omega‐3 index presents in Japanese population 
is 10% (von Schacky, 2009). 
 
Omega‐3 index is favoured as a marker for the CHD especially sudden death for many 
reasons.  Most importantly is the inverse relationship between omega‐3 index tissue 
levels and the risk of  cardiac events and sudden death (Harris, 2007a; Albert, 2002; 
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Siscovick  et al.,  1995;  Kuriki,  2006).  Omega‐3  FAs  have  a  lowering  effect  on  serum 
triglycerides level, blood pressure, and serum cholesterol (Anderson et al., 2009) which 
are  considered  as  the  main  risk  factors  for  cardiac  diseases.  Omega‐3  index  would 
reflect  CHD  more  than  other  known  risk  factors  plus  that  it  is  simple,  safe,  and 
inexpensive  (Harris,  2007a).  However,  EPA  and  DHA  were  found  to  work  as  anti‐ 
atherosclerotic and enhanced plaque stability (Harris and von Schacky, 2004), they are 
considered as an indicator of the risk of sudden death according to  the results of a 
prospective, nested case‐control analysis study established the effect of WB EPA  and 
DHA level (not the DPA and ALA) in lowering the risk of the sudden death (Albert et al., 
2002). 
 
 
The Omega‐3 Index 
 
 
 
Least Protection Greatest Protection 
 
 
 
 
 
4% 6% 8 % 10 
 
 
 
 
 
 
 
Fig 2.7.1. Summary of the proposed cut points for the Omega‐3 Index (Harris and von 
 
Schacky, 2004) 
 
 
The only two risk factors that have a statistically significant effect on CHD are: C‐reactive 
protein and  the blood omega‐3 index. The omega‐3 index is considered as a suitable 
biomarker  independent  from  other  risk  factors  for  the  sudden  cardiac  death  risk. 
Recently  Harris  and  Schacky  established  omega  3  index  for  cardiovascular  patients 
(Harris and von Schacky, 2004). Harris  found  in one study that EPA+DHA content was 
29% lower in patients with acute coronary syndrome than controls (1.7 ± 0.9% versus 
 
2.4 ± 1.4%, p<0.001) (Harris, 2007b). However, omega‐3 index is affected by the intake 
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of EPA + DHA, an increase of 0.24% will be noticed with each 4 g of EPA and DHA 
 
consumed monthly (von Schacky, 2010). 
 
 
In  another  study  Harris  and  von  Schacky  established  an  omega‐3  index  target  for 
cardioprotective to be about 8% and when the index is lower than 4% the risk of CHD 
death  increased (Harris and von Schacky, 2004; Ratnayake and Galli, 2009). However, 
8% or greater is considered the optimal levels (Harris, 2010c). While Aarsetoey could not 
 
establish the above index, he however did not find a significant correlation between 
omega‐3 index > 5.27% and all mortality risk reduction (Aarsetoey et al., 2008). In serum 
phospholipids, DHA ≥  4.5% from total fatty acids was found to decrease 34% of CHD, 
while omega‐3 index (EPA+DHA) ≥  4.6 % was shown  to lower  70% of the CHD risk 
(Halub, 2009). 
 
 
 
 
Fig 2.7.2. Proposed risk zone for the omega‐3 index (RBC EPA+DHA) (Harris, 2007a) 
 
 
Rupp distinguished between the two terms of omega‐3 level and omega‐3 index. The 
omega‐3  level  does not mean omega‐3 index as omega‐3 level includes other n‐3 FA 
while the index includes only EPA and DHA (Rupp et al., 2004) the most two important 
n‐3 LCPUFA in RBC membrane (Aarsetoey et al., 2008). 
 
To our knowledge, there is no omega‐3 index cut of point to compare between healthy 
subjects; this has lead to the urgent need for further studies to establish a valid omega‐3 
index. There is a rising requirement for a standardized method that assess EFA and the 
omega‐3 index which is believed to be a CVD biomarker (Harris and Thomas, 2009). It 
has been suggested to consider the omega‐3 index test as a part of routine blood test 
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(von Schacky, 2009). Similarity to the fact that HbA1c reflect glucose homeostasis (von 
Schacky and Harris, 2007), and LDL levels (LDL<100 mg/dl) (von Schacky, 2009) equal to 
(2.586 mmol/L) (Robins et al, 2001) omega‐3 index reflects omega‐3 fatty acids status 
(von Schacky and Harris, 2007). Only three laboratories in the world have installed the 
analytic methods to assess omega‐3 index as it  includes highly standardized analytic 
laboratories methodology (von Schacky, 2010). 
 
Omega‐3 index is considered as an accepted risk marker according to its consistency 
among  the  epidemiological  data,  between  and  within  population  in  addition  to  the 
prospective cohort  studies. In addition the strong associations between the omega‐3 
index and certain types of disease with low biological variability and being safe, quick, 
and cheap to be analyzed are all advantages for considering omega‐3 index a biomarker 
(Harris and von Schacky, 2004). 
 
2.8. Choices of tissue for measurement of fatty acids 
 
 
Fatty acid composition in tissue and blood have been used as a biomarker for dietary 
intake  because they are mainly derived from the intake (Hodson et al., 2008). Blood 
lipids a good  biomarker to reflect dietary long‐term intake and measure EFA status in 
animals (Holman, 1998; Ogura et al., 2010). Changing fat dietary intake will change fatty 
acid composition which would turn  back entirely within days (Kuang 2009). Analyzing 
fatty acids from blood components (single blood draw) is considered minimally invasive. 
 
Despite the huge publications regarding the fatty acids profile, it remains difficult to 
establish a general distribution level. This is because fat intake and its absorption and 
metabolism affect fatty acids profile in body tissues. Highly specialized cells contain high 
amount of AA and DHA in the structural lipids PLs. Higher intake of LA does not correlate 
with higher concentration of the AA in RBC. On the other hand, very high intake of LA 
enhances the storage of the LA in the adipose tissue (Ratnayake and Galli, 2009). 
 
The status of FA is influenced by many factors, dietary intake, food preparation method 
 
(which would affect the bioavailability),  individual  age, BMI, and total energy intake 
30 
 
 
 
 
(Aarsetoey et al., 2008). Yet, blood and tissues’ concentrations of PUFAs (n‐3 and n‐6) 
cannot reflect their accurate proportions in the dietary intake (MA et al., 1995; Sun et 
al., 2007). Assessing PUFAs’ level in body is the best biomarker to determine the dietary 
intake especially the levels of EPA, DHA, and n‐3 HUFA as they are not biosynthesized in 
humans  (Kuriki  et  al.,  2006).  However,  n‐3,  n‐6,  and  TFA  as  they  are  synthesized 
exogenously can be measured in blood specimens  (plasma,  serum, RBC) (Sun et al., 
2007). 
 
 
2.8.1. Whole blood 
 
 
The easiest in which it can be measured from a dried blood spot does not need pre‐ 
separation or lipid trans‐esterification like in RBC and Plasma (Harris, 2007a). There is no 
need for the TLC procedure, and FFA can be easily obtained by FAME method (Bailey‐ 
Hall et al., 2008). Intakes of  EPA and DHA were easily measured in whole blood, EPA 
increased from 0.6% to 1.4% within 10  days, while DHA increased from 2.9% to 4.3% 
(Rupp et  al.,  2004).  WB  lipids  composition  represents FA  of  all  the  circulating  lipid 
classes (Agostoni et al., 2011). 
 
2.8.2. Erythrocyte 
 
 
Erythrocyte has been widely examined throughout many studies. Harris has compared 
between  omega‐3 index that is measured in RBC, plasma and plasma phospholipids. 
However, he preferred using RBC to measure EPA+DHA as this index is not influenced by 
feeding  status  (blood  could  be  withdrawn  from  fed  or  fast  individual),  RBC  is  not 
influenced by day to day dietary intake according to its longer half life shelf (4 to 6 more 
time longer than plasma) (Sun et al., 2007), RBC  can be stored in ‐80 C° for 4 years 
(Harris, 2007a). The half‐life of EPA in RBC is 4 months thus RBC reflect the last months 
diet  intake  (Sun  et  al.,  2007).  RBC  omega‐3  status  is  believed  to  have  the  lowest 
biological variability because all the RBC’s FAs are esterified in the membrane PL, thus it 
reflects longer status than plasma beside it doesn’t alter by the fed state (Harris and 
Thomas, 2009; Ogura et al., 2010). 
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Plasma and RBC n‐3 LCPUFA composition are higher than those of other lipid fraction 
such  CE  and  TG.  Therefore,  RBC  and  plasma  PL  are  considered  as  an  n‐3  LCPUFA 
biomarker (Kawabata et al., 2011) 
 
The table below shows the advantages of using RBC as an omega‐3 FA intake biomarker 
[modified from (Harris and von Schacky, 2004)]. 
 
Table 2.8.2. Advantages of RBCs as biomarkers for omega‐3 FA intakes 
 
1.   Lipid bilayer—reflects tissue FA composition 
2.   The Omega‐3 Index half‐life is 4– 6 times longer than serum 
EPA + DHA , better reflecting long‐term exposure 
3.   Not influenced by fasting or fed state 
4.   Responsive towards increasing intakes 
5.   Correlates well with other biomarkers  of omega‐3 FA intake (with WB in this 
study) 
6.   Less influenced by dyslipidemias than serum FA 
7.   Less variable than serum EPA + DHA composition 
8.   Laboratory assessment is simpler than lipoprotein or lipid fraction FA 
9.   Stable to variations in pre‐analytical storage conditions 
 
 
 
2.8.3. Plasma 
 
 
Plasma and serum’ PUFA are useful to assess particularly the short term dietary intake 
(Kuriki et al.,  2006; Kobayashi et al., 2001). It is difficult to measure 22:5n6 in plasma 
because it presents in trace amount and the concentration go higher only in case of n‐3 
deficiency  (Galli  et  al.,  1971;   Ratnayake  and  Galli,  2009).  However,  plasma  FA 
composition is considered to be a biomarker for the marine origin n‐3 PUFA (Kobayashi 
et al., 2001). 
 
Plasma contains a mixture of lipoprotein associated FAs (cholesteryl ester, TG and PLs) 
plus  the   non   esterified  FAs  which  make  plasma  more  variable  in  assessing  FAs 
composition  (Harris  and  Thomas,  2009).  While  chylomicrons  reflect  the  last  meal 
consumed, triacylglycerols reflect  the previous few hours, and CE and PL reflect the 
previous few days (Arab, 2003). 
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Fatty acids’ changing  is faster  in plasma  than in RBC, and the later still faster than 
subcutaneous adipose tissue which has the slowest rate (Ogura et al., 2010). 
 
2.8.4. Plasma Phospholipids 
 
 
Thannhauser has illustrated that extracting phospholipids is efficient with the mixture of 
chloroform to methanol (2/1) (Thannhauser, 1936). Phospholipids’ PUFA in erythrocytes 
and platelets are useful to assess the medium term dietary intake (Kuriki et al., 2006) 
while fatty acids of plasma PLs pool tend to reflect day to day intake more than RBC FA 
pool (Harris and Thomas, 2009; Kawabata et al., 2011). Fatty acid composition in PL has 
been considered as a good biomarker for omega‐3 derived from  fish intake. Studies 
showed an  inverse  correlation between  omega‐3  in  serum PL and  CHD  risk  (Holub, 
2009). However, plasma phospholipids vary among countries, PLs from Caninio in Italy 
showed significant difference from Nurmijarv in Finland (Ching Kuang 2009). 
2.8.5. Plasma Cholesterol ester 
 
 
As for plasma phospholipids, plasma cholesterol ester content reflects weeks to months 
of the  dietary  intake (medium‐term) (MA et al., 1995). Fatty acid composition of CE 
reflects  FA  pattern   of  tissue  lipids.  In  1963,  Morris  isolated  acids  from  plasma 
cholesterol esters with 0, 1, 2, 3, 4, 5 and 6 double bonds (Nichols et al., 1966). 
 
Cholesterol ester plasma lipoprotein fatty acid composition is affected by the rate of FA 
synthesis,  FA  dietary intake, organism requires and their non‐enzymatic degradation 
(Tvrzická et al., 2002). Cholesterol ester was more sensitive to recent diet and EPA half‐ 
life was 4.8 days (Sun et al., 2007). 
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2.8.6. Adipose tissue 
 
 
Adipose tissue’ PUFAs are useful to assess the long term dietary intake (Kuriki et al., 
 
2006; MA et al., 1995) in which they are reflected in human over 2 and half years (Ogura 
et al., 2010;  Kobayashi  et al., 2001) to 3 years (Amiano et al., 2001). 680 days are 
estimated to be the half‐life of LA in adipose tissue (MA et al., 2007). 
 
For studying the EFA status, fatty acids’ biomarkers in plasma and RBC PLs seems to be 
more  favourable than adipose tissue. However, adipose tissue has the slowest rate in 
reflecting fatty acids changing when comparing with other lipids components (Amiano 
et al., 2001). In addition,  participants  prefer the blood withdrawal  than the adipose 
tissue biopsy (as it is more invasive)  (Amiano et al., 2001; MA et al., 1995) therefore, 
RBC and Plasma would be more appropriate  especially when dealing with large‐scale 
studies (Ogura et al., 2010). 
 
MUFAs are the predominant FAs in Adipose tissue, followed by SFAs while PUFAs has 
the   lowest   level   of   presence.   However,   according   to   their   liquid   form   room 
temperature; n‐3 PUFAs  do not accumulate in adipose tissue as it is not appropriate 
(Ogura et al., 2010). The correlation  between n‐6 FA, LA, and TFA were stronger in 
adipose tissue than in plasma or whole blood (Sun et al., 2007). The correlation between 
PUFA from subcutaneous adipose tissue and fat intake measured by FFQ were found to 
be positive (MA et al., 1995; Sun et al., 2007). 
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2.9. Recommendation of the quantity and quality of fat intake 
 
 
It is known that a fat macronutrient yields double the value of energy (E) from an equal 
amount  of  grams  weight  of  carbohydrate  and  protein.  Studies  approved  that  fat 
increases the palatability  and reduce the satiety. However, high fat foods have many 
effects on the body in a way that they are more able to be stored than carbohydrates 
and proteins are, also they increase the total  number and sizes of the body fat cells 
(Elmadfa and Kornsteiner, 2009) 
 
Table 2.9. Dietary recommendations for fat and fatty acid intake for adults (Elmadfa and 
 
Kornsteiner, 2009) 
 
Type of fat Amount 
Total fat E% 20‐35 
SFAs. E% 10 
MUFAs, E% By differences 
Total n3,n6 PUFAs, E% 6‐ 11 
n6 PUFA LA, E% 2.5‐9 
n3 PUFA : ALA, E% ≥ 0.5 
n3 PUFA : EPA + DHA 0.250‐ 2 g/day 
Trans fatty acids, E% 1 
 
 
2.9.1. Recommendation of fat and fatty acid intake 
 
2.9.1.1. Fats and fatty acid requirements for infant of 0‐2 years 
 
 
During the brain development, intake of LA and ALA is very important (Heude et al., 
 
2002). Energy from fat lay between 40‐60% of total energy during the first 6 months. At 
later stages, after 6 months till 3 years, the energy requirement from fat declined needs 
to be from 30‐35% of total energy depending on the child physical activity. Roles of the 
lipid as structural components are very important especially for tissues of brain, retina 
and neural tissues. Those tissues are rich in LCPs especially (Uauy and Dangour, 2009). 
However, adequate supplements of LCPUFA should be  provided to fetuses (Makrides, 
2000). 
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Human milk is a good source for the DHA and AA and their precursors LA and ALA. DHA 
level in human milk depends on the maternal diet while AA is more constant. Therefore 
to supply the infant who depends on his mother’s milk with DHA, mothers are therefore 
advised to be supplemented with DHA. While for the infant fed on formula, human milk 
considered the ideal to be matched in the concentration of LCPUFA, EPA, DHA and AA. 
DHA concentration is between 0.2 to 0.5% of total FAs. Added AA should be around the 
same concentration of DHA, also EPA should not exceed the DHA. EPA and DHA should 
be maximally account for 1.5% of the total energy in the formula (Uauy and  Dangour 
2009) 
 
 
In order to prevent nutrition‐related chronic diseases in infants aged 0‐2 years, total fat 
intake should lay between 30‐40 % according to the infant’s physical activity. PUFAs in 
total are between 5‐15% of total energy, including 4‐13% from n‐6 and 1‐2% from n‐3 of 
total energy. MUFA’s requirement has  no restriction within the total fat range while 
cholesterol  should  not  exceed  300  mg/day  (Uauy  and  Dangour,  2009).  There  is  a 
hypothesis that n‐3 intake during infancy reduce the risk of type  1  diabetes and both 
infection and non infection diseases (Undurti, 2008) 
 
2.9.1.2. Fats and fatty acid requirements for children of 2‐18 years 
 
 
For children over 2 years, intake of SFA should not exceed 10% of total energy. PUFA’s 
requirements lay between 5‐15% by giving attention to the ratio between omega 6 and 
omega 3 to be between 5:1 and 10:1. No restriction to MUFA’s within the total fat range 
with highly restricted to the hydrogenated fats (Uauy and Dangour, 2009). 
 
2.9.1.3. Fats and fatty acid requirements for adults 
 
 
Total fat intake requirements vary according to the individual’s physical activity. The 
moderate  physical activity  individual  would  need 30% of energy while  high physical 
activity individual  requirements increase to 35% of energy. However, the acceptable 
macronutrient distribution  range  (AMDR) varies between 20 and 35% of total energy 
(minimum 15%, maximum 35%). A  maximum level of SFAs should not exceed 10% of 
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total energy intake. However, MUFAs requirements depend on the total fat and fatty 
acid intake pattern. FAO/WHO calculated MUFAs intake by: Total fat intake minus SFAs 
minus PUFAs minus  TFAs.  The maximum PUFAs (n‐3 and n‐6) intake is 11%. ALA (n‐3 
FAs) requirements encouraged to achieve between 0.5 and 2% from total energy; 0.5% 
is the minimum in order to avoid deficiency symptoms. Therefore the lower range of LA 
(n‐6 FAs) would be 2.5 while the average can reach 9% from total energy. TFAs intake 
adjusted for gender. The average acceptaned values for humen are approximately 1.5 g 
and 0.9 g for men and women respectively. Alterantively, near 0.5% E for both genders 
(Elmadfa and Kornsteiner, 2009). 
 
However,  for  adults  in  the  US,  the  Food  And  Drug  Administration  (FDA)  in  1997 
considered  the safe dose is up to 3 g/day of EPA and DHA, although there were no 
significant clinical symptoms (bleeding) noticed with high dose of EPA and DHA (Harris 
and von Schacky, 2004). The  American Society for Nutrition has published that taking 
high  dose  of  EPA  and  DHA  (3.4  g/d)  lowers  significantly  serum  triglycerides  27% 
comparing with 0.85 g/d (Skulas‐Ray et al., 2011). 
 
2.9.1.4. Fats and fatty acid requirements for pregnancy and lactation 
 
 
FA n‐3 and n‐6 LCPUFA especially DHA requirement are high and very important during 
pregnancy  (especially during the last trimester) for the fetus development especially 
that maternal DHA plasma phospholipids significantly decrease during pregnancy. It also 
contributes in the structure of brain cell membrane and prostaglandins and eicosanoids 
production (Makrides, 2000). 
 
For the total fat intake requirements, pregnancy and lactating women needs do not 
differ from  the non‐pregnant and non‐lactating ones of the same age. No additional 
requirements for SFAs  and MUFAs while a warranty restriction for the food contain 
Partially Hydrogenated Vegetable Oil  (PHVO). DHA recommendation  in lactation and 
pregnancy is at least 200 mg/day, however, for pregnancy the highest demand will be in 
the third trimester. In case of pregnancy; the average for  both DHA and EPA is 300 
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mg/day, while the AA upper limit is 800 mg/day (Brenna and Lapillonne, 2009). LCPUFA 
status is generally decreased in maternal and infant during the lactating period (Kuipers 
et al., 2011). 
 
Smoking   during   pregnancy   will   affect   infant’s   PUFAs   level   and   reduce   plasma 
concentration (20:3n6, AA, DHA, 20:3n6/LA, AA/20:3n6 and DHA/ALA) of the newborns 
(Ratnayake and Galli, 2009). 
 
2.9.2. Recommendation of the n‐6/n‐3 ratio: 
 
 
Holman found that when ALA intake is increased, n‐6 family production is consequently 
suppressed.   In  contrast,   when   LA  intake  is  increased,   n‐3  family   production  is 
consequently suppressed. That would explain the competition between n‐3 and n‐6 on 
the metabolism reaction enzymes. Increasing the intake of ALA to < 2% suppresses n‐6 
metabolism while LA intake should be increased 10 times to suppress n‐3 metabolism to 
the same degree (Holman, 1998). 
 
n‐3   and   n‐6   hold   important   roles   as   precursors   of   bioactive   lipid   mediators, 
consequently the different ratios of n‐6/n‐3 might lead to different levels of those lipid 
mediators and metabolites (Gomolka et al., 2011). 
 
Decreasing the intake of LA from 7 to 3% energy increases the EPA synthesis  while 
increasing  the  intake of ALA from 0.3 to 1.1% energy decreases the DHA synthesis. In 
another   way,   increased   intake   of   ALA   and   decreased   intake   of   LA   would   be 
recommended to stimulate  the synthesis of EPA and DHA. ALA and LA biological roles 
depend  on  the  balance  of  their  dietary  intake,  thus  FAO/WHO  in  a  1994  meeting 
recommended a dietary intake balance to be between LA:ALA 5:2 and 10:1 (Ratnayake 
and Galli, 2009). 
 
Over  the  past  century,  LA  had  been  the  area  of  medical  interest  and  people  were 
encouraged to increase their LA intake as the only source of PUFA while n‐3 PUFA were 
ignored. The higher dietary intake of animal’s meat rather than fish led to a fat intake 
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rich in LA and poor in ALA. All of the previous points led to n‐3 EFAD especially in the 
 
American population (Holman, 1998). 
 
 
The ratio of LCPUFA n‐6:n‐3 is used to present n‐3 biostatus in addition to EPA+DHA 
(omega‐3 index) (Harris and Thomas, 2009). n‐6:n‐3 ratio would be decreased with diet 
high in EPA and DHA which found in Japanese participants (increased n‐3 and decreased 
n‐6) (Ogura et al., 2010). 
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2.10. History of Fatty acids analysis 
 
 
Through 1900s, fatty acids science was more sophisticated and had more achievement. 
Normann  patented his discovery of the conversion of unsaturated fatty acids or their 
glycerides into saturated compounds by hydrogenation (Normann, 1903). Morrison was 
the first to prepare FAME with described boron trifluoride (Morrison et al., 1964). 
 
It   was   the   first   time   when   Folch   described   the   isolation   of   phospholipids, 
phosphatidylserine  and  phosphatidylethanolamine  from  brain  (Folch,  1942).  Folch 
established the lipids extraction method that is still used by most laboratories. He used 
the mixture of chloroform/methanol (2/1 Vol) (Folch et al., 1957) 
 
Until mid 1940s, no method was established  yet to evaluate individual fatty acid in 
mixtures (Holman, 1998). Burr and his students were the first to work on the method to 
distinguish PUFA’s family. They measured the double bonds numbers by using alkaline 
isomerization  and  ultraviolet.  Via  this  method  they  found  the  lionleic  acid  was  the 
precursor of AA, that PUFA respond to fat intake, and finally that trienoic acid would be 
an index the EFA as its concentration increased (Burr and Holman, 1988). 
 
2.11. Analysis of fatty acids by Gas Chromatography 
 
 
Mikhail   Tswett   (a   Russian   botanist)   can   be   considered   the   first   who   applied 
chromatography to separate various plant pigments by passing solution through glass 
column on a chalk column in 1903. Afterwards, scientists tried to minimize the column 
sizes to increase the separated efficiency, till 1960 columns sizes reach as small as 3 to 
10 µm. then glass columns were replaced by stainless steel (Lin et al., 2009). 
 
 
James and Martin are considered the first to use and publish gas chromatography (GC) 
in assessing the underivatized fatty acids, they described the method of free fatty acids 
separation (from 1 to 12 C) (James and Martin, 1952), in later years they used shorter 
FAME form to assess fatty acids by GC (James and Martin, 1956; James and Wheatley, 
1956). However, Mohrhauer and Holman validated the EFA analyzing by GC method to 
40 
 
 
 
 
analyze  EFA  and  their  metabolic  products  in  liver,  with  the  alkaline  isomerization 
method. Results were the same which established all the old results from studies used 
the later method (Holman, 1998; Mohrhauer and Holman, 1963). 
 
The main three parts of the GC equipment are: 
 
 
• The instrument‐injector. 
 
• The column. 
 
• The detector. 
 
Through  those  three  parts,  fatty  acid  –in  the  past‐  might  lost  while  recently  such 
techniques are improved and losing problems are solved in which all the process being 
fully automated and computerized (Tvrzická et al., 2002). 
 
Analyzing fatty acids by GC involves main steps: lipid extraction from cells or tissue, 
methylation, then the injection into the GC (Ratnayake and Galli, 2009; Masoodet et al., 
2005; Kurik et al., 2006) which is called the conventional method. It is applied in most 
lipid analysis laboratories (Kang and Wang, 2004). 
 
However, there is an argument made about a simplified method in which the extraction 
(homogenate   using  organic  solvents)  is  combined  with  the  methylation.  This  has 
advantages such as saving time, materials and solvents, simple (easy to do), and can be 
used with dried or liquid small sample amount with large samples number. There is a 
study which has assessed the fatty acids profile in mouse heart tissue. Compareing the 
two methods (conventional method that  combine extraction before methylation and 
simplified method without prior extraction) has  concluded that the results from the 
simplified method is good. Also, It is more suitable for long chain PUFA ≥ 18 C. However, 
prior extraction is still needed for analyzing fatty acids from  Phospholipids (Kang and 
Wang, 2004). 
 
In another  study,  GC  technique  was  endeavoring  to  shorten  the  time  consumed  in 
analyzing  human plasma FAME. While the standard  method consume  approximately 
>70 minutes per sample, the adapted fast GC method reduces the time to <12 minutes 
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which  makes  it  more  reasonable  for  large  studies.  Nevertheless  24:1n9  would  be 
overlapped  with DHA thus this method is not appropriate for analyzing samples that 
contain those two fatty acids (Masood et al., 2005). 
 
TLC method is quite slow, time‐ and material‐wise comsuption (Kang and Wang, 2004). 
It can  oxidize  PUFA if exposed to air, thus it is not appropriate for large number of 
samples, it can also  generate organic waste and possible contamination which make 
cholesterol ester and phospholipid method inconvenient (Burdge et al., 2000). 
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3. Materials and methods 
 
3.1. Study design 
 
This study is a part of the Austrian Study on nutritional status and aimed to assess the 
essential fatty acids status at population level. The observational study included 140 
participants (69 female, 71 male). The mean age (years) at enrollment was 38.8 ± 11.1 
for the female, 37.8± 11.2 for the male. The mean body mass index (BMI) was 23.4 ± 
3.01 kg/m2   for the female and 24.53 ± 2.6 kg/m2   for the male. Dietary intakes were 
 
assessed by a 24h recall and  a food frequency questionnaire (FFQ). Fasting blood 
glucose (no  caloric intake within last 8 hours) ranges between 4‐6 mmol/l (60 ‐110 
mg/dl), it reflects normal  blood glucose. If the range goes higher than 110 mg/dl, it 
reflects hyperglycemia (Earl et al.,  2002) ranged from 6 to 11 mmol/l (Preissig and 
Rigby, 2010), while beneath 60 mg/dl it  reflects  hypoglycemia (Miller et al., 2001) 
similar to blood glucose ≤2∙2 mmol/l (Vlasselaers et al., 2009). 
 
The American Heart Association had established guidelines for triglyceride levels in 
which  Normal  range, low risk < 150 mg/dl (<1.7 mmol/l), borderline high 150‐ 199 
mg/dl  (1.7‐  2.2  mmol/l),  and  high  level  of  TG  when  higher  than  200  mg/dl  (>2.2 
mmol/L)(American Heart Association, 2010; Genest et al., 2009). 
3.2. Subjects characteristics 
 
Table 3.2.: Subject characteristics (age and BMI are shown as means ± SD) 
 
 
Total Female Male 
n 140 69 71 
Age (Years) 38.28 ± 11.13 38.8 ± 11.12 37.77 ±11.20 
BMI (kg/m
2
) 23.97 ± 2.86 23.4 ± 3.01 24.53 ± 2.6 
Smoking (Y) 
n  (% of sample) 
79 
(56%) 
35 
(51%) 
44 
(62%) 
Normal blood glucose (4‐6 mmol/l ) 
n  (% of sample) 
109 
(88%) 
54 
(78%) 
55 
(77%) 
Hypoglycemic blood glucose (< 2.2 
mmol/l) 
n  (% of sample) 
18 
(13%) 
11 
(16%) 
7 
(10%) 
Normal blood TG (<1.7 mmol/l) 
n  (% of sample) 
122 
(87%) 
65 
(94%) 
57 
(80%) 
Hyperlipidemia  (> 2.2 mmol/l) 
n  (% of sample) 
9 
(6%) 
2 
(3%) 
7 
(10%) 
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3.3. Analysis of fatty acids by Gas Chromatography 
 
Fatty acids pattern was analysed with gas chromatography (PERKIN Elmer, Vienna, 
Austria). Carrier gas was Helium and equipped with a 30m X 0.25 mm ID fused silica 
column (RTX‐2330) and a flame ionization detector (FID) which is a universal detector. 
Most nuitrition practisioners use capillary columns of 30m X 0.32 (or 0.25) mm length 
as it is adequate for analytic labour  (Ratnayake and Galli, 2009). The separation of 
FAME appears on the GC baseline according to the FA chain length, number of double 
bonds and their position (Tvrzická et al., 2002). 
The samples were  dissolved in 50 µl hexane (Vial: CHROMACOL C 821 UK; biolab 
Ges.m.b.H) and 1.0 µl was injected in the gas chromatography with 30:1 split flow with 
helium as a carrier gas.  The experiment time was 29.14 minutes, sampling rate was 
6.25000 pts/s and FAMEs were identified by FID which was 0.38 mV. FID is still used 
 
because of its reasonable price in comparison to mass spectrometric (Tvrzická et al., 
 
2002). The initial temperature was 90 deg, ramp 1 with 13/min to 155 C°, ramp 2 with 
 
2.9/min to  185  C°  and held for 5  min,  ramp  3  with  5/min  to  229 C°.  It  is worth 
mentioning  that  the  temperature  program  affect  the  resolution  of  all  interested 
components within suitable time (Tvrzická et al., 2002). 
The order of the fatty acids in the baseline depends on the numbers of carbon atoms 
and then the degree of unsaturation. The four or five double bonds are appeared after 
the SFA FAME, in addition PUFA n‐6 family appeared after PUFA n‐3 even if they have 
same carbon atoms number and double number (Tvrzická et al., 2002). 
The   methylation   was   controlled   by   methylating   Fatty   acid   supplement:   SAFC 
 
Biosciences F7050; 115K5410. Free Fatty Acids FFAs were identified with reference to 
standard mixture of known composition Standard ‐C37, Supelco analytic 18919‐1AMP; 
LB63416‐ is run on the same column under identical condition. The area % fatty acid 
compositions are calculated and all peak areas of the identified fatty acids were taken 
as 100%. 
Parameters Matrix Methods 
Fatty acids in whole blood Whole blood Methyl/ BF3; GC 
Fatty acids in Red Blood Cells Red Blood Cells Methyl/ BF3; GC 
Fatty acids in Plasma Plasma Methyl/ BF3; GC 
Fatty acids in Plasma Phospholipids Plasma TLC; Methyl/ BF3; GC 
Fatty acids in Plasma Cholesterol Ester Plasma TLC; Methyl/ BF3; GC 
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3.4. Overview of the parameters 
 
Table 3.4. Overview of the analysed parameters 
 
 
 
 
 
 
 
 
 
 
 
 
BF3= Boron trifluride methanol solution 14%, Methyl = Methanol for analysis, GC= Gas 
chromatography, TLC= Thin layer chromatography 
 
3.5. List of fatty acids analysed 
 
Table 3.5. List of fatty acids analysed (Adapted from Kornsteiner 2008) 
 
Fatty Acid abbr. common name systematic name 
14:0  Myristic acid Tetradecanoic acid 
15:0  pentadecanoic acid pentadecanoic acid 
16:0  Palmitic acid Hexadecaneoic acid 
17:0  Margaric acid Heptadecanoic acid 
18:0  Stearic acid Octadecanoic acid 
20:0  Arachidic acid Eicosanoic acid 
16:1n7  Palmitoleic acid cis9‐Hexadecenoic acid 
18:1n9 trans  Elaidic acid trans9‐Octadecenoic acid 
18:1n7 trans  trans‐Vaccenic acid trans11‐Octadecenoic acid 
18:1n9 Cis OA Oleic acid cis9‐Octadecenoic acid 
18:1n7 Cis  Vaccenic acid cis11‐Octadecenoic acid 
20:1n9  Gadoleic acid cis11‐Eicosenoic acid 
18:2n6 trans  Linolelaidic acid  
18:2n6 Cis LA Linoleic acid all‐cis9,cis12‐Octadecadienoic acid 
18:3n6 GLA γ‐Linolenic acid all‐cis6,9,12‐Octadecatrienoic acid 
20:2n6  Eicosadienoic acid all‐cis‐11,14‐eicosadienoic acid 
20:3n6 GDGLA Dihomo‐γ‐linolenic acid all‐cis8,11,14‐Eicosatrienoic acid 
20:4n6 AA Arachidonic acid all‐cis5,8,11,14‐Eicosatetraenoic acid 
22:4n6 DTAn‐6 Adrenic acid all‐cis7,10,13,16‐Docosatetraenoic acid 
18:3n3 ALA α‐Linolenic acid all‐cis9,12,15‐Octadecatrienoic acid 
20:5n3 EPA Timnodonic acid all‐cis5,8,11,14,17‐Eicosapentaenoic 
22:5n3 DPAn‐3 Docosapentaenoic acid all‐cis7,10,13,16,19‐Docosapentaenoic acid 
22:6n3 DHA Cervonic acid all‐cis4,7,10,13,16,19‐Docosahexaenoic acid 
20:3n9 MA Mead acid all‐cis11,14,17‐Eicosatrienoic acid 
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3.6. Calculations of the fatty acid indexes 
 
 
Table 3.6. Fatty acid indexes’ calculations. 
 
SFA 14:0 + 15:0 + 16:0 + 17:0 + 18:0 + 20:0 
Atherogenic SFA 14:0 + 16:0 
TFA 18:1n9t + 18:1n7t + 18:2n6t 
Atherogenic FA 14:0 + 16:0 + TFA 
Cis‐MUFA 16:1n7 + 18:1n9c + 18:1n7c + 20:1n9 
Total‐MUFA 16:1n7 + 18:1n9c + 18:1n7c + 20:1n9 + 18:1n9t + 18:1n7t 
 
Cis‐PUFA 
18:2n6c + 18:3n6 + 20:2n6 + 20:3n6 + 20:4n6 + 22:4n6 + 18:3n3 + 20:5n3 + 22:5n3 + 22:6n3 
+ 20:3n9 
 
Total‐PUFA 
18:2n6c + 18:3n6 + 20:2n6 + 20:3n6 + 20:4n6 + 22:4n6 + 18:3n3 + 20:5n3 + 22:5n3 + 22:6n3 
+ 20:3n9  + 18:2n6t 
USFA Cis‐MUFA + Cis‐PUFA 
LCP‐n 6 20:2n6 + 20:3n6 + 20:4n6 + 22:4n6 
LCP‐n 3 20:5n3 + 22:5n3 + 22:6n3 
n3 index 20:5n3 + 22:6n3 
n‐6 20:2n6 + 20:3n6 + 20:4n6 + 22:4n6 + 18:2n6c + 18:3n6 
n‐3 20:5n3 + 22:5n3 + 22:6n3 + 18:3n3 
n‐7 16:1n7 + 18:1n7t + 18:1n7c 
n‐9 18:1n9t + 18:1n9c + 20:1n9 + 20:3n9 
LA/ ALA 18:2n6c / 18:3n3 
Holman Index 20:3n9 / 20:4n6 
n3 HUFA score LCPn‐3 /  LCPn‐3+LCPn‐6 
 
 
 
3.7. Reagents 
 
 
• Methanol: Methanol for analysis, AMSURE. 1.06009.2500. 
 
• Standard fatty acid supplement: SAFC Biosciences F7050; 115K5410. 
 
• Sodium hydroxide: Riedel‐ de. Haën 06203. 
 
• n‐Hexane p.a. MERK KGaA 1.04367.2500. 
 
• Chloroform p.a. MERCK KGaA 1.02445.2500. 
 
• 2,6‐Di‐tert‐butyl‐p‐cersol (BHT) Butylated Hydroxytoluene  SIGMA  B‐1378 [128‐37‐0]. 
 
• BF3  Boron trifluride methanol solution 14% SIGMA B‐1252; Batch 078K5301. 
 
• Diethyl ether: ANALAR NORMAPUR 23811.326. 
 
• Heptane (Petroleum)  Riedel‐ de. Haën 32287. 
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• Acetic acid 99.8% SIGMA‐ ALDRICH 33209. 
 
• 11  mM  tris‐buffer  pH  7.6:  4  g  tris‐(hydroxymethyl)‐aminomethan  (Riedel‐de  Haën 
 
33742) are dissolved in 3000 ml demineralized water. 
 
• Cholesterol analytic calibration standard for GC, Serva CAS. No. 57‐88‐5. 
 
• MeOH  extracting  agent:  50  ml  Mehtanol+  3mg  BHT+1g  NaOH;  for  45  minutes  in 
ultrasonic bath. 
• Folch extract : Chloroform p.a.: Methanol p.a. 2:1 v:v + 50mg BHT. 
 
3.8. Equipments 
 
• Drier: CAMAG TLS Plate Heater III  CERAN SCHOTT ; cat: 022.3306 ; ser no: 121102. 
 
• TLC: CAMAG ; cat: 022.7808; ser no: 121027 LINOMAT 5 . 
 
• Freezer: SANYO model: MDF‐U53V; serial no: 09080772. 
 
• TLC Plates: Silica gel 60 F254  glass plates 20X20 cm, MERCK 1.05715.0001 HX 953371. 
 
• Vial: CHROMACOL C 821 UK; biolab Ges.m.b.H. 
 
• Needles: HAMILTON 1750 LTN; ga 22/51 mm/pst 2 ) 500 µl; P/N 8121 7/01; WO: 
 
137422. 
 
• Technospin Sorvall Centrifuges Instruments DU PONT. 
 
• Champers. 
 
 
3.9. Analyzing Fatty Acids from different tissues/systems 
 
3.9.1. Preparation and methylation 
 
In general, analyzing fatty acids from body tissues goes through 3 main steps: tissue 
preparation  to extract the lipids, transformation  the derivatives lipids to fatty acid 
methyl esters (FAMEs) (KANG and WANG, 2004), and then to detect fatty acids profile 
usually GC is used to analyze FAMEs (Ratnayake and Galli 2009). The method from the 
five systems resembles each other starting from the second step. However, extracting 
the lipids from the tissues and cells differ according to the system nature. 
Venous blood was drawn from the participants after an overnight fast into a tube with 
EDTA (as anticoagulant) and transferred to the institute laboratory in a locked dry ice 
box to avoid any  enzymatic lipolysis. From each participant; 100 µl of whole blood, 
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400 µl of plasma (300 µl in separated cup for CE and PL and 100 µl for total plasma), 
and 200  µl   of   erythrocyte  packed  cells  were  filled  in  cups  labelled  with  the 
participant’s ID number and stored in a ‐80 C0 freezer. During the analysis phase, cups 
were taken out from the freezer and  liquefied by hand temperature. Samples were 
saponified with 1 ml NaOh in methanol for 5 minutes at 100 C0  boiled water bath then 
fatty acids were methylated using 1 ml BF3  at 100 C
0  boiled water bath for 5 minutes 
then extracted with Hexane. A new bottle of BF3‐MeOH reagent; in  about weekly 
basis; was used to avoid any artifact production to prevent the loss of HUFA as the 
BF3‐MeOH has a limit shelf life even when refrigerated (Ratnayake and Galli, 2009). 
 
 
MeOH extract agent (50ml Methanol/1gNaOH/3mg BHT) was used for the analysis of 
fatty acids  by the method of (Folch et al., 1957). BHT is believed to minimize fatty 
acids  oxidation  (Bailey‐Hall,  2008).  Fatty  acids  were  transmethylated  by  alkaline 
methanolysis (1 ml) using the  BF3 (1 ml) reagent kit. However NaOH salt alters the 
lipids distribution and eradicates them from the upper phase while in the absence of 
it; lipids might be lost during washing (Folch et al., 1957). The antioxidant 2,6‐Di‐tert‐ 
butyl‐p‐cersol (60mg/l) was added to the MeOH to prevent the USFAs oxidation. 
 
 
Fatty acid methyl  esters (FAMEs) were  washed  and extracted with 500 µl Hexane 
(enhancing the efficiency of fatty acid methylation) (Araujo et al., 2008). The resulting 
assortment separated into two phases. The lower phase is the total pure lipids extract 
(Folch et al., 1957). The hexane upper layer was transferred to a new glass tube and 
evaporated  with  nitrogen  (N2)  then   FAMEs   were  ready  to  be  resolved  by  gas 
chromatography. The extracts  were  dissolved  with  50 µl hexane  and  flushed with 
nitrogen  then  stored  in  the  labelled  GC  Vials  (CHROMACOL   C   821  UK;  biolab 
Ges.m.b.H)  at  ‐80  C0    for  up  to  3  months  prior  to  GC  analysis  for  the  fatty  acid 
 
composition. 
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3.9.2. Extracting Fatty Acids Methyl Ester from venous whole 
blood 
A 35 µl of whole blood were transferred to glass tube and transmethylated using the 
method of Jordi Folch directly from the venous blood tubes to detect the fatty acids 
profile (Folch et al.,  1957). However, using BF3/MeOH FAME method transesterified 
TG thus it is appropriate for analyzing whole blood fatty acids (Bailey‐Hall et al., 2009). 
The CVs for the major fatty acids in  whole blood were as follows: 2.09% for 16:0, 
3.71% for 18:0, and 5.48 % for cis 18:1n–9, 3.82% for 18:2n–6, 5.06% for 20:4n–6, 
 
9.94% for 18:3n–3, 4.81% for 20:5n–3, and 5.73% for 22:6n–3. 
 
 
 
3.9.3.  Extracting Fatty Acids Methyl Ester from plasma 
 
 
Plasma was immediately separated from erythrocytes by centrifugation at 4000 rpm 
at room temperature for 10 minutes. A 35 µl of the sample were transferred to glass 
tube and transmethylated by the method of Jordi Folch (Folch et al., 1957). The CVs 
for the major fatty acids were as follows: 2.13% for 16:0, 1.86% for 18:0, 6.85% for cis 
18:1n–9, 3.37% for 18:2n–6, 5.10% for 18:3n–3, 7.08% for 20:5n–3, and 4.04% for 
 
22:6n–3. 
 
 
 
3.9.4.  Extracting Fatty Acids Methyl Ester from erythrocytes 
 
As  mentioned  above;  plasma  was  immediately  separated  from  erythrocytes  by 
centrifugation at 4000 rpm at room temperature for 10 minutes. Then erythrocytes‐ 
packed cells  (1.5 g) were treated with 11mM tris‐buffer. Erythrocytes packed cells 
were washed 3 times with an EDTA ‐containing saline solution to remove white cells 
and  plasma  contamination  (Bailey‐Hall  et  al.,  2008).  A  35  µl  of  the  sample  were 
transferred to glass tube and transmethylated by the method of Jordi Folch (Folch et 
al., 1957). 
49 
 
 
 
 
The CVs for the major fatty acids were as follows: 2.62% for 16:0, 2.41% for 18:0, 2.01 
 
% for cis 18:1n–9, 3.75 % for trans 18:1n–9, 2.22 % for 18:2n–6, 2.76% for 20:4n–6, 
 
4.11% for 18:3n–3, and 4.94% for 22:6n–3. 
 
 
 
3.9.5. Extracting Fatty Acids Methyl Ester from plasma 
phospholipids and plasma cholesterol ester 
 
Plasma  phospholipids  and  plasma  cholesterol  ester  were  extracted  from  blood 
plasma.  The   Isolation  of  the  lipids  classes  were  completed  by  TLC  (thin  layer 
chromatography).  However,  TLC  considered  as  the  most  convenient  technique  for 
small  amount  of  lipids  components  isolation  and  to  achieve  excellent  separation 
(Ratnayake and Galli, 2009). Separation can be achieved by 1 dimensional TLC in single 
run using mobile phases consisting of a mixture of Petroleum and diethyl ether with 
acetic acid. 
 
 
The lipids were extracted from 200µl Plasma by mixing the sample with 5ml Folch 
extract. The mixture was shacked in cool dark room for 1 hour. After centrifuged on 
4000 rpm for 15 minutes; upper layer was abated while the waste shifts to the base of 
the tube. The extract was evaporated with nitrogen (N2) gas in warm bath (40 C0) and 
the lipids were re‐dissolved in 100µl chloroform. 
 
 
However;  500µl  of  plasma  were  trailed  with  5ml  of  extract;  the  shake  mixtures 
outcome was not clear, harder to be abated with very high FFA concentration in the 
GC baseline. Therefore 200µl Plasma was used in this method. 
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500µl of plasma 200µl of plasma 
 
 
 
Fig 3.9.5. Lipids extracted from plasma by Folch extract. 
 
 
 
TLC was performed by using Silica gel 60 F254 glass plates 20X20 cm from MERCK. 
First  the  plates  were  activated  with  70  ml  methanol  in  the  chamber for  1hr  and 
15minutes. Standards and aliquots of the lipid extract were applied as narrow bands 
(0.5 cm in length) on the plate. During the sample injection and application; a flow of 
nitrogen was blown across the injection point to facilitate the spotting of a tight lipid 
band. Six samples were spotted per plate (1.5 cm space); though, 12 and 9 samples 
could be trailed per plate; but encountered CE separations materialized. 
 
 
Meanwhile the extraction chamber is activated by a modified solvent system of (85ml 
Petroleum+  15ml  diethyl  ether  +  2ml  acetic  acid)  for  35  minutes.  Solvent  system 
separated the sum of sphingo‐ and phospholipid fraction from the cholesterol fraction 
(Kornsteiner 2008). The plate with the injected samples was placed in the extraction 
chamber for 35 minutes in order to apply the  phospholipids and cholesterol ester 
extraction from the lipids. The PL and CE fractions were  made visible under iodine 
vapor. Lipids bands were identified by co‐migration with standard phospholipids and 
standard cholesterol ester and quantified under identical conditions. 
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The phospholipids and cholesterol ester fractions were scraped into separate labelled 
test tubes for the preparation of fatty acid methyl esters process. Each phospholipid 
and cholesterol ester sample was then esterified in the presence of methanolic NaCl/ 
BF3  and analyzed by gas ‐liquid chromatography. 
 
 
The CVs for the major fatty acids were as follows for  phospholipids: 6.97% for 16:0, 
 
5.32% for 18:0, 9.63% for 18:2n–6 cis, 7.95% for 18:2n‐6 trans, 9.20% for 20:4n–6, 
 
9.13% for 18:3n–3, 7.8% for 20:5n3. 
 
 
 
Additionally for  cholesterol ester: 7.67% for 16:0, 4.94% for 18:0, 10.85% for 18:2n–6 
 
cis, 7.98% for 18:2n‐6 trans, 9.7% for 20:4n6, 10.25% for 18:3n–3, 11.68% for 20:5n–3. 
 
 
 
Table 3.9. Summary for the main steps in analyzing: 
 
Sample/tissue Sample µl Me/NAOH 
ml
 
BF3/ml Extraction 
(ml)/N2
 
Dissolved 
µl Hexane
 
Whole Blood
 
35
 
1
 
1
 
2 (4x0,5)
 
50
 
Erythrocytes 35 1 1 2 (4x0,5) 50 
Plasma 35 1 1 2 (4x0,5) 50 
Fatty acid 
supplement 
15 1 1 2 (4x0,5) 50 
Phospholipids/ 
Cholesterol 
ester 
200 µl of 
the sample 
in 5 ml 
Folch 
extraction 
1 1 2 (4x0,5) 50 
 
 
3.10. Statistical analysis 
 
All statistical analyses were implemented by using version 17.0 of the SPSS statistical 
package.  GC  computer  program  for  fatty  acids  integration  was  performed  using 
version 6.3.0.0445 TotalChrom Workstation; PerkinElmer. Fatty acids’ Area [µV.s] from 
the Chromatogram were  completed and calculated by using Microsoft ®Office Excel 
2007 (12,0,4518,1014) MSO (12,0,4518,1014). 
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Student’s T‐Test was used to calculate the correlation between normal distribution 
values   while   Mann‐Whitney‐U‐Test   to   calculate   correlation   of   the   un‐normal 
distribution values. P‐values were considered as significant for p < 0.05. 
 
 
Partial Spearman’s rank‐correlation coefficients were calculated for the influence of 
BMI, age, gender, and smoking status on the fatty acids profile. Normally this Partial 
correlation can only be carried out with normal FA distribution. Explanatory variables 
were either continuous (age (y), body mass index (BMI kg/m2) or categorical (Gender 
(Male\Female), smoking (Y\N), blood glucose (normal, hyperglycemia and 
hypoglycemia),  triglyceride  (normal/  hyperlipidemia).  To  compare  the  continuous 
covariates  between  levels   of   the  categorical  factors,  two  sample  t‐tests  were 
performed, whilst associations between  the categorical factors were assessed using 
Pearson's  correlations  for  the  normal  distribution   and  Spearman  nonparametric 
coefficient correlation. 
 
 
 
For  each  of  the  whole  blood,  RBC,  plasma,  plasma  phospholipids  and  plasma 
cholesterol  ester  fatty  acids,  the  mean  and  two  standard  deviations  (2  SD)  were 
tabulated after checking  that the distribution of each fatty acid was approximately 
normal. Pearson's correlation was used to assess the relation between the FAs index 
in  the  5  different  methods.  Spearman  rank  correlation  coefficient  was  of  similar 
degree and was used to determine the strength of the association. 
 
The aim of the study is two‐fold: first, to find the best blood component for essential 
fatty acids  analys; and second, to assess the essential fatty acid status in the tested 
population. 
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4. Results 
 
 
Data on the range of the fatty acids contents of whole blood, RBC, plasma, plasma 
phospholipids  and  plasma  cholesterol  ester  of  140  Austrian  healthy  adults.  This 
present  study  attempts to find the most appropriate method for a large number of 
samples that: 
• Gives an accurate fatty acid profile (especially essential fatty acids in concern), 
 
• Is easy‐to‐do (may not require professional workers), 
 
• And consumes less time, less material, less agents and less sample size. 
 
 
 
4.1. Fatty  acids  in  whole  blood,  red  blood  cells,  plasma,  plasma 
cholesterol ester, plasma phospholipids 
 
Of the 140 blood samples; 120 WB samples, 131 RBC samples, 131 plasma samples, 
 
128 CE samples and 117 PL samples were analysed. Same ID of the blood samples 
were matched through the five blood components. 24 fatty acids were analysed and 
their means are tabulated in the next table. 
 
Table 4.1. Fatty acids of whole blood, red blood cells, plasma, plasma cholesterol ester, 
and plasma phospholipids (mean ±SD). 
 
% of total fatty acids 
 
Fatty Acid 
 
WB 
 
RBC 
 
Plasma 
 
CE 
 
PL 
Total n= 120 total n=131 total n= 131 Total n=128 total n=117 
14:0 0.65 ± 0.28 0.21 ± 0.07 0.88 ± 0.36 0.83 ± 0.26 0.46 ± 0.15 
15:0 0.42 ± 0.22 0.30 ± 0.14 0.38 ± 0.18 1.00 ± 0.53 0.78 ± 0.24 
16:0 21.54 ± 1.83 19.35 ± 1.28 23.03 ± 2.42 12.51 ± 1.25 31.0 ± 3.13 
17:0 0.30 ± 0.06 0.34 ± 0.13 0.30 ± 0.08 0.19 ± 0.12 0.65 ± 0.19 
18:0 11.41 ± 1.08 19.82 ± 1.14 7.63 ± 0.95 1.69 ± 0.81 19.84 ± 3.08 
20:0 0.17 ± 0.08 0.21 ± 0.06 0.11 ± 0.07 0.09 ± 0.10 0.23 ± 0.19 
16:1n7 1.54 ± 0.54 0.40 ± 0.11 2.12 ± 0.70 2.63 ± 1.04 0.69 ± 0.20 
18:1n9 trans 0.18 ± 0.07 0.22 ± 0.06 0.15 ± 0.05 0.25 ± 0.17 0.17 ± 0.05 
18:1n7 trans 0.22 ± 0.08 0.24 ± 0.07 0.17 ± 0.07 traces 0.24 ± 0.08 
18:1n9 Cis 19.21 ± 1.85 14.13 ± 0.91 21.04 ± 2.59 18.37 ± 2.20 8.72 ± 1.72 
18:1n7 Cis 1.59 ± 0.21 1.32 ± 0.15 1.69 ± 0.25 1.21 ± 0.37 1.47 ± 0.29 
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Fatty Acid WB RBC Plasma CE PL 
20:1n9 0.36 ± 0.10 0.43 ± 0.10 0.33 ± 0.14 0.11 ± 0.08 0.21 ± 0.19 
18:2n6 trans 0.12 ± 0.06 0.12 ± 0.09 0.13 ± 0.11 0.23 ± 0.18 0.21 ± 0.19 
18:2n6 Cis 22.57 ± 2.37 10.34 ± 1.11 28.11 ± 3.61 49.47 ± 3.39 18.41 ± 2.44 
18:3n6 0.31 ± 0.10 0.08 ± 0.08 0.43 ± 0.14 0.88 ± 0.32 0.15 ± 0.09 
20:2n6 0.31 ± 0.07 0.34 ± 0.07 0.29 ± 0.13 0.34 ± 0.27 0.68 ± 0.20 
20:3n6 1.86 ± 0.37 2.08 ± 0.42 1.72 ± 0.39 0.82 ± 0.22 2.61 ± 0.85 
20:4n6 10.60 ± 1.49 17.23 ± 1.28 7.19 ± 1.46 6.39 ± 1.60 9.64 ± 1.57 
22:4n6 1.29 ± 0.40 3.94 ± 0.66 0.36 ± 0.29 0.75 ± 0.51 0.29 ± 0.24 
18:3n3 0.47 ± 0.18 0.18 ± 0.06 0.66 ± 0.17 0.62 ± 0.18 0.21 ± 0.07 
20:5n3 0.71 ± 0.27 0.72 ± 0.25 0.73 ± 0.35 0.64 ± 0.33 0.58 ± 0.30 
22:5n3 1.26 ± 0.24 2.77 ± 0.45 0.56 ± 0.17 0.17 ± 0.13 0.82 ± 0.29 
22:6n3 2.77 ± 0.64 5.10 ± 1.00 1.82 ± 0.52 0.74 ± 0.37 1.80 ± 0.58 
20:3n9 0.14 ± 0.05 0.13 ± 0.05 0.16 ± 0.07 0.08 ± 0.04 0.14 ± 0.05 
SFA 34.48 ± 1.70 40.23 ± 1.51 32.33 ± 2.61 16.31 ± 1.81 52.95 ± 3.37 
TFA 0.52 ± 0.16 0.59 ± 0.16 0.46 ± 0.17 0.47 ± 0.28 0.62 ± 0.23 
Atherogenic FA 22.71 ± 2.08 20.14 ± 1.35 24.37 ± 2.71 13.82 ± 1.32 32.08 ± 3.04 
∑ MUFA 23.10 ± 2.15 16.75 ± 0.94 25.51 ± 2.91 22.57 ± 2.92 11.51 ± 1.94 
∑ PUFA 42.42 ± 3.05 43.02 ± 1.65 42.17 ± 4.17 61.11 ± 3.02 35.54 ± 2.56 
USFA 64.99 ± 1.77 59.18 ± 1.56 67.21 ± 2.66 83.21 ± 1.90 46.43 ± 3.43 
PUFA/SFA 1.23 ± 0.14 1.07 ± 0.07 1.32 ± 0.21 3.78 ± 0.50 0.67 ± 0.09 
USFA/SFA 1.89 ± 0.14 1.47 ± 0.09 2.10 ± 0.24 5.17 ± 0.64 0.88 ± 0.12 
LCP n6 14.06 ± 1.77 23.59 ± 1.70 9.56 ± 1.55 8.29 ± 1.66 13.22 ± 1.77 
LCP n3 4.74 ± 0.91 8.59 ± 1.33 3.12 ± 0.82 1.55 ± 0.58 3.20 ± 0.76 
∑ LCPUFA 18.80 ± 2.14 32.18 ± 1.84 12.68 ± 2.00 9.85 ± 1.92 16.42 ± 1.95 
∑ n3 5.21 ± 0.91 8.76 ± 1.34 3.31 ± 0.82 2.17 ± 0.62 3.41 ± 0.77 
∑ n6 36.94 ± 2.83 34.00 ± 1.72 38.23 ± 3.98 58.64 ± 3.09 31.78 ± 2.58 
∑ n7 3.35 ± 0.63 1.96 ± 0.20 3.99 ± 0.79 3.84 ± 1.10 2.41 ± 0.38 
∑ n9 19.89 ± 1.87 14.91 ± 0.93 21.68 ± 2.60 18.81 ± 2.22 9.24 ± 1.74 
n6/n3 7.29 ± 1.34 3.99 ± 0.72 3.22 ± 0.77 29.31 ± 8.56 9.81 ± 2.41 
n3/n6 0.14 ± 0.03 0.26 ± 0.05 0.33 ± 0.08 0.04 ± 0.01 0.11 ± 0.03 
LA/ALA 52.51 ± 15.84 64.33 ± 21.74 45.64 ± 13.21 85.99 ± 22.13 97.01 ± 32.11 
AA/ EPA 16.94 ± 6.32 26.79 ± 9.00 11.59 ± 4.72 1.83 ± 2.43 22.69 ± 16.17 
DPA/ DHA 0.48 ± 0.13 0.56 ± 0.14 0.33 ± 0.12 0.28 ± 0.26 0.50 ± 0.24 
Omega 3 index 3.48 ± 0.80 5.82 ± 1.13 2.55 ± 0.74 1.38 ± 0.56 2.38 ± 0.71 
Holman Index 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.21 ± 0.25 0.02 ± 0.01 
n3 HUFA score 0.25 ± 0.04 0.27 ± 0.04 0.25 ± 0.05 0.16 ± 0.05 0.20 ± 0.04 
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Fatty acid  values  of  different  blood  components  have  been  found  different  due  to 
variation in the concentration of the FFA, PLs and steryl esters (Bailey‐Hall, 2008). 
 
The most abundant family of fatty acids in all fractions was PUFAs except for PL where 
more than half of the fatty acids were saturated (52.95 %). In WB, RBC and plasma the 
second abundant FAs  family was SFA followed by MUFA, while  CE fraction was the 
poorest in SFAs. 
 
4.1.1. Saturated Fatty Acids SFA 
 
 
PL fraction was the richest in SFAs as palmitic acid alone was approximately one third 
(31.0%) of the total fatty acids and Stearic acid was around 20% (19.84%). Among all FAs 
in  Plasma  PL,  palmitic  acid  (16:0)  was  the  highest  proportion  (Ogura  et  al.,  2010). 
However, RBC was the poorest in palmitic acid. It was noticed that plasma CE had the 
lowest of the Stearic acid (1.69%) which was  extremely different from the highest for 
the same FA in RBC and PL (19.82% and 19.84%, respectively). However; the presence of 
C 18:0 was higher in WB than in plasma (11.41% vs. 7.63%). CE was the poorest fraction 
in SFA (16 %). 
 
4.1.2. Cis Monounsaturated Fatty Acids 
 
 
PL fraction was the poorest in MUFA’s family, because oleic acid was very low (8.72%) 
while in other fractions its level was in close range. Oleic acid (18:1n9) predominant in 
CE in comparison to PL and RBC (Riséa et al., 2007). Palmitoleic acid (16:1n7) in RBC was 
the lowest in comparison to  other  fractions followed by PL (0.4%, 0.69% respectively) 
while  in  CE  was  the  highest  followed  by  plasma  then  WB  (2.63%,  2.12%,  1.54% 
respectively). 
 
4.1.3. n‐6 Polyunsaturated Fatty Acids 
 
 
Amongst the tested systems, CE fraction was the richest in n‐6 fatty acids as more than 
 
58% of total fatty acids in CE were n‐6 PUFA. LA concentrations are the highest in CE 
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(Arab, 2003) which was confirmed by our results; it was close to become half of all the 
fatty  acids  presence  (49.47%).  However,  the  lowest  LA  content  was  found  in  RBC 
(10.34%). A study done by Riséa in 10 healthy subjects showed that plasma is known to 
have a higher level of LA than in RBC while AA, DTAn‐6 and DPAn‐6 is higher in RBC than 
in plasma (Riséa et al., 2007) which is shown in this study’s obtained results. 
 
Although the level of 18:3n6 is low in all analysed fractions (<1.0%), the lowest was 
found in RBC (0.08%) while the highest found in CE (0.88%). AA was the highest in RBC 
(17.23%) while the lowest in CE (6.39%), plasma’s level was close to CE’s (7.19%), WB 
(10.6%) and PL (9.64%). The presence  of  n‐6 was highest in CE (58.64%), lowest in PL 
(31.78%). 
4.1.4. n‐3 Polyunsaturated Fatty Acids 
 
 
ALA was higher in plasma and CE as compared to other analysed fractions (0.66% and 
 
0.62%, respectively) such as RBC (0.18%) and PL (0.21%). Usually ALA concentration in 
PL is not more than 0.5% (Holman, 1998). No trace for ALA in RBC (Riséa et al., 2007), in 
our results RBC had the lowest percentage of ALA. 
 
RBC were  the richest  while  CE  had  the lowest  level  of  DHA level (5.1% vs. 0.74%). 
However;  DHA  was  higher  than  EPA  in  all  analysed  fractions.  Long  term  intake  of 
vegetable oils that contain a high level of ALA and a low level of LA would increase the 
DHA levels in blood (Ratnayake and Galli, 2009). Plasma and RBC concentration of DHA 
is a better indicator of fish and n‐3 intake than is EPA because the latter is affected by 
some factors. EPA is mobilized faster form the  adipose  tissue than DHA (Sun et al., 
2008). 
 
 
EPA  presence  in  WB,  RBC,  and  plasma  were  similar  (0.71%,  0.72%,  and  0.73%, 
respectively).  For DPA, the richest fraction was RBC (2.77%) followed by WB (1.26%), 
while the lowest was CE  fraction (0.17%). DPA (22‐5n3) level in the tissue reflect the 
overall  metabolic  pathway  because   it   mediates   the  conversion  of  EPA  to  DHA 
(Ratnayake and Galli, 2009). 
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In regards to omega 3, the highest was found in RBC (8.76%), followed by WB (5.21%) 
and  the  lowest  in  plasma  CE  (2.17%)  which  confirms  the  idea  of  that  WB  might 
substitute the RBC as test system for an omega‐3 indicator. n‐3 HUFA score were very 
close and in similar range in WB,  RBC, Plasma, PL (0.25, 0.27, 0.25, 0.20 respectively) 
while  in  CE  the  ratio  was  lower  (0.16%).  n‐3  HUFA  (in  the  total  HUFA  pool)  was 
considered  to  be  the  tissue  biomarker  of  blood  omega‐3   fatty  acids.  It  showed 
constantly (low variable) and strong correlation with animal tissues (Stark 2008). From 
our data, n‐3 HUFA were similar in WB, RBC, plasma followed by PL while it was lower in 
CE. 
 
4.1.5. Omega‐3 Index 
 
Omega‐3 index was the highest in RBC (5.82%) followed by WB (3.48%), plasma (2.55%) 
and PL (2.38%) while the lowest was found in CE (1.38%). This supports that RBC would 
be the best compartment to establish omega‐3 index followed by WB. 
 
4.1.6. n6/n3 ratio 
 
According to the high concentration of n‐6 FAs in plasma CE thus the highest ratio of 
n6/n3 was  in  CE while the lowest was found in plasma and RBC (3.22 and 3.99). Vice 
versa holds for the lowest value of the ratio of n3/n6 was in CE while the highest found 
in plasma followed by RBC  (0.33  and 0.29). 4:1 was the suggested ratio of n6:n3 for 
optimal functional by Yehuda and Carasso (Holman, 1998; Yehuda and Carasso, 1993). 
 
AA/EPA+DHA might be used as an indicator of n‐6/n‐3 status which  showed  a high 
correlation  between capillary WB, RBC and PL (Bailey‐Hall et al., 2009). Differences in 
n6/n3 ratio would highly increase cell membrane composition of AA concentration and 
slightly EPA,  consequently  increase  the production  of  eicosanoids  and  inflammatory 
mediators (Adams et al., 1996). A high n6/n3  ratio in plasma inversely correlates with 
health consequences which can be corrected by either increase the dietary n‐3 intake 
and/or decrease n‐6 intake (Harris et al., 2006). High n3/n6 ratio  was correlated with 
low incidence of the cancer mortality (Adams et al., 1996). Low n3/n6 ratio might be an 
index for the risk of cognitive impairment and dementia (Heude et al., 2002). 
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4.1.7. n‐7, n‐9 Polyunsaturated Fatty Acids and Holman Index 
 
 
The lowest n‐7 was found in RBC, while the lowest for n‐9 was found in PL. For the mead 
acid (an index of EFAD concentrations), levels were similar in WB, RBC, plasma, PL while 
in CE the concentration was lower (0.08%). Usually 20:3n9 (Mead Acid) has a very low 
concentration makes it  difficult to be detectable (Strijbosch et al., 2008) and it’s an 
indication  of  the  EFAD  if  elevated  (Holman,  1970).  Holman  index  in  RBC,  WB,  and 
plasma were  equal while  the highest found in  CE  (0.21). None  of the five fractions 
showed any EFAD laboratory signs as Holman index was ≤ 0.2. 
 
Holman has published that triene/tetraene ratio of > 0.2 to be abnormal and EFAD ratio 
is greater than 0.4 in PL fraction (Holman, 1960; Holman et al., 1979). Holman index is 
being used as a predictor of EFAD especially with the EFAD clinical signs such as growth 
retardation (Strijbosch et al.,  2008) and it was suggested to consider 20:3n9/20:4n6 > 
0.2 as cutoff point for the EFAD diagnosis (Jeppesen et al., 1998). The Holman index 
which  used   to  be  called  (triene‐to‐tetraene)  in  previous  works,  is  considered  to 
determine the fat  deficiency status in rats, swine and other species (Mohrhauer and 
Holman, 1963). 
 
4.1.8. Total Polyunsaturated Fatty Acids 
 
 
CE fraction was the richest in PUFA family. LA and ALA have the strongest correlation 
with dietary intake because those PUFAs are derived only from diet (Popitt et al., 2005). 
LA/ALA ratio was massively highest in PL (97.01) followed by CE (85.99) which might be 
explained to the high of LA in PL and CE. LA/ ALA ratio intake should be 14:1 for equal 
metabolized competitive (Holman, 1998).  However; LA/ALA and ALA levels affect the 
conversion of ALA to its derivatives (Ratnayake and Galli, 2009). 
 
The highest content of PUFAs (cis and total) was found in CE while the lowest was in PL. 
However, WB, RBC and Plasma were very similar, but the SD in RBC is the lowest which 
might  be  explained  by  the  long  term  dietary  intake  reflection  and  low  biological 
variability. WB and Plasma SD  were higher than the RBC SD (plasma SD is also higher 
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than WB SD) which also be explained by the short term dietary intake variation (and 
individual variations). 
 
The highest level of the USFA were found in CE (83.21%), WB and plasma were in close 
range  (64.99%, 67.99%), not far RBC (59.18%) while PL had the lowest (46.43%). For 
LCPUFA, RBC had  the highest concentration (32.18%) while the lowest was found in 
plasma CE (9.85%). However, sum of LCPUFA in WB, PL and Plasma somehow in close 
average (18.8%, 16.42%, and 12.68%). LCPUFA ’correlations are the main consideration 
in  most  studies  since  they  indicate  the  dietary  intake  of  them  (as  they  are  not 
biosynthesized in vivo) (Bailey‐Hall et al., 2008). 
 
DPA/ DHA ratio in RBC and PL were similar (0.56, 0.5) and it was low in CE (0.28). 
AA/EPA ratio was higher in RBC followed by PL (26.79, 22.69) while it was extremely low 
in CE (1.83). Plasma PL AA/EPA showed to have correlations with some chronic disorders 
and positively with clinical  symptoms of depression while the AA/DHA ratio showed 
correlation with neuroticism (Holub  2009).  AA/EPA level would reflect the depression 
grade. In plasma PL; AA/EPA ratio was strongly correlated with the Hamilton depression 
rating scale (Adams et al., 1996). 
 
HUFA (20‐ to 22‐ carbon fatty acids with 3 to 6 double bonds) are precursors for the 
eicosanoids. In fish eating, eicosanoids derived from EPA while in non‐fish eating they 
are derived from AA.  Thus  the AA/EPA ratio affects the biochemical and physiological 
responses to stress (Harris et al., 2006). In our results, RBC would be a good indicator as 
it shows the highest ratio followed by PL and not from plasma CE. 
 
AA/homo‐g‐LA  is  considered  as  an  index  for  the  ∆5  desaturase  enzyme  which  is 
responsible to insert the double bond to the ninth carbon starting from the COOH side. 
AA/LA  (product/precursor) is an index for the AA metabolic pathway activity (Lewis‐ 
Barbed et al., 2000).  The plasma P/S ratio indicates the risk of death from coronary 
heart disease (Anderson et al., 2009) since it reflects the double bond index (Lepage et 
al., 1989). Since the PUFA was the highest  among CE thus the P/S ratio was also the 
highest in CE fraction, while the lowest was in PL since the SFA was predominant. 
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4.1.9. trans Fatty Acids TFA 
 
 
Trans fatty acids were the highest in plasma PL (0.62%). Atherogenic SFA was found to 
be the  highest in PL followed by plasma and WB while the lowest concentration was 
found in CE. 
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4.2. Comparison between fatty acids composition from our data and 
other studies 
Our results of the five different blood components were compared with other studies 
which  analysed  same  blood  components  and  using  the  same  method.  Our  results 
appear in the range of the other studies outcomes. 
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4.2.1. Comparison between fatty acids composition in whole 
blood 
 
The percentage of total analysed fatty acids in WB from our results are mentioned in 
table (4.2.1.)  in order to compare our results with other studies that used WB and 
same analysing method as  well. Number of subjects from our data was 120 mixed 
genders (male and female) and the number of analysed fatty acids was 24 FA. 
 
In Italy; Marangoni analysed FAs from fasting WB in 6 healthy subjects from both 
genders  where  their  age  ranged  between  22  to  72  years  who  worked  in  the 
Department  of   Pharmacological  Science  in  Milan.  No  differences   were  found 
between WB FAs from arm venous artery and fingertip blood drop (Marangoni et al., 
2004). On the other hand, Marangoni in 2007 analysed 19 FAs from fasting fingertip 
 
WB in healthy 47 males and 53 females separately aged from 22 to 70 years who 
were attending to the Department of Pharmacological Science in Milan (Marangoni et 
al., 2007). 
 
In 2008, Armestrong analysed 24 FAs from WB in 4 healthy males in Waterloo Ontario 
 
Canada (Armestrong et al., 2008). However; his colleagues Metherel in 2009 analysed 
 
21 FAs from fasting venous artery WB in healthy 9 males and 7 females separately 
 
(Metherel et al., 2009). 
 
 
In Costa Rica 2005, a study was done to analyse 31 FAs from fasting WB in healthy 99 
males and 101 females aged between 56 and 62 years (Baylin et al., 2005). Chavarro 
analysed 8 FAs from fasting WB in 476 healthy males (aged between 53 to 63 years 
old)  in  a  USA  study  that  compared  the  FAs  status  differences  between  prostate 
cancer  cases  and  control  cases.  In  the  following  table  control  cases  were  stated 
(Chavarro et al., 2007). 
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Table 4.2.1. Comparison between whole blood fatty acids composition from our data with other References 
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Austria 
o
 
 
120 
 
3 
 
24 
 
0.65 
 
0.52 
 
21.54 
 
0.30 
 
11.41 
 
0.14 
 
1.54 
 
0.18 
 
0.22 
 
19.21 
 
1.59 
 
0.36 
 
0.12 
 
22.57 
 
0.31 
 
0.31 
 
1.86 
 
10.60 
 
1.29 
 
0.47 
 
0.71 
 
1.26 
 
2.77 
 
34.48 
 
23.10 
 
42.42 
 
36.94 
 
5.21 
Italy
1
 
 
47 
 
1 
 
19 
 
‐ 
 
‐ 
 
25.17 
 
‐ 
 
13.42 
 
0.55 
 
3.06 
 
‐ 
 
‐ 
 
21.34 
 
2.09 
 
0.32 
 
‐ 
 
16.40 
 
‐ 
 
‐ 
 
1.10 
 
6.68 
 
1.19 
 
0.70 
 
0.61 
 
1.08 
 
1.75 
 
41.86 
 
28.33 
 
29.81 
 
24.89 
 
4.11 
Italy
2
 
 
34 
 
2 
 
19 
 
‐  
 
25.17 
 
‐ 
 
13.64 
 
0.59 
 
2.75 
 
‐ 
 
‐ 
 
19.63 
 
2.10 
 
0.23 
 
‐ 
 
17.99 
 
‐ 
 
‐ 
 
1.21 
 
7.05 
 
0.94 
 
0.62 
 
0.59 
 
0.71 
 
1.97 
 
42.11 
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31.46 
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3.89 
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‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
11.46 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
21.93 
 
‐ 
 
‐ 
 
‐ 
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‐ 
 
‐ 
 
‐ 
 
10.46 
 
‐ 
 
0.28 
 
1.25 
 
1.36 
 
4.59 
 
32.33 
 
27.84 
 
39.83 
 
‐ 
 
‐ 
Canada
4
 4 1 24 1.01 ‐ 23.07 ‐ 8.87 0.19 0.89 ‐ ‐ 17.02 1.53 0.29 ‐ 23.14 0.29 0.10 0.73 8.75 1.22 0.65 0.53 1.11 1.17 35.09 22.95 37.82 34.37 3.45 
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0.76 
 
‐ 
 
21.33 
 
‐ 
 
10.17 
 
0.18 
 
1.60 
 
‐ 
 
‐ 
 
17.53 
 
1.83 
 
0.33 
 
‐ 
 
21.72 
 
0.20 
 
‐ 
 
1.62 
 
9.22 
 
1.42 
 
0.39 
 
0.39 
 
1.15 
 
1.68 
 
35.25 
 
22.53 
 
38.33 
 
34.73 
 
3.60 
 
7 
 
2 
 
21 
 
0.94 
 
‐ 
 
23.57 
 
‐ 
 
9.23 
 
0.16 
 
1.82 
 
‐ 
 
‐ 
 
18.72 
 
1.90 
 
0.23 
 
‐ 
 
22.09 
 
0.19 
 
‐ 
 
1.38 
 
8.36 
 
1.16 
 
0.41 
 
0.30 
 
0.72 
 
2.06 
 
35.92 
 
23.82 
 
37.21 
 
33.72 
 
2.06 
Costa Rica
6
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3 
 
31 
 
0.52 
 
0.14 
 
21.92 
 
0.28 
 
9.42 
 
0.26 
 
1.86 
 
0.24 
 
0.25 
 
18.23 
 
1.52 
 
0.17 
 
0.12 
 
22.38 
 
0.28 
 
‐ 
 
1.75 
 
9.08 
 
1.28 
 
0.37 
 
0.81 
 
0.90 
 
2.39 
 
34.07 
 
23.32 
 
39.87 
 
35.10 
 
4.54 
USA
7
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1 
 
8 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
25.30 
 
0.26 
 
‐ 
 
1.36 
 
10.10 
 
‐ 
 
0.35 
 
1.79 
 
0.97 
 
2.19 
 
‐ 
 
‐ 
 
‐ 
 
‐ 
 
4.96 
Values = % of total fatty acids. 
Gender: 1= Male, 2= Female, 3= Mix 
n of FA= number of total fatty acids analyzed. 
1 and  2 
Marangoni et al., 2007, 
3 
Marangoni et al., 2004, 
4 
Armestrong et al., 2008, 
5   
Metherel et al., 2009, 
6   
Baylin et al., 2005, 
7   
Chavarro et al., 2007, 
o   
our data 2010 
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4.2.2.Comparison between fatty acids composition in Red Blood 
Cells 
 
The percentage of total analysed fatty acids in RBC from our results is mentioned in 
table (4.2.2.) in order to compare our results with other studies that analysed RBC using 
the same analysing method. Number of subjects from our data was 131 mixed genders 
(male and female) and the number of analysed fatty acids was 24 FA. 
 
In South Africa, Koorts  analysed  22 FAs from RBC in 10 healthy  subjects from both 
genders (6 males and 4 females), the mean age was 38 years (Koorts et al., 2002). King 
analysed 21 FAs from RBC in 30 healthy postmenopausal females aged 50‐79 years (King 
et al., 2006). Armestrong analysed  24 FAs from RBC in 4 healthy males in Waterloo 
Ontario Canada (Armestrong et al., 2008) while his colleagues Metherel analysed 21 FAs 
from RBC in healthy 9 males and 7 females separately (Metherel et al., 2009). 
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Table 4.2.2. Comparison between red blood cells fatty acids composition from our data with other References 
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S
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n
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Austria
0
 
131 3 24 0.21 19.35 19.82 0.21 0.40 1.32 0.43 10.34 0.08 0.34 2.08 17.23 3.94 0.18 0.72 2.77 5.10 40.23 16.75 43.02 34.00 8.76 
South Africa
1
 
10 3 22 0.39 21.21 16.64 0.38 0.17 
 
0.22 12.11 0.03 0.42 1.62 15.92 0.39 0.13 0.28 1.56 4.26 
     
USA, Washington 
Seattle
2
 
30 2 21 0.26 18.96 13.97 0.39 0.37 0.99 0.24 8.56 
 
0.25 1.57 14.17 2.93 0.14 0.68 2.29 5.05 40.09 16.81 35.68 27.51 8.17 
Canada Waterloo
3
 
4 1 24 0.45 24.59 13.06 0.33 0.89 1.53 0.36 11.35 0.08 0.30 0.75 13.23 3.06 0.18 0.53 2.22 1.99 41.92 18.54 34.14 29.22 4.92 
Canada Ontario 
Waterloo
4
 
9 1 21 0.63 22.27 13.62 0.25 0.32 1.45 0.26 9.82 0.01 
 
1.60 12.30 3.12 0.12 0.38 2.05 2.51 42.90 17.65 32.65 27.60 5.07 
7 2 21 0.74 23.50 12.79 0.26 0.39 1.49 0.28 9.83 0.01 
 
1.36 12.01 2.99 0.12 0.31 1.48 3.44 42.74 17.85 32.35 27.00 5.35 
Values = % of total fatty acids. 
Gender: 1= Male, 2= Female, 3= Mix 
n of FA= number of total fatty acids analyzed. 
1
Koorts et al., 2002, 
2 
King et al., 2006, 
3 
Armestrong et al., 2008, 
4 
Metherel et al., 2009, 
o   
our data 2010 
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4.2.3.Comparison between fatty acids composition in plasma 
 
The percentage of total analysed fatty acids in plasma from our results are mentioned in 
table (4.2.3.) in order to compare our results with other studies that used plasma and 
the same analysis method as well. Number of subjects from in this experiment was 131 
mixed genders (male and female) and the number of analysed fatty acids was 24 FA. 
 
However, Akiko and his colleagues analysed 9 FAs from plasma in healthy subjects from 
different  Asian ethnic groups  (Japan, Korea, and Mongolians); 411 healthy Japanese 
(194 males and 217 females) aged 30‐60 years, 418 healthy Koreans (240 males and 178 
females) aged 30‐60 years, and 215 Mongolians (100 males and 152 females) (Akiko et 
al., 2007). 
 
In Costa Rica 2005, a study was done to analyse 31 FAs from plasma in healthy 99 males 
and 101  females aged between 56 and 62 years old (Baylin et al., 2005). In Canada, 
Metherel analysed 21  FAs from plasma in healthy 9 males and 7 females separately 
(Metherel et al., 2009). 
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Table 4.2.3. Comparison between Plasma fatty acids composition from our data with other References 
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A
 
 
n
-
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n
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Austria
0
 
 
131 
 
3 
 
24 
 
0.88 
 
23.03 
 
7.63 
 
0.11 
 
2.12 
 
21.04 
 
1.69 
 
0.33 
 
28.11 
 
0.43 
 
1.70 
 
7.19 
 
0.36 
 
0.66 
 
0.73 
 
0.56 
 
1.82 
 
32.33 
 
25.51 
 
42.17 
 
38.23 
 
3.31 
Japanese
1
 411 3 
 
9  
 
24.40 
 
7.80   
 
18.50   
 
33.70   
 
6.30  
 
0.50 
 
2.50 
 
0.90 
 
5.50 
 
32.10 
 
18.50 
 
48.50 
 
39.90 
 
8.50 
Koreans
1
 418 3 
 
9  
 
23.60 
 
6.70   
 
19.60   
 
37.20   
 
6.40  
 
0.60 
 
1.40 
 
0.50 
 
4.00 
 
30.20 
 
19.60 
 
50.10 
 
43.60 
 
6.50 
Mongolians
1
 215 3 
 
9  
 
23.90 
 
8.30   
 
20.70   
 
34.60   
 
6.30  
 
0.70 
 
1.00 
 
1.10 
 
3.50 
 
32.20 
 
20.70 
 
46.00 
 
40.80 
 
5.10 
Canada 
Ontario 
Waterloo
2
 
 
9 
 
1 
 
21 
 
0.97 
 
21.66 
 
6.53 
 
0.13 
 
2.14 
 
20.66 
 
1.95 
 
0.15 
 
29.39 
 
0.32 
 
1.43 
 
6.17 
 
0.19 
 
0.57 
 
0.39 
 
0.42 
 
1.07 
 
30.51 
 
25.43 
 
40.29 
 
37.85 
 
2.45 
 
7 
 
2 
 
21 
 
1.10 
 
23.72 
 
6.12 
 
0.12 
 
3.03 
 
20.95 
 
2.09 
 
0.21 
 
26.96 
 
0.31 
 
1.51 
 
5.50 
 
0.21 
 
0.56 
 
0.30 
 
0.30 
 
1.34 
 
32.11 
 
26.81 
 
37.44 
 
34.94 
 
2.51 
Costa Rica
3
 
 
200 
 
3 
 
31 
 
0.74 
 
22.78 
 
6.76 
 
0.19 
 
2.64 
 
20.74 
 
1.71 
 
0.14 
 
28.09 
 
0.30 
 
1.68 
 
6.02 
 
0.26 
 
0.49 
 
0.34 
 
0.41 
 
1.49 
 
31.85 
 
25.91 
 
38.39 
 
36.74 
 
2.62 
Values = % of total fatty acids. 
Gender: 1= Male, 2= Female, 3= Mix 
n of FA= number of total fatty acids analyzed. 
1
Akiko et al., 2007, 
2 
Metherel et al., 2009, 
3 
Baylin et al., 2005, 
o   
our data 2010 
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4.2.4.Comparison between fatty acids composition in plasma 
phospholipid 
 
The percentage of total analysed fatty acids in PLs from our results are mentioned in 
table  (4.2.4.)  in  order  to  compare  our  results  with  other  studies  that  used  plasma 
phospholipids (PL) and used the same analysing method. Number of subjects from our 
data was 117 mixed genders (male and female) and the number of analysed fatty acids 
was 24 FA. 
 
Wang analysed 11 FAs from PL in 3309 subjects in middle age adults (45‐ to 64‐ years) in 
a study was  held to investigate the relation of PL composition with incidence of CHD. 
They compared subjects with CHD incident vs. no CHD. In the following table, no CHD 
subjects PL’s FAs profile was stated (Wang et al., 2003). 
 
King analysed 21 FAs from PL in 30 healthy postmenopausal females aged 50‐79 years 
(King et al., 2006). Armestrong analysed 24 FAs from PL in 4 healthy males in Waterloo 
Ontario Canada (Armestrong et al., 2008). 
 
However, a recent study was conducted to examine the association between breast 
cancer  risk   and  the  FA  composition  of  PLs.  PLs  profile  was  analysed  from  257 
postmenopausal women aged 50‐69 years (Takata et al., 2009). 
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Table 4.2.4. Comparison between Plasma phospholipids fatty acids composition from our data with other References 
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Austria
0
 117 3 24 0.46 31.00 19.84 0.23 0.69 8.72 1.47 18.41 0.15 2.61 9.64 0.29 0.21 0.58 0.82 1.80 52.95 11.51 35.54 31.78 3.41 
Minneapolis 
USA
2
 
 
3309  
 
11  
 
25.40 
 
13.30  
 
0.64 
 
8.60  
 
22.00 
 
0.11 
 
3.32 
 
11.50  
 
0.15 
 
0.56  
 
2.80 
 
40.60 
 
9.97 
 
42.70 
 
38.20 
 
4.42 
Seattle USA 
3
 
30 2 21 0.25 25.56 12.92 0.56 0.65 8.37 1.41 18.62 
 
3.45 11.19 0.45 0.21 0.99 0.98 4.14 42.48 12.96 40.42 34.10 6.11 
Canada 
Waterloo
4
 
 
4 
 
1 
 
24 
 
0.77 
 
30.44 
 
12.09 
 
0.33 
 
0.84 
 
8.26 
 
1.51 
 
22.17 
 
0.07 
 
1.57 
 
9.40 
 
0.41 
 
0.28 
 
0.81 
 
0.94 
 
1.52 
 
46.30 
 
12.37 
 
37.87 
 
34.28 
 
3.59 
USA
5
 
257 2 39 0.29 26.20 13.30 0.41 0.57 8.06 1.27 19.60 0.09 3.21 11.0 0.42 0.10 0.65 0.82 2.77 43.50 13.00 
 
34.00 4.33 
Values = % of total fatty acids. 
Gender: 1= Male, 2= Female, 3= Mix 
n of FA= number of total fatty acids analyzed. 
1
Wang et al., 2003, 
2 
King et al., 2006, 
3
Armestrong 2008, 
4
Takata et al., 2009, 
o   
our data 2010 
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4.2.5. Comparison between fatty acids composition in plasma 
cholesterol ester 
 
The percentage of total analysed fatty acids in CE from our results are mentioned in 
table (4.2.5.) in order to compare our results with previous studies that determined the 
fatty acid pattern in CE using the same analysing method. Number of subjects from our 
data was 128 mixed genders (male and female) and the number of analysed fatty acids 
was 24 FA. 
 
Wang analysed 11 FAs from CE in 3309 subjects in middle age adults (45‐ to 64‐ years) in 
a study was held to investigate the relation of CE composition with incidence of CHD. 
They compared subjects with CHD incident vs. no CHD. In the following table, no CHD 
subjects CE’s FAs profile was stated (Wang et al., 2003). 
 
King analysed 21 FAs from CE in 30 healthy postmenopausal females aged 50‐79 years 
 
(King et al., 2006). 
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Table 4.2.5. Comparison between Plasma cholesterol ester fatty acids composition from our data with other References 
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Austria
0
 
 
128 
 
3 
 
24 
 
0.83 
 
12.51 
 
1.69 
 
0.09 
 
2.63 
 
18.37 
 
1.21 
 
0.11 
 
49.47 
 
0.88 
 
0.34 
 
0.82 
 
6.39 
 
0.75 
 
0.62 
 
0.64 
 
0.17 
 
0.74 
 
16.31 
 
22.57 
 
61.11 
 
58.64 
 
2.17 
Minneapolis 
USA
1
 
 
3309 
 
 
11 
 
 
10.00 
 
0.89 
 
 
2.58 
 
16.00 
  
 
54.10 
 
1.02 
 
 
0.76 
 
8.25 
 
 
0.41 
 
0.54 
 
 
0.44 
 
11.60 
 
18.60 
 
65.70 
 
64.20 
 
1.41 
Seattle USA
2
 
 
30 
 
2 
 
21 
 
0.63 
 
11.14 
 
0.96 
 
0.62 
 
3.57 
 
17.81 
 
1.29 
 
N/A 
 
49.53  
 
N/A 
 
0.88 
 
7.99 
 
N/A 
 
0.61 
 
0.91 
 
0.06 
 
0.72 
 
13.76 
 
23.21 
 
60.86 
 
58.56 
 
2.30 
Values = % of total fatty acids. 
Gender: 1= Male, 2= Female, 3= Mix 
n of FA= number of total fatty acids analyzed. 
1
Wang et al., 2003, 
2 
King et al., 2005, 
o   
our data 2010 
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Tabels 4.2.1. to 4.2.5. show evaluation of our results with other published studies that 
used folch method in analysing FAs. 
 
In table 4.2.1. FAs% in WB were compared from our data (Austria) with WB FAs% from 
Italy,  Canada,  USA and Costa Rica. SFA and MUFA from Austira were in the range of 
Canada, USA, and Costa Rica while PUFA and n‐3 from our data were higher. However, 
Italy showed higher SFA, MUFA lower PUFA and n‐3 as the case for Austria. 
 
In table 4.2.2. FAs% in RBC from our data (Austria) were compared with RBC FA% from 
South Africa, USA, and Canada. While USA Washington Seattle showed very similar n‐3, 
SFA, and MUFA with Austria, Canada appears to have lower n‐3. 
 
In table 4.2.3. FAs % in plasma from Austria were compared with FA% in plasma from 
Japan, Korea, Mongolia, Canada, and Costa Rica. Japan had the highest n‐3 followed by 
Korea while Canada and Costa Rica had the lowest. SFA and PUFA were in similar range 
between Austria and other countries. 
 
In table 4.2.4. FAs % in PLs from Austria were compared with FA% in PLs from USA and 
Canada. Austria appeared to be similar to Canada Waterloo in n‐3 and PUFA however, 
SFA looked higher in Austria than other compared countries. 
 
In table 4.2.5. FAs % in CE from Austria  were  compared  with  FA% in CE from USA 
(Minneapolis  and Washington Seattle). Austria’s n‐3 was similar to Seattle but higher 
than Minneapolis. However, SFA in Austria was higher. 
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4.3. Correlation coefficient between the five blood components 
Bivariate correlations were  measured between  each  FA and Index among WB, RBC, 
plasma, CE, and PL. Table 4.3 shows  summary of the correlation coefficients for each 
fatty acid between the tested systems. 
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Table 4.3: Summary of the correlation coefficients between each fatty acid between the tested system 
 
Fatty Acid WB, RBC WB, Plasma WB ,CE WB, PL RBC, plasma RBC, CE RBC, PL Plasma, PL Plasma, CE PL, CE 
14:0 0.374** 0.686** 0.306** 0.406** 0.345** 0.424** 0.245** .348** .243** .455** 
15:0 0.342** 0.197** 0.258** ‐0.004 ‐0.038 0.012 ‐0.026 0.040 0.066 .430** 
16:0 0.460** 0.720** ‐0.014 0.207* 0.348** ‐0.120 0.277** .265** 0.111 0.041 
17:0 0.692** 0.496** 0.435** 0.485** 0.515** 0.318** 0.406** .404** .409** .372** 
18:0 0.270** 0.644** 0.271** 0.358** 0.188* 0.175 0.401** .389** .390** .451** 
20:0 0.217* 0.544** 0.331** 0.303** 0.238** 0.108 0.113 .332** .204* .234* 
16:1n7 0.523** 0.821** 0.752** 0.691** 0.428** 0.521** 0.543** .731** .831** .769** 
18:1n9trans 0.217* 0.216* 0.208* 0.318** 0.083 ‐0.016 0.073 0.127 0.075 .344** 
18:1n7trans 0.441** 0.593** N/A 0.522** 0.189* N/A 0.253** .511** N/A N/A 
18:1n9Cis 0.365** 0.768** 0.084 0.200* 0.392** 0.138 0.098 .332** ‐0.002 .506** 
18:1n7Cis 0.551** 0.667** 0.000 0.484** 0.388** 0.092 0.238* .524** .418** .359** 
20:1n9 0.247** 0.615** 0.134 0.388** 0.209* 0.049 0.087 .301** ‐0.02 .194* 
18:2n6 trans 0.296** 0.345** 0.225* 0.256* 0.199* 0.079 0.167 0.107 .252** .433** 
18:2n6 Cis 0.511** 0.732** 0.552** 0.371** 0.583** 0.435** 0.455** .397** .576** .357** 
18:3n6 0.408** 0.820** 0.719** 0.300** 0.504** 0.407** 0.207* .391** .712** .334** 
20:2n6 0.518** 0.537** 0.125 0.374** 0.396** 0.166 0.385** .241* .186* .447** 
20:3n6 0.752** 0.829** ‐0.033 0.434** 0.578** ‐0.124 0.234* .489** 0.032 0.097 
20:4n6 0.419** 0.732** 0.121 0.046 0.307** ‐0.057 ‐0.022 0.028 .206* 0.123 
22:4n6 0.389** 0.16 ‐0.03 0.223* 0.184* 0.041 0.020 ‐0.050 0.091 ‐0.083 
18:3n3 0.269** 0.727** 0.618** 0.581** 0.163 0.468** 0.270** .558** .656** .715** 
20:5n3 0.616** 0.796** 0.606** 0.449** 0.597** 0.413** 0.247** .412** .471** .475** 
22:5n3 0.572** 0.515** 0.154 ‐0.017 0.231* 0.137 0.071 0.116 0.059 ‐0.014 
22:6n3 0.746** 0.841** 0.496** 0.490** 0.687** 0.468** 0.454** .567** .535** .456** 
20:3n9 0.234* 0.566** 0.352** 0.398** 0.102 0.178 0.241* .338** .179* 0.172 
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Continue table 4.3: Summary of the correlation coefficients between each fatty acid between the tested system 
 
Fatty Acid WB, RBC WB, plasma WB ,CE WB, PL RBC, plasma RBC, CE RBC, PL Plasma, PL Plasma, CE PL, CE 
SFA 0.152 0.597** 0.025 ‐0.059 0.211* ‐0.081 0.091 ‐0.071 ‐0.038 0.128 
Atherogenic FA 0.415** 0.698** 0.021 0.010 0.305** ‐0.102 0.246** 0.237* 0.099 ‐0.003 
TFA 0.304** 0.508** 0.240* 0.198 0.246** 0.131 0.270** 0.245* 0.156 .447** 
cis‐MUFA 0.291** 0.762** 0.399** 0.292** 0.335** 0.082 0.101 0.411** .464** .588** 
∑ MUFA 0.264** 0.763** 0.401** 0.289** 0.295** 0.060 0.071 0.402** .464** .576** 
cis‐PUFA 0.253** 0.768** 0.317** 0.178 0.220* ‐0.070 0.170 0.252** .418** 0.131 
∑ PUFA 0.251** 0.770** 0.323** 0.197 0.139 ‐0.061 0.171 0.265** .428** 0.132 
USFA 0.14 0.577** 0.04 ‐0.068 0.195* ‐0.078 0.104 ‐0.079 ‐0.038 0.143 
LCP n6 0.457** 0.694** 0.403** 0.015 0.290** ‐0.169 0.027 0.026 .553** ‐0.096 
LCP n3 0.702** 0.790** 0.518** 0.386** 0.542** 0.480** 0.378** 0.568** .639** .614** 
Omega 3 index 0.770** 0.856** 0.522** 0.526** 0.640** 0.494** 0.468** 0.593** .679** .656** 
∑ LCPUFA 0.291** 0.689** 0.366** 0.141 0.247** 0.174 0.230* 0.174 .568** 0.116 
∑ n6 0.385** 0.730** 0.387** 0.231* 0.212* 0.083 0.131 0.280** .546** 0.146 
∑ n3 0.730** 0.799* 0.539** 0.411** 0.550** 0.500** 0.340** 0.572** .592** .587** 
∑ n7 0.315** 0.845** 0.723** 0.515** 0.207* 0.226* 0.206* 0.474** .787** .470** 
∑ n9 0.362** 0.778** 0.357** 0.213* 0.394** 0.144 0.074 0.351** .389** .522** 
n6/n3 0.792** 0.720** 0.594** 0.400** 0.641** 0.523** 0.306** 0.284** .495** .483** 
n3/n6 0.831** 0.704** 0.641** 0.459** 0.662** 0.544** 0.369** 0.284** .515** .574** 
PUFA/SFA 0.186* 0.826** 0.092 0.077 0.189* ‐0.101 0.132 0.085 0.091 0.058 
USFA/SFA 0.141 0.725** 0.049 ‐0.059 0.203* ‐0.070 0.086 ‐0.090 ‐0.019 0.103 
LA/ALA 0.394** 0.614** 0.546** 0.519** 0.112 0.333** 0.302** 0.564** .612** .643** 
AA/ EPA 0.610** 0.730** 0.176 0.290** 0.553** 0.099 0.192* 0.395** .208* 0.099 
DPA/ DHA 0.824** 0.809** 0.308** 0.396** 0.726** 0.275** 0.262** .204* .213* .198* 
Holman Index 0.263** 0.263** 0.113 0.342** 1.000** 0.017 0.130 0.130 0.017 .193* 
n3 HUFA score 0.883** 0.834** 0.578** 0.245* 0.678** 0.510** 0.277* 0.376** .579** .341** 
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**. Correlation is significant at the 0.01 level (2‐tailed). 
*. Correlation is significant at the 0.05 level (2‐tailed). 
 
From FAs means value in table 4.1. two types of correlation were calculated, parametric 
Pearson  correlation and nonparametric Spearman's rho. Correlations via the 5 blood 
components would  give a good estimate about the connection of one FA in a blood 
component with the same FA in other blood component. This would allow the worker to 
choose the blood component according to the FA in interest. 
 
No negative correlations were found between WB and RBC, WB and plasma, WB and CE 
(except for 16:0, 20:3n6 and 22:4n6), RBC and plasma except for 15:0 (r= ‐0.038), RBC 
and PL except for (15:0 and AA), plasma and PL except for (22:4n6, SFA, and U/S) and 
between PL and CE except for (DPA,  LCPn‐3 and atherogenic FA). The most fractions 
were noticed to have negative correlation were between RBC and CE. 
 
The correlations between WB and CE were noticed to have negative correlations for the 
fatty acids of 16:0 (r= ‐0.014), 20:3n6 (r= ‐0.033), and 22:4n6 (r= ‐0.03). The correlations 
between WB and PL were negative among the fatty acids of 15:0 (r= ‐0.004), DPA (r= ‐ 
0.017), SFA (r= ‐0.059), USFA (r= ‐0.068) and for the ratio of U/S (r= ‐0.059). However, 
the correlations between RBC and plasma were all positive except for the fatty acid 15:0 
(r= ‐0.038) being negative. 
 
With regards to the CE fraction; the correlation with RBC method was noticed to have 
the most negative linear relationship which would be explained in that CE reflects fatty 
acids of the very short term intake while RBC reflect longer intake term; (SFA index, the 
Atherogenic indexes, PUFA, LCPn‐6,  P/S, U/S, fatty acid of 16:0, 18:1n9t, 20:3n9 and 
AA).  Correlations  with  plasma  were  also  found  to  have  many  negative  correlations 
among (SFA, USFA, U/S, oleic acid, and 20:1n9). In addition,  the correlations with PL 
were negative among TFA, LCPn‐6, and DPA. 
 
Correlation  coefficients  were  weak,  absent  or  negative  between  RBC  and  PL,  CE 
especially  among (15:0, 16:0, 20:0, 18:1n9t, 18:1n9c, 20:3n9, 18:2n6t, DPA, AA, SFA, 
MUFA, PUFA, USFA, P/S, U/S, and Holman index). 
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The strongest significant positive correlations (at p. value < 0.01 level (2‐tailed) and r < 
 
0.05 strong degree of linear relationship) were found mostly between WB and plasma 
except for 22:4n6, while a medium significant positive correlation was found for (15:0, 
17:0,  18:1n9t,  18:2n6t  and  holman  index)  since  the  correlation  were  positive  but 
middling than the other FAs (r < 0.05). 
 
Although the entire correlation coefficients were positive for the LA in all the 5 fractions, 
the strength degree between WB and plasma was the highest in comparison to others 
(r= 0.732 at p. value < 0.01 level). 
 
According  to  ALA,  the  strongest  correlation  was  found  between  WB  and  plasma 
followed by CE and PL, the weakest correlation was between RBC and plasma. While for 
EPA the strongest correlation was between WB and plasma; the weakest was between 
RBC and PL. DHA strongest correlation were noticed between WB and Plasma followed 
by WB and RBC. Two negative correlations were noticed for the DPA between WB and 
PL, and PL with CE. 
 
For  SFA,  many  negative  correlations  were  noticed.  In  general  the  only  positive 
correlations were between WB and plasma followed by RBC and plasma. 
 
WB and plasma showed the strongest correlations for MUFA, PUFA, USFA, LCPUFA, n‐6, 
n‐3,  n‐7,  n‐9,  Omega‐3  index  and  P/S  ratio.  However,  the  next  highly  significant 
correlations were found between WB and RBC after WB and plasma. 
 
For the omega‐3 index, the correlations were positive and close to (r ≥ 0.5 at p. value < 
 
0.01 level) but the strongest as mentioned before was between WB and plasma (r= 
 
0.856, p‐value 0.01 level followed by WB and RBC (r=0.770 at p. value < 0.01 level). 
 
 
The highest correlation among all the 5 methods were found for the 16:1n7, LA, EPA, 
DHA,  LCPn‐3,  omega 3 index, n‐3, and  n‐3  HUFA score. However  the perfect  linear 
relationship r=1.00 was found for holman index between RBC and plasma. 
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Bailey‐Hall  concluded  from  their  study  done  to  validate  capillary  WB  with  RBC,  PLs 
LCPUFA status, that DHA level in RBC is higher than in WB since RBC is rich in PL. They 
also reported the weak correlation between WB AA and AA from RBC and PLs (Bailey‐ 
Hall et al., 2008). 
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4.4. Linear plot relationship 
 
 
To illustrate the correlations of the FAs between blood components, scatter plot Bivar 
linear  relationship were computed. In the following sections; omega‐3 index, LA/ALA 
and EFA (LA with ALA) correlations are demonstrated. 
 
4.4.1. Linear plot of omega‐3 index between fractions 
 
 
 
Fig 4.4.1.1 Correlation between WB Omega‐3 index and RBC n‐3 index Fig 4.4.1.2 Correlation between WB Omega‐3 index and plasma n‐3 index 
r
2
= 0.592, p. value < 0.01  r
2
= 0.733, p. value < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.1.3 Correlation between WB Omega‐3 index and CE n‐3 index Fig 4.4.1.4. Correlation between WB Omega‐3 index and PL n‐3 index 
r
2
= 0.304, p. value < 0.01 r
2
= 0.277, p. value < 0.01 
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Fig 4.4.1.5 Correlation between RBC Omega‐3 index and PL n‐3 index Fig 4.4.1.6 Correlation between RBC Omega‐3 index and CE n‐3 index 
r
2
= 0.219, p. value < 0.01 r
2
= 0.244, p. value < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.1.7 Correlation between RBC Omega‐3 index and Plasma n‐3 index Fig 4.4.1.8 Correlation between Plasma Omega‐3 index and CE n‐3 index 
r
2
= 0.409, p. value < 0.01  r
2
= 0.461, p. value < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.1.9 Correlation between Plasma Omega‐3 index and PL n‐3 index Fig 4.4.1.10 Correlation between PL Omega‐3 index and CE n‐3 index 
r
2
= 0.351, p. value < 0.01 r
2
= 0.431, p. value < 0.01 
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From the previous figures, the scatter plot Bivar linear relationship between omega‐3 index 
(EPA+ DHA) concentrations through the 5 fractions show positive correlations. However, linear 
plot relationships matched that correlation coefficient. 
 
Omega‐3 index of WB and plasma showed the highest correlation r2= 0.733 at p. value 0.01 (fig 
 
4.4.1.1) followed by WB and RBC r2= 0.592 at p. value 0.01 (fig 4.4.1.2), while the lowest were 
between  omega‐3 index RBC and PL r2= 0.219 at p. value 0.01 (fig 4.4.1.5), RBC and CE r2= 
0.244 at p. value 0.01 (fig 4.4.1.6). 
 
 
These results strengthen  selecting  WB blood  components as an omega‐3 index  biomarker 
along with RBC and plasma according to the high correlations between those compartments. 
In analogous, choosing PL and CE is not favourable to validate the status. 
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4.4.2. Linear plot relationship of ratio (LA/ALA) between fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.2.1 Correlation between WB LA/ALA and RBC LA/ALA Fig 4.4.2.2 Correlation between WB LA/ALA and Plasma LA/ALA 
r
2
= 0.155, p. value < 0.01 r
2
= 0.533, p. value < 0.01 
 
 
Fig 4.4.2.3 Correlation between WB LA/ALA and PL LA/ALA Fig 4.4.2.4 Correlation between WB LA/ALA and CE LA/ALA 
r
2
= 0.27, p. value < 0.01 r
2
= 0.298, p. value < 0.01 
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Fig 4.4.2.5 Correlation between RBC LA/ALA and plasma LA/ALA Fig 4.4.2.6 Correlation between RBC LA/ALA and PL LA/ALA 
r
2
= 0.012, r
2
= 0.091, p. value < 0.01 
 
 
Fig 4.4.2.7 Correlation between RBC LA/ALA and CE LA/ALA Fig 4.4.2.8 Correlation between Plasma LA/ALA and PL LA/ALA 
r
2
= 0.111, p. value < 0.01 r
2
= 0.318, p. value < 0.01 
 
 
Fig 4.4.2.9 Correlation between Plasma LA/ALA and CE LA/ALA Fig 4.4.2.10 Correlation between CE LA/ALA and PL LA/ALA 
r
2
= 0.374, p. value < 0.01 r
2
= 0.413, p. value < 0.01 
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From the previous figures, the scatter plot Bivar linear relationship between the EFA LA/ALA 
ratios through the 5 fractions shows positive correlations. However, the highest correlations 
were between WB and plasma followed by PL and CE, while the lowest were between RBC 
and Plasma, RBC and PL. 
 
LA/ALA of WB and plasma showed the highest correlation r2= 0.533 at p. value 0.01 (fig 
 
4.4.2.2) followed by PL and CE r2= 0.413 at p. value 0.01 (fig 4.4.2.10), while the lowest 
were  between RBC and PL r2= 0.019 at p. value 0.01 (fig 4.4.2.6), RBC and plasma r2= 
0.012 (fig 4.4.2.5). 
 
 
These results strengthen selecting WB blood components as an LA/ALA biomarker along 
with  plasma   according  to  the  high  correlations  between  those  compartments.  In 
analogous, choosing RBC is not favourable. 
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4.4.3. Linear  plot  relationship  of  concentrations  of  LA  and  ALA 
 
within tested systems 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.3.1 Correlation between WB LA and ALA Fig 4.4.3.2 Correlation between RBC LA and ALA 
R
2
= 0.007 R
2
= 0.04, at p.value < 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4.3.3 Correlation between plasma LA and ALA Fig 4.4.3.4 Correlation between PL LA and ALA 
R
2
= 0.002 R
2
= 0.009 
86 
 
 
 
 
 
Fig 4.4.3.5 Correlation between CE LA and ALA 
R
2
= 0.047, at p. value < 0.05 
 
 
 
From the above figures, the scatter plot Bivar linear relationship between the EFA presence 
among the 5  blood components LA and ALA within the 5 fractions shows weak positive 
correlations.  However,  the  strongest  significant  correlations  were  for  RBC  r2= 0.04,  at 
p.value < 0.05 (fig 4.4.3.2) followed by CE r2= 0.047, at p. value < 0.05 (fig 4.4.3.5), while 
the weakest was for plasma r2= 0.002. 
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4.5. Fatty acid analysis in correlation to individuals characters 
 
The plasma FA composition of a person was found to be influenced by age, body weight, 
sex and health status as well as habitual life smoking status, alcohol drinking (MA et al., 
1995). 
 
Tables 4.5 1.to 4.5.5 show the analyzed fatty acids in relation to the following: sex, age, 
smoking status, blood glucose and blood lipids. 
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4.5.1. Gender differences 
 
Distribution amongst the five parameters: 
 
Table 4.5.1.1.  Subjects characters according to gender. 
 
 
Male Female 
WB 59 61 
RBC 64 67 
PLAMSA 65 66 
CE 62 66 
PL 51 66 
 
 
The following table summarize the significant and none significant values amongst the 
five fractions. For example, within the WB fraction, the comparison was between the 
total fatty acids mean of 59 males and 61 females. 
Table 4.5.1.2. Comparison of the fatty acids status according to the gender. 
 
fatty acids WB RBC Plasma CE PL 
14:0 n.s. 0.004 n.s. n.s. n.s. 
15:0 n.s. n.s. 0.000 n.s. n.s. 
16:0 n.s. n.s. n.s. n.s. n.s. 
17:0 0.008 n.s. n.s. n.s. 0.004 
18:0 0.006 0.001 0.010 0.000 0.000 
20:0 n.s. 0.001 n.s. n.s. n.s. 
16:1n7 0.000 n.s. 0.012 0.001 0.001 
18:1n9trans n.s. 0.040 n.s. n.s. n.s. 
18:1n7trans n.s. n.s. n.s.  n.s. 
18:1n9Cis n.s. 0.000 0.000 n.s. n.s. 
18:1n7Cis n.s. n.s. n.s. n.s. n.s. 
20:1n9 n.s. n.s. n.s. n.s. n.s. 
18:2n6 trans 0.040 n.s. 0.009 n.s. n.s. 
18:2n6 Cis 0.050 n.s. n.s. n.s. n.s. 
18:3n6 n.s. n.s. n.s. n.s. n.s. 
20:2n6 n.s. n.s. n.s. n.s. 0.005 
20:3n6 0.000 n.s. 0.007 n.s. 0.031 
20:4n6 n.s. n.s. n.s. n.s. n.s. 
22:4n6 0.000 n.s. n.s. n.s. 0.000 
18:3n3 n.s. 0.034 n.s. n.s. n.s. 
20:5n3 n.s. n.s. n.s. n.s. n.s. 
22:5n3 0.001 0.001 n.s. n.s. n.s. 
22:6n3 0.019 0.001 0.000 n.s. 0.021 
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Continue table 4.5.1.2. 
fatty acids WB RBC Plasma CE PL 
20:3n9 0.036 n.s. 0.017 n.s. n.s. 
SFA n.s. n.s. n.s. 0.045 0.011 
Atherogenic FA n.s. n.s. n.s. n.s. n.s. 
TFA n.s. n.s. 0.028 n.s. n.s. 
∑ MUFA n.s. 0.000 0.006 n.s. 0.054 
∑ PUFA n.s. 0.000 n.s. n.s. n.s. 
USFA n.s. n.s. n.s. n.s. 0.010 
LCP n6 n.s. n.s. n.s. n.s. n.s. 
LCP n3 n.s. n.s. 0.013 n.s. 0.051 
Omega 3 index 0.037 0.003 0.003 n.s. 0.013 
∑ LCPUFA n.s. 0.024 n.s. n.s. n.s. 
∑ n6 n.s. 0.020 n.s. n.s. n.s. 
∑ n3 n.s. n.s. 0.048 0.034 0.037 
∑ n7 0.000 n.s. 0.055 0.003 0.006 
∑ n9 n.s. 0.000 0.000 n.s. n.s. 
n6/n3 n.s. n.s. 0.013 n.s. n.s. 
n3/n6 n.s. n.s. 0.010 0.047 n.s. 
P/S n.s. 0.004 n.s. n.s. 0.022 
U/S n.s. n.s. n.s. n.s. 0.013 
LA/ALA n.s. 0.025 n.s. n.s. n.s. 
AA/ EPA n.s. n.s. n.s. n.s. n.s. 
DPA/ DHA 0.000 0.000 0.000 n.s. 0.051 
Holman Index n.s. n.s. n.s. n.s. n.s. 
n3 HUFA score n.s. n.s. 0.008 n.s. 0.034 
n.s. not significant at p >0.05 
 
 
Due to  the  differences  in  hormonal  balance,  age, dietary  intake  or disease  status 
(cholesterol gallstones which showed significant lower EPA levels) gendre differences 
occurred (Ogura et al.,  2010). In healthy women, an inverse correlation was found 
between the LA intake and serum homo‐g‐LA (Lweis‐Barned et al., 2000). 
There were no significant differences between men and women among all fractions of 
 
the fatty acids of 16:0, 18:1n7t,c , 20:1n9, GLA, AA, EPA, Atherogenic FA, LCPn‐6, 
AA/EPA, and holman index. 
However, in FA 18:0 and omega‐3 index the differences between men and women 
were highly significant among all the fractions. For DHA, and DPA/DHA the differences 
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were significant among all the fractions except in CE. For n‐7, and their ratio (16:1n7/ 
 
18:1n7) the differences were significant among all the fractions except in RBC. Oleic 
acid was highly significantly differing in RBC and plasma. 
 
In adipose tissue, LA and DHA were shown to be higher in Scottish women than in 
Scottish  men  while  in  Japan  a  study  by  Ogura  showed  no  significant  differences 
between genders in PUFAs of the plasma PL (Ogura et al., 2010). In our study LA found 
to be different among WB, only in the other fractions no significant differences were 
noticed. 
 
Estrogen effects might lower the conversion of the ALA to EPA and DHA in women 
than in men  in the same age (Ratnayake and Galli, 2009). Although no significant 
differences in their concentrations were found in our PL fractions. 
 
Welch noticed  that  DPA  concentration  was  higher  in  men  than  in  women  which 
agreed  with  our  results;  while  plasma  fatty  acids  concentrations  were  higher  in 
women than in men. In addition, fatty acids of plasma phospholipids concentrations 
are higher in women than in men even with same amount of fish intake. That might be 
explained  according  to  the  body  size  and  plasma  volume  differences.  In  addition, 
among non dietary n‐3 PUFA consumers, women still have higher n‐3 PUFAs than men 
which could be returned to the oestrogen concentration (Welch et al., 2006). 
 
In the study of MA et al.,1995 study, plasma PL and CE SFA and MUFA were higher in 
men than in  women while PUFA were lower (MA et al.,   1995). In this study it was 
noticed that men had higher SFA and lower MUFA and PUFA than women. Men had 
higher % of 16:0 in RBC PL than in women (Heude et al., 2002). However; in our data it 
was found that both RBC and plasma PL were higher in females than males although 
no significant differences were noticed. 
 
As for the serum CE fraction, females’ concentration of LA decreases with age faster 
than males  while AA increases in males faster than females. However, it was found 
that PUFA and n‐6 fatty  acids have different falling curve, they decrease faster in 
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females than in males with getting old which reflect the decreasing in EFA status. 
Males had higher USFA indexes than females (Holman et al., 1979) while in this study, 
PL shows significant high USFA level in women. 
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4.5.2. Age differences 
 
The ranges of age used in this work were 19‐30 for youth subjects, and 40‐62 for 
adult subjects. 
Table 4.5.2.1. Shows the age groups characters categorized according to gender. 
 
 
Female (n) Male (n) 
 
19‐ 39 40‐ 62 19‐ 39 40‐ 62 
WB 32 29 31 28 
RBC 34 33 36 28 
plasma 33 33 36 29 
CE 32 34 37 25 
PL 33 33 30 21 
 
 
The  following  table  summarizes  the  differences  between  age  groups  within  each 
fraction. For  example in WB, fatty acids levels were compared between females aged 
from 19 to 39 yrs old and females aged from 40 to 62 yrs old, similar within male. 
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Table 4.5.2.2: Comparison of the fatty acids in regards to age and differentiated according to Gender. 
 
 
Female Male 
Fatty Acids WB RBC plasma CE PL WB RBC plasma CE PL 
14:0 n.s. n.s. n.s. n.s. n.s. n.s. 0.017 n.s. n.s. n.s. 
15:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.020 n.s. 
16:0 n.s. n.s. n.s. n.s. n.s. n.s. 0.024 n.s. n.s. n.s. 
17:0 n.s. n.s. n.s. n.s. 0.046 n.s. n.s. n.s. n.s. n.s. 
18:0 n.s. n.s. n.s. n.s. n.s. 0.053 n.s. n.s. n.s. 0.017 
20:0 n.s. n.s. n.s. n.s. n.s. 0.007 n.s. 0.014 n.s. 0.023 
16:1n7 n.s. n.s. n.s. n.s. n.s. 0.005 0.053 0.018 0.016 0.012 
18:1n9trans n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.003 n.s. 
18:1n7trans n.s. 0.016 n.s. N/A n.s. n.s. n.s. n.s. N/A n.s. 
18:1n9Cis n.s. 0.008 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.015 
18:1n7Cis n.s. n.s. n.s. 0.016 n.s. n.s. n.s. n.s. n.s. n.s. 
20:1n9 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:2n6 trans n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.013 n.s. 
18:2n6 Cis n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:3n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:2n6 0.009 0.056 0.049 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:3n6 0.001 0.030 0.002 0.002 n.s. n.s. n.s. n.s. n.s. n.s. 
20:4n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
22:4n6 n.s. 0.014 n.s. n.s. n.s. 0.009 0.025 n.s. n.s. n.s. 
18:3n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:5n3 0.018 n.s. 0.021 0.054 n.s. 0.010 0.004 n.s. 0.011 n.s. 
22:5n3 0.029 0.004 0.000 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
22:6n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.042 
20:3n9 n.s. n.s. 0.009 n.s. n.s. n.s. 0.005 0.044 n.s. n.s. 
SFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Atherogenic FA n.s. n.s. n.s. n.s. n.s. n.s. 0.023 n.s. n.s. n.s. 
TFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.003 n.s. 
∑ MUFA n.s. 0.012 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.013 
∑ PUFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
USFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.050 n.s. 
LCP n6 n.s. 0.012 n.s. n.s. n.s. 0.028 0.007 n.s. n.s. n.s. 
LCP n3 n.s. n.s. 0.021 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Omega 3 index n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.012 n.s. 
∑ LCPUFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n6 n.s. n.s. n.s. n.s. n.s. n.s. 0.000 n.s. n.s. n.s. 
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Continue table 4.5.2.2. 
 
 
Female Male 
Fatty Acids WB RBC plasma CE PL WB RBC plasma CE PL 
∑ n3 n.s. n.s. 0.042 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n7 n.s. n.s. n.s. n.s. n.s. 0.051 n.s. 0.054 0.031 0.030 
∑ n9 n.s. 0.010 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.016 
n6/n3 n.s. n.s. 0.004 0.055 n.s. n.s. n.s. n.s. n.s. n.s. 
n3/n6 n.s. n.s. 0.006 n.s. n.s. n.s. 0.021 n.s. 0.041 n.s. 
P/S n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
U/S n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
LA/ALA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
AA/ EPA 0.002 n.s. 0.001 n.s. n.s. 0.006 0.001 n.s. n.s. n.s. 
DPA/ DHA n.s. 0.018 0.038 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Holman Index n.s. n.s. n.s. n.s. n.s. n.s. 0.003 0.002 n.s. 0.064 
n3 HUFA score 0.014 0.063 0.005 n.s. n.s. 0.034 0.023 n.s. 0.055 n.s. 
n.s. not significant. N/A not available 
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Within serum CE fraction, females’ concentration of LA decreased with age faster than 
males while AA increased in males faster than females. However, it was found that PUFA 
and n‐6 fatty acids have different falling curve, they decreased faster in females than in 
males with getting old which reflect the decreasing in EFA status (Holman et al., 1979). 
This shows that age and sex have an evident  effect on fatty acid composition. Aging 
reduces the activity  of ∆6  desaturase  which  is important  for the formation  of GLA, 
DGLA, AA, EPA, and DHA (Undurti 2008). 
 
Omega‐3 index is affected by age (+0.50% per decade) (von Schacky, 2010) which was 
noticed  to  be  significant  in  the  CE  fractions  among  males.  Although  no  significant 
differences were noticed  within the other fractions, the values were higher in older 
groups than younger groups in both genders amongst the 5 fractions. Rabini noticed a 
significant increase (p < 0.05) in RBC membrane U/S ratio amongst younger group (aged 
21‐40 yrs old) than in older group (aged > 41 yrs old) (Rabini et al., 2002). 
 
 
Among  Females  there  were  no  significant  differences  in  regard  to  age  categorizes 
among all fractions for 14:0, 15:0, 16:0, 20:0, 16:1n7, 18:1n9t, 18:2n6t, 18:2n6, 18:3n6, 
20:4n6,  ALA,  DHA,  SFA, TFA,  PUFA,EFA,  omega‐3  index,  LCPUFA,  n‐6,  n‐7,  P/S,  U/S, 
LA/ALA, and the Holman index. In Males there were no significant differences in regard 
to age categorizes in  17:0,  18:1n7t, 18:1n7c, 20:1n9, 18:2n6, 18:3n6, 20:2n6, 20:3n6, 
20:4n6, ALA, DPA, LCPUFA, n‐3, U/S, LA/ALA, and DPA/DHA. 
 
 
Amongst fractions: 
 
WB: it was found that DGLA, EPA, and DPA increased significantly with age in females 
while AA/EPA decreased. In males 16:1n7 and atherogenic acids significantly increased 
with age while 18:0, 20:0, AA, USFA, n‐7, LCPn‐6, and AA/EPA decreased. 
RBC: oleic acid, DPA, MUFA, n‐9, DPA/DHA and n‐3 HUFA score significantly increased in 
 
females with age while DGLA, 22:4n6, and LCPn‐6 decreased. However, in males, 14:0, 
 
16:0, 16:1n7, 22:4n6, EPA, and atherogenic acids significantly increased with age while 
 
PUFA, n‐6, LCPn‐6 and AA/EPA decreased. 
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Plasma: in females, EPA, DPA, DHA, mead acid, n‐3 and LCPn‐3 significantly increased 
with  age  while  AA/EPA  decreased.  However,  in  males,  16:1n7,  mead  acid  and  n‐7 
significantly increased with age while 20:0 and LA decreased. 
 
CE: in females, adult women showed higher levels of 18:1n7, EPA, DHA and lower level 
of 22:4n6  than younger  women.  In males,  adult males showed  lower level of 15:0, 
18:1n9trans, 18:2n6trans, atherogenic acid, TFA and higher level of 16:1n7, EPA, USFA, 
 
LCPn‐3 and omega‐3 index than younger males. 
 
 
PLs: significant increasing with age was noticed in females for 17:0 and 18:0 fatty acids. 
In males, significant increasing with age had been noticed for 16:1n7, OA, DHA, MUFA, 
USFA, n‐7 and n‐9 and significant decreasing for 18:0, 20:0, and SFA. 
 
Although age (19 ‐ 64 years) has an influence on the serum fatty acids’ absorption, 
synthesis, and metabolism; it is not associated with the marine origin n‐3 PUFA in serum 
PL (Kobayashi et al., 2001). 
 
In a study done in Japan among 75 adults (≤ 49 till 70≥ years old), correlations were 
noticed between age and PUFAs as a result of the dietary factors. While this correlation 
was positive with n‐3 PUFA, it was negative with n‐6 PUFAs (Ogura et al., 2010). AA in 
PLs was higher in young than in  elderly even with identical AA intake. However, fish 
consumption  increased  significantly  with  age  but  no  difference  was  notice  with  AA 
intake with age (Kawabata et al., 2011). 
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4.5.3. BMI differentiation: 
 
Normal BMI stands for subjects with body mass index lay between 19‐ 24.99 kg/m2 
 
while overweight BMI stands for over 25 kg/m2. 
 
Table 4.5.3.1. Shows the BMI groups characters categorized according to gender. 
 
 Female Male 
 Normal BMI
 
Overweight
 
Normal BMI
 
Overweight
 
WB 47 14 34 25 
RBC 53 14 40 24 
plasma 51 15 39 26 
CE 52 14 40 22 
PL 52 14 35 16 
 
 
The  following  table  summarizes  the  differences  between  BMI  groups  within  each 
fraction. For example in WB, fatty acids levels were compared between normal weight 
females with overweight females, similar within male. 
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Table 4.5.3.2. Comparison of the fatty acids in regards to BMI and categorized according to genders. 
 
 
BMI Differences in Female BMI  Differences in Male 
Fatty acid WB RBC plasma CE PL WB RBC plasma CE PL 
14:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
15:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.007 n.s. 
16:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
17:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.037 n.s. 
18:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.017 n.s. 
16:1n7 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:1n9 trans n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:1n7 trans n.s. n.s. n.s. N/A n.s. n.s. n.s. n.s. N/A n.s. 
18:1n9 Cis n.s. n.s. 0.040 n.s. n.s. n.s. n.s. n.s. 0.056 n.s. 
18:1n7 Cis n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:1n9 n.s. n.s. n.s. n.s. n.s. 0.042 n.s. n.s. n.s. n.s. 
18:2n6 trans n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:2n6 Cis n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:3n6 0.034 n.s. 0.039 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:2n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:3n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:4n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
22:4n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
18:3n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:5n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
22:5n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
22:6n3 0.059 n.s. 0.047 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
20:3n9 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
SFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Atherogenic FA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
TFA n.s. n.s. n.s. 
 
n.s. n.s. n.s. n.s. n.s. n.s. 
∑ MUFA n.s. n.s. 0.017 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ PUFA 0.040 n.s. 0.018 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
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Continue table 4.5.3.2. 
 
 
BMI Differences in Female BMI  Differences in Male 
Fatty acid WB RBC plasma CE PL WB RBC plasma CE PL 
USFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
LCP n6 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
LCP n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Omega 3 index n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ LCPUFA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n6 n.s. n.s. 0.037 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n7 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
∑ n9 n.s. n.s. 0.031 n.s. n.s. n.s. n.s. n.s. 0.056 n.s. 
n6/n3 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
n3/n6 n.s. n.s. n.s. 0.027 n.s. n.s. n.s. n.s. n.s. n.s. 
P/S n.s. n.s. 0.056 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
U/S n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
LA/ALA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
AA/ EPA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.032 n.s. 
DPA/ DHA n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Holman Index n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
n3 HUFA score n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
n.s. not significant , N/A not available. 
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Amongst  females,   males   and   both   BMI   categories;   there   were   no   significant 
differences in LA, ALA, AA, EPA, DPA, mead acid, SFA, TFA, USFA, LCPn‐6, LCPn‐3, EFA, 
omega 3 index, n‐7, and holman index. 
 
Although BMI has an influence on the serum fatty acids’ absorption, synthesis, and 
metabolism;  it  has  no  association  with  the  marine  origin  n‐3  PUFA  in  serum  PL 
(Kobayashi et al., 2001). Omega‐3 index is affected by BMI (‐0.30 % per three units) 
(von  Schacky  2010)  although  that   wasn’t  noticed  in  this  study  since  no  obese 
participant was included. 
 
The relationship between quality of fat intake and obesity is still controversial. A study 
done in Spain  reported no role of the fat intake and obesity, another study found a 
positive  association   between  fat  intake  (rather  than  vegetable  fats)  and  BMI. 
However, it has been reported  that  BMI was not correlated with any FAs. Amongst 
Australians, a negative association was found between n‐3 PUFA and obesity. Plasma 
cholesterol  ester  fatty  acids  composition  showed   significant  positive  association 
between BMI and EPA and AA, and negative association with LA (Ogura et al., 2010). 
However, this study might suggest that females’ fatty acids composition  would be 
affected by BMI more than males since fatty acids amongst males WB, RBC, plasma, PL 
and most CE didn’t differ significantly between both BMI groups. 
 
Since no obese (BMI > 30 kg/m2) subjects were enrolled in this study, little significant 
differences   were  found  between  categories.  Plasma  MUFA  and  OA  significantly 
increased in female  overweight than normal weight while plasma n‐6 and PUFA in 
plasma and WB decreased. 
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4.5.4. Smoking differentiation 
 
Table 4.5.4.1. Shows the smoking groups characters. 
 
 Smoker
 
None Smoker
 
WB 67 42 
RBC 72 48 
Plasma 72 48 
CE 71 45 
PL 66 40 
 
 
Smoker indicates  current  smoker  subjects,  while  none  smoker can be either former 
smoker subjects or subjects who never smoked. 
The following table summarizes the differences between smoking groups within each 
fraction. For  example in WB, fatty acids levels were compared between smoker and 
none smoker subjects. 
Table 4.5.4.2. Comparison of the fatty acids levels according to the smoking status. 
 
Fatty acids WB RBC Plasma CE PL 
14:0 n.s. n.s. n.s. n.s. n.s. 
15:0 n.s. n.s. n.s. n.s. n.s. 
16:0 n.s. n.s. n.s. n.s. n.s. 
17:0 n.s. n.s. n.s. 0.034 n.s. 
18:0 n.s. n.s. n.s. n.s. n.s. 
20:0 n.s. n.s. n.s. 0.048 n.s. 
16:1n7 n.s. n.s. n.s. n.s. n.s. 
18:1n9trans n.s. n.s. n.s. n.s. n.s. 
18:1n7trans 0.006 n.s. 0.010 N/A n.s. 
18:1n9Cis n.s. n.s. n.s. n.s. n.s. 
18:1n7Cis n.s. n.s. n.s. n.s. n.s. 
20:1n9 0.005 n.s. n.s. n.s. 0.057 
18:2n6 trans n.s. n.s. n.s. n.s. n.s. 
18:2n6 Cis n.s. n.s. n.s. n.s. n.s. 
18:3n6 n.s. 0.024 n.s. n.s. n.s. 
20:2n6 n.s. 0.026 n.s. n.s. n.s. 
20:3n6 n.s. n.s. n.s. n.s. n.s. 
20:4n6 n.s. n.s. n.s. n.s. 0.044 
22:4n6 n.s. n.s. n.s. n.s. n.s. 
18:3n3 n.s. n.s. n.s. n.s. n.s. 
20:5n3 n.s. n.s. n.s. 0.028 0.028 
22:5n3 n.s. 0.004 n.s. n.s. n.s. 
22:6n3 n.s. 0.033 n.s. n.s. n.s. 
20:3n9 n.s. n.s. n.s. n.s. n.s. 
SFA n.s. n.s. n.s. n.s. n.s. 
Atherogenic FA n.s. n.s. n.s. n.s. n.s. 
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Continue table 4.5.4.2. 
Fatty acids WB RBC Plasma CE PL 
TFA n.s. n.s. n.s. n.s. n.s. 
∑ MUFA n.s. n.s. n.s. n.s. n.s. 
∑ PUFA n.s. n.s. n.s. n.s. n.s. 
USFA n.s. n.s. n.s. n.s. n.s. 
LCP n6 n.s. n.s. n.s. n.s. 0.043 
LCP n3 n.s. 0.008 n.s. n.s. n.s. 
Omega 3 index n.s. 0.043 n.s. n.s. 0.047 
∑ LCPUFA n.s. 0.009 n.s. n.s. 0.012 
∑ n6 n.s. n.s. n.s. n.s. n.s. 
∑ n3 0.057 0.008 n.s. 0.048 n.s. 
∑ n7 n.s. n.s. n.s. n.s. 0.047 
∑ n9 n.s. n.s. n.s. n.s. n.s. 
n6/n3 0.027 0.004 n.s. 0.023 n.s. 
n3/n6 0.032 0.019 n.s. n.s. n.s. 
P/S n.s. n.s. n.s. n.s. n.s. 
U/S n.s. n.s. n.s. n.s. n.s. 
LA/ALA n.s. n.s. n.s. n.s. n.s. 
AA/ EPA n.s. n.s. n.s. n.s. n.s. 
DPA/ DHA n.s. n.s. n.s. n.s. n.s. 
Holman Index n.s. n.s. n.s. n.s. n.s. 
n3 HUFA score n.s. 0.047 n.s. n.s. n.s. 
n.s. not significant , N/A not available 
 
 
Although smoking status might have an influence on the serum fatty acids’ absorption, 
synthesis,  and  metabolism; it is not associated with the marine origin n‐3 PUFA in 
serum PL (Kobayashi et  al., 2001). Fatty acids composition in both cigarette smoker 
and non‐smoker has been described. Tobacco is thought to have an inhibitory effect 
on the essential fatty acids metabolism (Simon et al., 1996). 
 
WB, plasma and CE n‐3 fatty acids concentration decreased significantly in smoker 
subject. PUFAs concentrations (both n‐3 and n‐6) in the membrane were found to be 
depleted as a result of smoking (Chiu et al., 2003). 
 
In a study done in 2002 on male physicians in Boston, it was noticed that current 
smokers   have   significantly  lower  level  or  LCPUFAn‐3  (Albert  CM,  2002)  which 
conformed  to  our  RBC  LCPn‐3  levels.  However,  RBC  fraction  showed  the  more 
significant differences than other fraction which may raise a hypothesis that smoking 
would  affect  the  FA  long‐term  composition.   18:3n6,  20:2n6,  and  n‐3:n6  ratios 
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increased  significantly  in  smoker  than  non  smoker,  while  DPA,  DHA,  n‐3,  LCPn‐3, 
omega‐3 index, sum of LCPUFA decreased. EPA in both CE and PL showed significant 
reduction in their concentrations in smoker subjects than non‐smokers. Similar results 
were shown in another study; where smokers had lower percentage of EPA in RBC PL 
than none smoker (Heude et al., 2002). 
 
Male smokers have high BMI (overweight or obesity) and alcohol consumption leads 
to  high  SFA  in  plasma  PL  and  CE  with  low  LA.  That  would  be  explained  by  the 
hypothesis of conversion alcohol to SFA endogenously or that those conditions would 
affect FA metabolism. SFA in plasma PL and CE were higher and 18:2n6 was lower in 
overweight, male smokers than non‐smoking with normal BMI males (MA et al., 1995). 
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4.5.5. Glycaemic status and fatty acids composition 
 
 
Table 4.5.5.1.Subjects characteristics according to glycaemic status. 
 
 Hypoglycemia
 
Normal blood glucose
 
WB 16 93 
RBC 18 100 
plasma 18 100 
CE 16 100 
PL
 
15
 
90
 
 
 
When fasting, blood glucose (no caloric intake within last 8 hours) ranges between 4‐6 
mmol/L (60  ‐110 mg/dl),  it reflects normal blood glucose. If the range  exceeds 110 
mg/dl, it reflects hyperglycemia (Earl et al., 2002) ranged from 6 to 11 mmol/l (Preissig 
and Rigby, 2010), while beneath 60 mg/dl it reflects hypoglycemia (Miller et al., 2001) 
alike to blood glucose ≤2∙2 mmol/l (Vlasselaers et al., 2009). 
 
 
Table (4.9.2.) summarizes the differences between normal glycaemic and hypoglycemic 
groups  within  each  fraction.  For  example  in  WB,  fatty  acids  levels  were  compared 
between normal‐ with hypo‐glycaemic. 
Table  4.5.5.2.  Comparison  of  fatty  acids  composition  between  hypo‐  and  normal‐ 
 
glycaemic subjects. 
 
Fatty acids WB RBC Plasma CE PL 
14:0 n.s. n.s. n.s. n.s. n.s. 
15:0 n.s. n.s. n.s. n.s. n.s. 
16:0 n.s. n.s. n.s. 0.049 n.s. 
17:0 n.s. n.s. n.s. n.s. n.s. 
18:0 n.s. n.s. n.s. n.s. n.s. 
20:0 n.s. n.s. n.s. n.s. n.s. 
16:1n7 n.s. n.s. n.s. n.s. n.s. 
18:1n9trans n.s. n.s. n.s. n.s. 0.052 
18:1n7trans n.s. n.s. n.s. N/A n.s. 
18:1n9Cis n.s. n.s. n.s. n.s. n.s. 
18:1n7Cis 0.034 n.s. n.s. n.s. n.s. 
20:1n9 0.023 n.s. n.s. 0.043 0.015 
18:2n6 trans n.s. n.s. n.s. n.s. n.s. 
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Continue table 4.5.5.2. 
Fatty acids WB RBC Plasma CE PL 
18:2n6 Cis n.s. n.s. n.s. n.s. n.s. 
18:3n6 n.s. 0.035 n.s. n.s. 0.000 
20:2n6 n.s. n.s. n.s. n.s. 0.057 
20:3n6 n.s. n.s. n.s. n.s. n.s. 
20:4n6 n.s. n.s. n.s. n.s. n.s. 
22:4n6 0.021 n.s. n.s. n.s. 0.000 
18:3n3 n.s. n.s. n.s. n.s. n.s. 
20:5n3 n.s. 0.000 n.s. n.s. n.s. 
22:5n3 n.s. 0.042 n.s. n.s. n.s. 
22:6n3 n.s. n.s. n.s. n.s. n.s. 
20:3n9 n.s. 0.021 n.s. n.s. n.s. 
SFA n.s. n.s. n.s. n.s. n.s. 
Atherogenic SFA n.s. n.s. n.s. n.s. n.s. 
Atherogenic FA n.s. n.s. n.s. n.s. n.s. 
TFA n.s. n.s. n.s. n.s. 0.051 
∑ MUFA n.s. n.s. n.s. n.s. n.s. 
∑ PUFA n.s. n.s. n.s. n.s. n.s. 
USFA n.s. n.s. n.s. n.s. n.s. 
LCP n6 n.s. n.s. n.s. n.s. n.s. 
LCP n3 n.s. 0.054 n.s. n.s. n.s. 
Omega 3 index n.s. n.s. n.s. n.s. n.s. 
∑ LCPUFA n.s. n.s. n.s. n.s. n.s. 
∑ n6 n.s. 0.009 n.s. n.s. n.s. 
∑ n3 n.s. 0.054 n.s. n.s. n.s. 
∑ n7 n.s. n.s. n.s. n.s. n.s. 
∑ n9 n.s. n.s. n.s. n.s. n.s. 
n6/n3 n.s. 0.029 n.s. n.s. n.s. 
n3/n6 0.051 0.021 n.s. n.s. n.s. 
LCPn6/ LCPn3 0.015 0.043 n.s. n.s. n.s. 
P/S n.s. n.s. n.s. n.s. n.s. 
USFA/SFA n.s. n.s. n.s. n.s. n.s. 
LA/ALA n.s. n.s. n.s. n.s. n.s. 
AA/ EPA 0.005 0.000 n.s. n.s. n.s. 
DPA/ DHA n.s. n.s. n.s. n.s. n.s. 
Holman Index n.s. n.s. 0.058 0.037 n.s. 
161n7/181n7 n.s. n.s. 0.004 n.s. n.s. 
n3 HUFA score 0.013 0.029 n.s. n.s. n.s. 
n.s. not significant, N/A not available 
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No significant differences were found between the groups amongst all the fractions for 
 
OA, LA, ALA, AA, SFA, MUFA, PUFA, USFA, omega‐3 index, n‐7 and n‐9. 
 
 
EPA, DPA, n‐3 and n‐3 HUFA in RBC fraction were found to be significantly lower in 
hypoglycemic  subjects than normal blood glucose subjects, and the opposite with n‐6 
and n6/n3. 
 
Holman index was found to be significantly higher in hypoglycemic group in plasma CE 
fraction.   20:1n9   were   significantly   lower   in   normal   blood   glucose   subject   than 
hypoglycemic in WB, CE, and PL. 
 
The AA/EPA ratio in WB, RBC were significantly lower in normal blood glucose subject 
than the hypoglycemic group (p=0.005 and p= 0.000, respectively). 
 
A threshold and modest association was observed between omega 3 index (EPA and 
DHA) intake  and type 2 diabetes incidents. However, no association as observed with 
ALA intake (Djoussé et al., 2011). 
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4.5.6. Lipidemia status and fatty acids composition 
 
 
Table 4.5.6.1.  Subjects characteristics according to lipidemia status. 
 
 Hyperlipidemia
 
Normal blood TG
 
WB 8 105 
RBC 8 114 
Plasma 9 113 
CE 9 110 
PL
 
8
 
100
 
 
The American Heart Association had established guidelines for triglyceride levels in 
which  Normal  range, low risk < 150 mg/dl (<1.7 mmol/l), borderline high 150‐ 199 
mg/dl  (1.7‐  2.2  mmol/l),  and  high  level  of  TG  when  higher  than  200  mg/dl  (>2.2 
mmol/l) (American heart association, 2010; Genest et al., 2009). 
 
 
 
Table 4.5.6.2. Comparison of fatty acids composition between normal‐ and hyper‐ 
lipidemia subjects. 
 
Fatty acids WB RBC Plasma CE PL 
14:0 0.005 n.s. 0.051 n.s. n.s. 
15:0 n.s. n.s. n.s. n.s. n.s. 
16:0 0.007 n.s. 0.008 n.s. n.s. 
17:0 n.s. n.s. n.s. n.s. n.s. 
18:0 n.s. n.s. n.s. n.s. n.s. 
20:0 n.s. n.s. n.s. n.s. 0.016 
16:1n7 n.s. n.s. n.s. n.s. n.s. 
18:1n9trans n.s. n.s. n.s. n.s. n.s. 
18:1n7trans n.s. 0.004 n.s. N/A n.s. 
18:1n9Cis 0.000 0.002 0.000 n.s. n.s. 
18:1n7Cis n.s. n.s. n.s. 0.009 0.002 
20:1n9 n.s. n.s. n.s. n.s. n.s. 
18:2n6 trans n.s. n.s. n.s. n.s. n.s. 
18:2n6 Cis n.s. n.s. 0.000 n.s. n.s. 
18:3n6 0.008 0.057 n.s. 0.035 n.s. 
20:2n6 n.s. n.s. n.s. n.s. n.s. 
20:3n6 0.019 n.s. 0.013 n.s. n.s. 
20:4n6 0.001 n.s. 0.000 n.s. n.s. 
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Continue table 4.10.2. 
Fatty acids WB RBC Plasma CE PL 
22:4n6 n.s. n.s. 0.001 n.s. n.s. 
18:3n3 0.029 n.s. n.s. n.s. n.s. 
20:5n3 n.s. n.s. n.s. n.s. n.s. 
22:5n3 n.s. n.s. 0.001 n.s. n.s. 
22:6n3 0.002 n.s. 0.001 n.s. n.s. 
20:3n9 n.s. n.s. n.s. n.s. n.s. 
SFA 0.017 n.s. 0.007 n.s. n.s. 
Atherogenic FA 0.004 n.s. 0.006 n.s. n.s. 
TFA n.s. n.s. n.s. n.s. n.s. 
∑ MUFA 0.001 0.003 0.000 n.s. n.s. 
∑ PUFA 0.000 n.s. 0.000 n.s. n.s. 
USFA 0.021 n.s. 0.009 n.s. n.s. 
LCP n6 0.000 n.s. 0.000 n.s. n.s. 
LCP n3 0.007 n.s. 0.015 n.s. n.s. 
Omega 3 index 0.009 n.s. 0.018 n.s. n.s. 
∑ LCPUFA 0.000 n.s. 0.000 n.s. n.s. 
∑ n6 0.001 n.s. 0.000 n.s. n.s. 
∑ n3 0.016 n.s. 0.018 n.s. n.s. 
∑ n7 n.s. n.s. n.s. n.s. 0.028 
∑ n9 0.000 0.002 0.000 n.s. n.s. 
n6/n3 n.s. n.s. n.s. n.s. n.s. 
n3/n6 n.s. n.s. n.s. n.s. n.s. 
P/S 0.001 0.056 0.000 n.s. n.s. 
U/S 0.020 n.s. 0.011 n.s. n.s. 
LA/ALA 0.054 0.046 0.020 n.s. n.s. 
AA/ EPA n.s. 0.015 n.s. n.s. n.s. 
DPA/ DHA 0.033 n.s. n.s. n.s. n.s. 
Holman Index n.s. n.s. n.s. n.s. 0.044 
n3 HUFA score n.s. n.s. n.s. n.s. n.s. 
n.s. not significant, N/A not available 
 
 
Sum of SFA concentration and atherogenic FA increased significantly in hyperlipidemic 
subjects in both WB and plasma. Fatty acid 14:0 significantly increased in hyperlipidemic 
WB  and  plasma.  While  16:0  significantly  increased  in  hyperlipidemic  plasma,  18:0 
significantly decreased in WB. 
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OA increased significantly in WB, RBC, and plasma in hyperlipidemic subjects. 18:3n6 
were significantly higher in hyperlipidemic subjects in WB, RBC, and CE. While ALA was 
significantly  higher  in  WB  hyperlipidemic  subjects,  LA  was  found  to  be  significantly 
higher  in  plasma  normal  TG  level  subjects.  Similarly  the  case  was  with  AA  as  its 
concentration was significantly higher  among normal TG subjects in WB and Plasma. 
DPA and DHA were significantly higher in plasma normal TG. 
 
MUFA levels were significantly higher in hyperlipidemic of WB, RBC and plasma, while 
both PUFA and USFA levels were significantly lower in WB and plasma. 
 
WB  and  plasma  n‐3,  n‐6,  LCPn‐3,  LCPn‐6,  omega  3  index,  P/S,  U/S,  LA/ALA  were 
significantly higher in normal TG subject while n‐9 was significantly lower. 
 
However, it was noticed that WB and plasma were the most affected fractions by the TG 
 
levels variation, while CE and PL were the lowest. 
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5. Discussion 
 
The objective  of  this  study  is  to  evaluate  the  best  blood  component  for  assessing 
essential fatty acids and omega‐3 index status that can give accurate profiles, easy‐to‐ 
do, consumes less time, less material, less agents and less sample size. 
5.1. Essential fatty acid status 
 
The fatty acid analysis in the venous blood fractions demonstrated that the five blood 
components  have  lead to  different  concentrations  of SFAs, MUFAs,  PUFAs  although 
some fractions were close in some fatty acids but in general they were not alike. 
The most abundant family of fatty acids in all fractions was PUFAs except for PL where 
more than  half of the fatty acids were saturated. In WB, RBC and plasma the second 
abundant FAs family was  SFA followed by MUFA, while CE had the lowest content of 
SFAs. 
 
The concentrations of the SFAs in the fractions were: PL> RBC> WB> Plasma > CE. Of the 
MUFA, the distributions were, plasma> WB> CE> RBC> PL while for the PUFA, CE> RBC> 
WB> Plasma> PL. In regard to USFA, the proportions were, CE> Plasma> WB> RBC> PL. 
 
The percentage of EFA (LA + ALA) was not equal in the different fractions which were 
noticed in  the ratio of LA/ALA. The percentage of LA was much higher in all fractions 
than ALA. However, LA (18:2n6c) was abundant in CE followed by plasma, WB, PL and 
the  lowest  was  in  RBC.  ALA  (18:3n3)  showed  similar  series  although  the  highest 
proportion of ALA was found in plasma followed by CE, then WB, PL and the lowest was 
in RBC. 
 
Usually ALA concentration in plasma phospholipids is not more the 0.5% (Holman 1998) 
while no trace for ALA in RBC (Riséa et al., 2007). RBC might contain the lowest levels of 
EFA since EFA aren’t stored in their intake forms but they are stored in their derivations 
forms. CE would be the best to  assess EFA intake as their concentrations (ALA + LA) 
were found to be the highest in CE while the  lowest were in RBC ,as RBC does not 
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influenced by day to day dietary intake according to its longer half life shelf (4 to 6 more 
time longer than plasma) (Sun et al., 2007). 
 
As DHA concentrations were found to be the highest in RBC followed by WB therefore, 
the omega‐3 index was highest in RBC followed by WB. n‐3 and LCPn‐3 fatty acids were 
also highest in RBC followed by WB whereas the lowest was in CE. n‐6 (since it includes 
LA) concentrations were highest in CE followed by WB and the lowest in PL, while LCPn‐ 
6 (since it doesn’t include LA) concentrations were the highest in RBC (according to the 
 
high level of AA) followed by WB whereas the lowest was found in CE. However, sum of 
 
LCPUFA were highest in RBC followed by WB and the lowest was in CE. 
 
 
Omega‐3 index in plasma might be affected with the most recently consumed meal. A 
meal poor in n‐3 FAs and contain other FAs will enrich the plasma FA pool with other 
FAs but not n‐3 FAs,  which will decrease n‐3 FAs content consequently. This will not 
happen in RBC FAs pool as RBC is not affected by recently consumed meals whatever 
were the FAs content of those meals. According to the stability of RBC Omega‐3 index 
(EPA+ DHA) and since it isn’t affected by the last meal, RBC are considered to be better 
biomarker than plasma or plasma PL (Harris and Thomas, 2009). Omega‐3 index is found 
higher in coastal population than in land communities (3.8% Vs 3.2%) (Dewaillya et al., 
2003). 
 
 
Although there were significant differences between the different groups  that were 
analysed, it was recognized from this study that blood triglycerides are more affected by 
the fatty acids than  glycaemic status. No significant differences were found between 
glycaemic   groups   while   SFAs,   MUFAs,   PUFAs,   USFAs,   omega‐3   index,   LCPUFA 
significantly differ between lipidemia groups. BMI had little effect after the exclusion of 
obese subjects; however, females’ fatty acids composition  would be affected by BMI 
more than males. 
 
The interesting results will be the fatty acids and the indexes that relate to the EFA as 
they have  been correlated with the risk for CVD and CHD. The major fatty acids that 
contribute  to  the  total  concentration  of  n‐3  FA  in  human  blood  components  are 
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EPA+DHA+DPA while ALA being the minor, AA +LA were the major components to the 
total n‐6 FA. 
 
5.2. Importance of omega‐3 index for human health 
 
 
n‐3 fatty acids were established to assess the fatty acid pattern and the risk of death 
from CHD. In  western populations, high concentrations  of n‐3 fatty acids (especially 
omega‐3 index EPA+ DHA) in dietary intake and blood levels decrease the risk of sudden 
cardiac  death.  However,  EPA+  DHA  lower  triacylglycerols,  they  also  work  as  anti‐ 
hypertensive, and have anti‐inflammatory roles in lowering CHD risk. Therefore, omega‐ 
3 index is hypothesized to be predictor for CHD mortality (Stark 2008). 
 
 
One of the first studies was DART (the Diet and Reinfarction Trial) which investigated 
the  association between dietary intake of n‐3 fatty acids and secondary prevention of 
myocardial infarction. GISSI‐Prevemzione Trial is one of the largest recent studies that 
concluded  toward  omega‐3  fatty  acids  to  reduce  45%  of  sudden  death  and  20% 
reduction in all cause mortality (Covington 2004). 
 
n‐3 fatty acids were found to be low in patients with bipolar disorder, schizophrenia 
(Ranjekar  et  al.,  2003),  depression  (Sontrop  and  Campell,  2006),  child  hyperactivity 
(Chen et al., 2004) and autism (Vancassel et al., 2001). 
 
5.3. Correlations between fatty acids status among methods 
 
 
Comparisons between fatty acids were limited. Several blood biomarkers of omega‐3 
fatty acids intake have been reported; including the percentage of EPA + DHA omega‐3 
index in erythrocytes (Harris and Von Schacky, 2004), in plasma phospholipids (Prisco et 
al., 1996), EPA/AA ratio (Rupp et  al.,2004), n‐6/n‐3 ratios (Harris et a., 2006), and n‐3 
HUFA score (Stark et al., 2005). 
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5.3.1. Choosing the biomarker depends on many considerations 
 
1.   Fatty acids or indexes that are the focus of the study. 
 
2.   Sensitivity of the biomarker; so if the interest was the short‐term changes in n‐ 
 
3 status then plasma, PLs, CE will be more favourable than RBC. However, in 
the  steady  state  all  the  medians  would  be  fine  according  to  their  highly 
correlated between their values (Harris and Thomas, 2009). 
3.   For large observational and clinical trials, blood based biomarkers are more 
 
favourable than adipose tissue (Stark 2008) especially when dealing with large 
number of  participants  (Ogura  et al., 2010)  as participants  would  be more 
compliant  if  the  samples  are  taken  as  blood  more  than  an  adipose  tissue 
biopsy  (MA et al.,  1995). 
 
 
5.3.2. Parallelism between fractions 
 
 
The intake correlation is better in n‐3 RBC than in n‐3 adipose tissue. However, RBC is 
better  as  a   biomarker  for  the  intake  than  in  plasma  which  might  make  RBC  a 
replacement of the  adipose  tissue especially for the long term evaluation (Sun et al., 
2007). 
 
 
Plasma PL and CE might not give an exact reflection of the intake of fat and fatty acids. 
RBC cannot be used as a biomarker for SFA in short‐term studies (3 wks) (Popitt et al., 
2005). 
 
 
In a study done by Qi Sun, RBC DHA concentration was better as a biomarker of the DHA 
intake than plasma DHA, although the correlation between both biomarkers and DHA’s 
intake were very strong.  The same was noticed with total trans fatty acids. While the 
associations between dietary MUFA and SFA with plasma and RBC were weak according 
to their endogenously synthesized from carbohydrates. Thus this study concluded that 
for long‐term intake, RBC n‐3 FA and TFA are suitable biomarkers (Sun et al., 2007). 
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5.3.3. Whole blood: favourable method 
 
 
Since total blood fatty acids are analyzed in venous whole blood, thus values obtained 
from WB give a general overview of all dietary intake terms (short, medium, and long 
term). Whole blood method saves many steps that must be done for the other methods: 
1.   No   need   for   the   separation   of   WB   into   RBC,   plasma   (usually   done   by 
centrifugation) which also might save sample amount. 
2.   RBC needs washing to remove the white cells and plasma contamination. 
 
3.   Plasma PL and CE need separation by TLC which need around 3‐5 hours (Bailey‐ 
 
Hall et al., 2008). 
 
4.   Since WB necessitate one step only to be analyzed, therefore it requires less 
agents, less time, and save materials. 
WB represents two different LCPUFAn‐3 pools, short term (plasma) and stored term 
(RBC), which would reflect the complementary profiles (Albert et al., 2002). Through the 
linear omega‐3 index  graphs, it was clear that WB had a stronger positive correlation 
with RBC and with plasma than between other fractions, which strengthen considering 
WB also as a system for an omega‐3 index  biomarker. The highest concentration of 
omega‐3 index was in RBC (5.82%) followed by WB (3.48%), then plasma (2.55%), and PL 
(2.38%) while the lowest was found in CE (1.38%). This shows that  RBC is the best 
according to the highest concentration followed by WB. Thus WB would be also a good 
indicator as the omega‐3 index is also high and the analyzing process is the easiest 
amongst other methods. 
 
Skeaff suggested whole blood for fatty acids analysing as it gives adequate approach 
(Skeaff et al., 2006) in addition, Riséa reported that blood fatty acids profile are mainly 
determined  from  plasma   and  RBC  phospholipids  but  not  for  EPA.  Therefore  he 
suggested plasma and whole blood to be the best two methods for assessing FA status 
(Riséa et al., 2007). However, the whole blood method is characterized as simple, rapid 
(Ratnayake and  Galli  2009)  and  useful  for  fatty  acids  status  from  large  populations 
(Agostoni et al., 2011). 
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6. Summary 
 
 
The objective of the study was to set up the appropriate system for assessing fatty acids 
profiles especially essential fatty acids and omega‐3 index status that can give accurate 
profiles, easy‐to‐do, consumes less time, less material, less agents and less sample size. 
The present study included 140 Austrian adults of both genders of which 69 female, 71 
male.  Five  blood  components  had  been  analysed  to  assess  24  fatty  acids  and  to 
calculate  omega  3  index.  Whole  blood,  red  blood  cells,  plasma  total  lipids,  plasma 
phospholipids and plasma cholesterol ester were all assessed from fasting venous blood. 
The interesting fatty acids those that are related to essential fatty acids, since they have 
been correlated to CVD and CHD risks. The major fatty acids that contribute to the total 
concentration of n‐3 fatty acids in human blood components are EPA and DHA and DPA 
while ALA being the minor; AA and LA are the major components to the total n‐6 fatty 
acids 
Many papers suggested RBC to be the best indicator for omega‐3 index as RBC has the 
highest   concentration  with   low   variability.   However,   WB   is  the   second   highest 
parameters with  omega‐3 index especially that analysing omega‐3 index from WB is 
easier than RBC since it does not need any extractions. Through the five tested systems, 
the best correlations were between WB and plasma followed by WB and RBC especially 
for the omega‐3 index. 
WB parameter was found to be the most favourable blood component to assess the 
 
omega‐3 index and essential fatty acids due to the following aspect: 
 
1. Reflects general indications of the short, medium and long term dietary intake. 
2. Saves the separation steps which save: 
.2.1 Time. 
.2.2 Sample size. 
.2.3 Materials and agents. 
3. Simple 
4. Rapid. 
5. Gives accurate values. 
6. Easy to do and does not require professional worker such as PL and CE methods. 
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According to this study, assessing EFA and omega‐3 index from venous whole blood 
parameter are recommended. 
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7. Fazit: 
 
Das Ziel der Studie war die Etablierung eines geeigneten Systems zur Bewertung des 
Fettsäuremusters,   insbesondere   essentieller   Fettsäuren   und   des   Omega‐3‐Index, 
welches ein genaues Profil reflektiert, einfach durchzuführen ist, weniger Zeit, Material 
und finanzielle Mittel sowie ein geringes Proteinvolumen benötigt. 
Die vorliegende Studie umfasste 140 österreichische Erwachsene beiderlei Geschlechts 
 
davon 69  weiblich,  71  männlich.  Fünf  Blutkomponenten  wurden  verwendet  um  24 
 
Fettsäuren  zu  bewerten  und  den  Omega‐3‐Index  zu  berechnen.  Vollblut  (VB),  rote 
Blutkörperchen   (RBZ),   Plasma,   Plasma‐Phospholipide   und   Plasma‐Cholesterinester 
wurden im venösen Nüchternblut untersucht. 
Die essentiellen Fettsäuren, die in Verbindung mit dem Risiko für CVD und KHK stehen, 
bildeten den  Schwerpunkt der Arbeit. Hierzu zählen die n‐3‐Fettsäuren EPA und DHA, 
DPA und ALA; sowie AA  und LA sind die wichtigsten n‐6‐Fettsäuren im menschlichen 
Körper. 
RBZ  werden  aufgrund  der  Fettsäuren‐Konzentration  und  der  geringen  Variabilität 
 
vielfach als bestes Kompartiment zur Errechnung des Omega‐3‐Index angesehen. VB ist 
jedoch  ebenfalls  zur  Bestimmung  des  Omega‐3‐Index  geeignet,  wobei  die  Analytik 
einfacher ist als in den RBZ, da keine Extraktionen durchgeführt werden müssen. Bei den 
fünf  getesteten  Komponenten  wurden  die  besten  Korrelationen  zwischen  VB  und 
Plasma, gefolgt  von VB und RBZ speziell für den Omega‐3‐Index gefunden. 
VB  konnte  basierend  auf  folgenden  Aspekten  als  bevorzugte  Blutkomponente  zur 
 
Beurteilung des Omega‐3‐Index und essentieller Fettsäuren erfasst werden: 
 
1. Reflektiert die kurz‐, mittel‐ und langfristige Aufnahme an Fett über die Nahrung. 
2. Speichert die Trennungsschritte und spart daher: 
.2.1 Zeit 
.2.2 Stichprobenumfang 
.2.3 Materialien und Reagenzien 
3. Einfach 
4. Schnell 
5. Ergibt genaue Werte 
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6. Einfach durchzuführen und erfordert keine speziellen Fachkräfte   wie PL und CE‐ 
Methoden 
 
 
Laut dieser Studie, kann die Beurteilung der EFA und des Omega‐3‐Index in venösem 
 
Vollblut empfohlen werden. 
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2004-2005 M.Med.Sci: Human Nutrition. 
Sheffield University, United Kingdom 
2002-2003 Jeddah Economic Room 
Diploma in Management and Administration. 
1996-2001 BSc: Nutrition and Food Science Department – 
Agriculture Engineering College 
Damascus University- Syria 
 
Career Goals 
To apply my knowledge of Human Nutrition in a context which will use my management skills, 
client communication, and academic background. 
 
Human Nutrition Master 
I read for my MSc in Human Nutrition Department, at Sheffield University UK. 
Majoring credits: 
1-Biochemistry. 
2-Epidemiolog. 
3-Physiolog. 
4-Third World Nutrition. 
5-Clinical Nutrition. 
Essays: 
• AIDS/HIV Physiology changes in European adult. 
• Comparison between Fast and Starvation. 
• Food policy for infant in Sub-Saharan African. 
• African Nutrition deficiency. 
• Food policy history. 
• Lab report: Resting Energy Requirement, Maximum heart rate. 
• Nigerian children nutrition. 
• Hormonal effective on Baby Growth 
  
 
MSc Research 
Investigation  the  effects  of  frequent  feeding  on  overall  bone  turnover  in  healthy 
adults. Dealing with volunteers by measuring human urine biomarkers following particular meals 
in particular times. 
 
The BSc 
I read for my BSc in Nutrition and food Science Department, at Agriculture Engineering College 
at Damascus University- Syria. 
Majoring 
Food manufacture and Analysis, Food preservation and Nutrition and Food security strategy. 
Research: 
Chocolate Manufacture and Chemistry, Microbiology and Physical Analysis. 
Visited Syrian Chocolate Factories and analyse Micro flora and Bacteria’s Environment. 
 
Work Experience 
Jan-July 01 Nutritional  Lecturer  And  Educator,  ABBOTT  Company  for  Babies, 
Lactating and Pregnancy Women's Food in Jeddah's  Hospitals and 
Health Clinics,  Saudi Arabia. 
Sep-05 to Nov 06 Dietician and Nutritional Consultant in Nutrition  and  Diet   Centre. 
Jeddah, Saudi Arabia. 
Jan- 2007 to Sep 2008 Member in Nutrition and food science Department / Health  Science 
College at Al­Kalamoon University, 
Full  Time  Lecturer,   Assistance  in  Management  Matters,   Teach 
Nutritional  Courses  (Introduction  to  Human  Nutrition,  Community 
Nutrition Courses, Protein Biochemistry Course, Therapeutic Nutrition 
(Theory and Lab Sessions), Nutritional Assessment, and Food Safety 
Lab   Session),   Supervise   Graduated   Thesis,   Schedules   Control, 
Supervise Students' Scientific Training in Hospitals, Students’ 
Tutorial. 
Deratiah, Damascus- Syria. 
28
th 
to 30
th  
Participation in The Conference of "Chronic 
June 2007 Constipation In Infant And Toddlers" With Lecture Titled "The Role Of 
Fiber Dietary Intake In Treating Constipation In Infant And Toddlers" 
Tartous City- Syria. 
21
st   
Of Feb 2008 Participation In The Conference Of "Promotion of Breast Feeding 
In  Syria"  With  Lecture  Titled  "The  Nutritional  Needs  Of  Lactating 
Women"; Under UNICEF Sponsored. 
Tadmur City- Syria. 
24TH   Of June 2008 Participation  In  The  Conference  Of  "Arab  Doctors  Pan"  With 
Lecture Titled "MyPyramid for kids"; 
Damascus city- Syria 
 
 
 
Languages 
Fluent in Arabic, English. 
IELTS 6.5 from Canterbury, UK. 
Skills 
